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Abstract 
Rectal cancer is a common and complex form of colorectal malignancy which is the second 
largest cause of cancer death in the United Kingdom. 
The need for an accurate method of staging as a guide to selecting treatment has become 
increasingly important with the recent advances in options for preoperative therapy. 
It is now clearly understood that there are a number of prognostic features that can predict a 
poor outlook.  These include; local tumour extent, involved circumferential resection margin, 
involved lymph nodes and extramural venous invasion. Traditionally these factors have been 
noted on histopathology of the resected specimen by which time the opportunity to institute 
preoperative therapy has been lost.  Identification of these factors prior to surgery would be of 
paramount importance in potentially improving the outcome for these selected patients.   
MRI has now been shown to be proficient at identifying many of these features. The 
MERCURY study (Magnetic Resonance Imaging and Rectal Cancer European Equivalence 
Study) recruited 679 patients from 11 different centres, prior to surgery (in 2002-2003) and was 
able to demonstrate the ability of MRI to predict margin involvement and local extent of 
tumour invasion. 
 Data has been collected on the 5 year outcome of 374 patients consenting to follow up in the 
MERCURY study. This thesis explores the relationship of the distance to the circumferential 
resection margin, the prognostic significance of predicted involvement of the margin and the 
ability of MRI to identify patients with early tumours, good prognosis tumours and those with 
poor prognostic features.  The aim is to investigate the significance of these factors in 
predicting the long term outcome of these patients. 
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Figure 0.1: Composition of the MERCURY group 
 
 
 
 
Patients studied in this thesis were taken from the MERCURY rectal cancer study.  Patients 
presenting consecutively with biopsy proven rectal adenocarcinoma were included in the study.  
Patients were taken from 11 hospitals in European centres from 2002-2003. The Chapters that 
looked at the follow up of patients were based upon the analysis of the 374 patients with 
complete data consenting to follow up.  (see flow diagram – Figure 0.1) 
 
Chapter 3 looked at a cohort of original patients with complete histological and MRI data 
All early tumours with histopathological measurements of extramural depth (T1, T2, and T3a) 
and preoperative MRI were included in this analysis. 
Chapter 4 Identified patients with MRI predicted good prognosis (141) and looked at the cohort 
that were treated with surgery alone. (122) 
Chapters 5, 6 and 7 analysed all 374 patients with complete data. 
 20 
As of December 2008, surviving patients had been followed for a median of 61.5 months 
(range: 0-81 months) Patients were followed according to local protocols, namely three-month 
intervals for two years and then at six-month intervals for five years. Clinical follow up 
comprised physical examination, routine blood tests and yearly CT of the thorax, abdomen and 
pelvis. Histopathological confirmation of local or distant recurrence was sought when 
appropriate or based on clinical or radiological enlargement of a recurrent mass. The details of 
surgery, including the dates, operation performed and quality of the specimen were recorded 
prospectively; the date of last follow-up, and the date and cause of death were also collected. 
The presence of distant metastatic disease or local recurrence at the time of death was recorded 
as a rectal cancer-specific death.  
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Chapter 1 - Introduction 
Chapter Overview: 
 Background and literature review 
 Anatomy of the rectum 
 Pathological staging system 
 Prognostic features 
 Current staging modalities 
 Treatment options 
 Special considerations 
 
1.1 Background and Literature Review 
Rectal cancer is defined as carcinoma occurring within 15 cm of the anal verge. One of the 
most common tumours in industrialised countries (40 per 100 000), there is a slight male 
predilection and the prevalence increases steadily after 50 years of age, 98% are 
adenocarcinomas.  
In the United Kingdom around 110 new cases of colorectal cancer are diagnosed each day, 
being the third most frequent cancer after prostate and lung. In 2010 there were 40,695 new 
cases of large bowel cancer registered in the UK: around two-thirds (27,130) in the colon and 
one-third (13,565) in the rectum. The lifetime risk for men being diagnosed with colorectal 
cancer in the UK is estimated to be 1 in 14 and for women 1 in 19 (Statistical Information 
Team  Cancer Research UK, 2011). Survival in rectal cancer is strongly related to the stage at 
diagnosis and although survival rates have improved considerably, overall rates remain at only 
around 55 % in England. 
There are a number of pathological characteristics of rectal cancer that have become recognised 
determinants of future prognosis. The identification of these features pre-operatively and their 
significance in the long term has been the main stimulus for this research. Treatment for rectal 
cancer has improved over the last ten years and the development of more aggressive 
preoperative therapy has highlighted a need for improved preoperative staging. 
At presentation approximately 70-80% of patients have tumour invasion through the muscularis 
propria, with, or without metastases to regional lymph nodes or distant organs, with 
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approximately one third having advanced disease. The aim of accurate pre-operative staging is 
to enable stratification of patients to allow better targeting of preoperative therapy. For 
example, more aggressive preoperative therapy for those patients with advanced disease or, for 
others with no high risk features, proceeding straight to surgery.  If patients can be accurately 
placed into variable prognostic categories it will enable more exact comparison of different 
treatment regimes. Improving the ability to predict long term prognosis would also allow a 
more efficient allocation of resources regarding follow up.   
1.1.1 MRI Has Now Been Shown to be Proficient at Identifying Many of these 
Features 
The MERCURY (Magnetic Resonance Imaging and Rectal Cancer European Equivalence 
Study) study recruited 679 patients from 11 different centres, prior to surgery (in 2002-2003) 
and was able to demonstrate the ability of MRI to predict margin involvement and extent of 
tumour invasion. 
The aim of this thesis was to investigate a number of prognostic features identified on 
preoperative MRI and the significance of these factors against the long term outcome. Data has 
been collected on the 5 year outcome of 374 patients consenting to follow up in the 
MERCURY study to enable the development of a preoperative staging system that will aid in 
the prediction of outcome for patients with rectal cancer. 
In this background chapter the main existing staging modalities will be considered in relation to 
the various prognostic features along with the evidence for the different treatment options that 
are currently the standard of care for patients with rectal cancer. This chapter will also explore 
the current evidence with regards to the identification of the different factors and the prognostic 
significance of these factors based on histopathological examination.  Statements will be made 
regarding the questions raised and an attempt made to answer these in the discussion and 
conclusion. 
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1.2 Anatomy of the Rectum and Methods of Cancer Spread 
The rectum can be divided into three parts, the upper third, which is covered with peritoneum 
on the anterior and lateral aspects, the middle third which is covered at the sides and the lower 
third which is below the level of the peritoneum. 
The blood supply is principally derived from the superior rectal artery with further contribution 
from the middle and inferior rectal and median sacral vessels.  The inferior mesenteric artery 
crosses the pelvic brim and becomes the superior rectal artery. At the level of the S3 vertebra, it 
divides into two branches, which descend on either side of the rectum before dividing into 
smaller branches.  The middle rectal arteries, occasionally absent, arise on each side from the 
internal iliac artery and reach the lower rectum along the lateral rectal ligaments. The inferior 
rectal artery arises on each side from the internal pudendal artery as it enters Alcock’s canal.  
The veins correspond to the arteries but freely anastomose with each other forming the internal 
rectal plexus in the submucosa and the external rectal plexus outside the muscular wall. 
Drainage is therefore to both the portal and systemic systems. 
Figure 1.1: Anatomy of the rectum 
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Lymphatic drainage is mostly upwards, to pararectal nodes on the surface of the rectum and 
proximally via the inferior mesenteric artery to pre-aortic nodes. Lymphatics from the lower 
rectum may reach the internal iliac nodes or to the hollow of the sacrum. 
1.2.1 Methods of Spread for Rectal Cancer 
It is well understood that most carcinomas arise from adenomas in a stepwise process.  Local 
spread starts in a circumferential manner rather than longitudinal. After penetrating the 
muscularis propria, the tumour invades the mesorectum. The mesorectum is defined as the 
adipose tissue with lymphovascular and neural structures that surrounds the bowel wall.  It is 
encapsulated by a fascia, the mesorectal fascia.  The mesorectal fascia is separated from the 
parietal/pelvic fascia by thin areolar tissue.  The anatomical plane between these two layers is 
called the TME plane (total mesorectal excision) and is surgically the most important layer in 
the operative treatment of rectal cancer.  If the tumour is anterior it will start to involve the 
prostate, seminal vesicles or the bladder in males or the vagina/uterus in women.  Lateral 
involvement may include the ureter and posteriorly the sacrum or sacral plexus.  It is rare to 
spread distally for more than a few centimetres. 
Lymphatic spread above the peritoneal reflection will extend in an upwards direction, but 
below the reflection and within the field of the middle rectal artery, lateral spread is not 
infrequent. Venous spread is primarily to liver (34%), lungs (22%) and adrenals (11%).  
Peritoneal dissemination may occur in the high rectal cancers. 
In an effort to classify tumours into prognostic groups, there are several staging systems that 
have evolved over the years. 
The next section will give an overview of the pathological staging systems. 
1.3 Current Pathological Staging in Rectal Cancer, the Dukes Classification 
and the TNM staging 
1.3.1 Dukes Classification 
Dukes’ original presentation in 1932 outlined the classification of cancer of the rectum that has 
shown remarkable sustainability and is still used in much of the staging process today.  He 
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outlined three basic stages and linked the survival to each stage demonstrating marked 
differences in outcomes between the different groups. 
Dukes’ A – carcinoma limited to the wall of the rectum (3 yr survival – 80%) 
Dukes’ B – Spread of the carcinoma into extrarectal tissues but no nodal involvement (3 
yr survival – 73%)  
Dukes’ C – lymph node involvement is present. (3 year survival 7%) 
 
In 1949 Kirklin et al. modified Dukes’ classification: Type A lesions limited to the mucosa, 
Type B divided into B1 (tumour into but not through the muscularis propria) and B2 (tumour 
penetrates the muscularis propria)(Kirklin et al., 1949).  In 1954 Astler and Coller noted 
statistically significant differences in overall survival between different depths of tumour 
penetration. They proposed a subdivision of Dukes’ C cases into C1 (B1 with positive nodes) 
and C2 (B2 with positive nodes).  They showed an overall five year survival of 100% for Type 
A, 66.6% for Type B1, 53.9% for B2, 42.8% for C1 and 22.4% for C2.  This underlined the 
importance of the degree of local tumour extension in the presence of involved lymph nodes 
(Astler, et al. 1954).  In 1958 Dukes and Bussey acknowledged these modifications and 
demonstrated that both local recurrence and survival could be correlated with depth of invasion 
again highlighting the association between increasing depth of invasion and a higher incidence 
of lymph node metastases (Dukes and Bussey, 1958). 
The main disadvantage of Dukes’ classification is the lack of a category for distant metastases 
and locally advanced, irresectable tumours. He also failed to identify a group of patients with 
nodal involvement but early local disease, thus indicating that there are other factors likely to 
be involved.   
1.3.2 TNM Staging (Tumour Node Metastasis) 
The TNM staging system was first presented byDenoix (1954).  The American Joint committee 
for cancer staging and end results reporting proceeded to adapt the system to colorectal cancer 
(AJCC).  
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Wood et al. (1979) presented the survival rates of a large series of rectal cancer patients (1826 
cases) according to the TNM staging. This again confirmed the major influence of lymphatic 
involvement in determining survival. 
The TNM system for staging cancer of the colon and rectum was originally devised to 
correspond with the Dukes’ staging system but has been modified and reviewed progressively 
over the years and therefore, the latest (7th) revision published in 2010 is significantly different 
from the original template.  
Both T1 and T2 tumours have high 5-year survival. TNM 6 and TNM 7 both suggested an 
optional sub-classification of T3 tumours according to measured depth of extramural invasion. 
A four-tiered sub classification was proposed (<1mm; 1-5mm; >5-15mm; >15mm) (Wittekind, 
2003). 
This was to address the wide range of survival reported in patients with T3 tumours, which 
make up 80% of patients with colorectal cancer seen in clinical practice.  Several authors have 
demonstrated the prognostic impact of sub classification of the depth of invasion of the T3 
tumours and this will be discussed in detail later in this chapter (Merkel et al., 2001, Steel et al., 
2002, Hermanek et al., 1989a). 
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Table 1.1: AJCC (7
th
 Edition) 
Category Description 
Tx The primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ (intraepithelial or intramucosal carcinoma) 
T1 Tumour invades into the submucosa 
T2 Tumour invades into the muscularis propria 
T3 Tumour invades through the muscularis propria into the subserosa, or 
into non-peritonealised pericolic or perirectal tissues 
Optional subdivision of T3: 
T3a  Minimal invasion: <1mm beyond the border of the muscularis 
propria 
T3b  Slight invasion: 1-5mm beyond the border of the muscularis 
propria 
T3c  Moderate invasion: >5-15mm beyond the border of the muscularis 
propria 
T3d  Extensive invasion: >15mm beyond the border of the muscularis 
propria  
T4 Tumour directly invades into other organs or structures (T4a) or 
perforates the visceral peritoneum (T4b) 
Nx Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastases 
N1 
 
Metastatic tumour in 1 to 3 pericolic or perirectal lymph nodes 
N1a  Metastasis in one regional lymph node  
N1b  Metastasis in 2–3 regional lymph nodes 
N1c  Tumour deposit(s) in the subserosa, mesentery, or 
nonperitonealised pericolic or perirectal tissues without regional nodal 
metastasis  
N2 Metastatic tumour in 4 or more pericolic or perirectal lymph nodes 
N2a  Metastasis in 4–6 regional lymph nodes  
N2b  Metastasis in 7 or more regional lymph nodes 
Mx The presence of distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis present 
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Table 1.2: Overall 7
th
 Edition TNM staging summary from the American Joint 
Committee on Cancer 
Stage    
0 Tis   N0 M0 
I T1      N0      M0 
 T2       N0 M0 
IIA T3 N0   M0 
IIB T4a   N0       M0 
IIC T4b     N0   M0 
IIIA T1-2           N1/N1c      M0 
 T1   N2a      M0 
IIIB T3-T4a       N1/N1c      M0 
 T2-T3         N2a   M0 
 T1-T2         N2b     M0 
IIIC T4a    N2a      M0 
 T3-T4a       N2b     M0 
 T4b     N1-N2         M0 
IVA Any T         Any N          M1 
 
 
 
1.3.3 Pre operative Staging Modalities 
Rectal cancer staging is now mostly based upon the TNM or UICC staging with reference to 
Duke’s staging (Jass et al., 1987, Sobin and Wittekind, 1997, Wolmark et al., 1986).  
Traditionally staging techniques have relied upon digital rectal examination (DRE) and 
sigmoidoscopy, and more recently endoscopic ultrasound (EUS) (Nicholls et al., 1982). 
At the time of commencing this study, there had been several studies demonstrating the ability 
of MRI to accurately stage rectal cancer and to clearly identify the relevant anatomy (Brown et 
al., 2004, Brown et al., 2003, Martling et al., 2003, Beets-Tan et al., 2001).  In this literature 
review the value of the main staging modalities will be considered in relation to the various 
prognostic features. 
Clinical Staging 
Staging is the method used to assess the anatomical extent of a tumour to allow for evaluation 
of prognosis and to decide the best method of treatment. 
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1.3.4 Digital Rectal Examination and Sigmoidoscopy 
In the past, patients diagnosed with rectal cancer were assessed only on digital rectal 
examination and sigmoidoscopy.  Sigmoidoscopy enabled biopsies to be taken and gave some 
information on tumour mobility.  Neither procedure provided any information about the nodal 
status or any other prognostic features of the tumour.  
Tumour mobility is a very crude measurement of local spread and may be inaccurate 
particularly in cases with large pelvic masses, when the tumour can become wedged in the 
pelvis without necessarily being attached to any surrounding structures.   However, despite the 
limitations, many surgeons still use clinical staging as an adjunct to the assessment of 
operability and consider it to be an important part of the pre-operative assessment (Nicholls et 
al., 1982). 
1.3.5 Investigative Staging 
Over the past 20 years advances in radiological and ultrasonic techniques have facilitated more 
accurate preoperative assessment.  Most of these imaging techniques are based around the 
pathological staging systems (TNM) allowing a comparison to be made between the various 
methods. 
1.3.6 Endoscopic Ultrasound (EUS) 
Trans-anal endoscopic ultrasound (EUS) has shown some good results. It utilises an 
endoluminal device that assesses the layers of tissue that comprise the bowel wall from the 
luminal side. It has the ability to detect tumours and assess the depth of invasion. However it is 
significantly operator dependent, and problems arise when scanning high or stricturing lesions 
(Katsura et al., 1992).  The limited field of view makes assessment of structures beyond the 
mesorectum difficult to interpret.  The accuracy to stage mural penetration varies from 69%-
97% with sensitivity for the detection of involved nodes in the mesorectum only being between 
50-83% (Pijl et al., 2002, Glaser et al., 1990, Rifkin et al., 1989, Milsom and Graffner, 1990, 
Garcia-Aguilar et al., 2002). 
In several  important clinical trials the main staging assessment was performed by EUS but a 
multi-centre trial showed significant overstaging of patients and consequent overtreatment of 
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some tumours (Bartram and Brown, 2002, Sauer et al., 2004, Peeters et al., 2007, Pahlman and 
Glimelius, 1995, Kapiteijn et al., 2001). 
Therefore, EUS is ideally suited for T staging of early flat lesions and best assessed using a 
high frequency probe. The high frequency probe gives very accurate depiction of bowel wall 
layers but suffers from an inherently limited depth of penetration, which restricts evaluation of 
tumour spread beyond the bowel wall. 
The inability of EUS to define the outer edge of infiltrative tumours, to distinguish tumour from 
desmoplastic reaction, and its inability to interrogate the entire mesorectal envelope with 
adequate resolution are the main limitations (Maier et al., 1997). 
In assessing other prognostic features such as mesorectal lymph nodes (Massari, et al. 1998; 
Palacios Fanlo, et al. 2000; Spinelli, et al. 1999), EMVI, tumour distance to mesorectal fascia, 
tumour spread beyond the muscularis in millimetres, peritoneal infiltration- EUS has not been 
shown to approach acceptable accuracy (Massari et al., 1998, Spinelli et al., 1999). 
1.3.7 Computerised Tomography (CT) 
Early reports for CT staging with identification of the mesorectal fascia were promising.  
However, poor results from later studies have shown that this technique has no real role in the 
local staging of rectal cancers (Shank et al., 1990). 
When multi-slice CT, which allows for multiplanar imaging, was introduced in 2000 it was 
hoped that this would improve the assessment value (Hundt et al., 1999). Matsuoka et al. 
(2002) looked at 20 patients comparing multislice with conventional CT staging and concluded 
that while multislice was superior in assessing the depth of tumour invasion, it was no better in 
the evaluation of lymph node metastases. 
Although spatial resolution has improved considerably with the multidetector CT it does still 
have low contrast resolution.  Carcinomas of the rectum are demonstrated as irregular wall 
thickening and small tumours are particularly difficult to detect (Vliegen et al., 2008, Kwok et 
al., 2000).   A meta-analysis of 78 studies showed an accuracy of 73% for T staging but lacked 
accuracy in detecting metastatic lymph nodes.  The conclusion was reached that CT had a 
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lower overall accuracy generally compared with EUS or MRI (Kwok et al., 2000 (Taylor et al., 
2007). Taylor et al. compared the accuracy of CT with MRI and concluded that they both have 
high negative predictive values for a subsequently uninvolved margin, but that CT tended to 
overstage patients.  They did however use a cut off of 5mm for the CRM and this may have 
been improved with a smaller margin (Taylor et al., 2007). 
The role of CT for local staging was investigated in a Dutch multicentre study (SPICTRE 
study) for which results have suggested that multislice spiral CT can accurately predict a 
negative CRM in high rectal cancer but is unable to predict margins for low tumours (Beets-
Tan et al., 2000, Wolberink et al., 2009, Maizlin et al., 2010). 
For the present CT is not used for local staging in the UK but, remains useful for the 
identification of distant metastases.  For many countries with limited access to MRI (or MRI 
reporting expertise) CT, clinical examination and DRE remain the main methods of staging. 
1.3.8 Magnetic Resonance Imaging (MRI) 
In the UK, the National Institute for Clinical Excellence (NICE) recommends that for patients 
in whom surgery is being considered, MRI should be performed before treatment begins to 
determine who might benefit from either neoadjuvant therapy or surgery alone. 
MRI offers the benefit of objective assessment of all the relevant anatomy leaving a permanent 
record to review.  It has been shown to be adequately able to identify important surgical and 
pathological risk factors.  In particular prediction of a tumour-free CRM, involvement of the 
serosa at, or above the peritoneal reflection and extramural vascular invasion and lymph node 
metastases (Blomqvist et al., 1997). 
Initial studies were performed using the endorectal coil.  This has shown some good results in 
specialist centres, but remains problematical for stenotic lesions and has now been largely 
replaced by the surface coils (Brown et al., 2004, Torricelli et al., 2002).  This study was only a 
small number of patients; there are no large series to support this – largely due to the inherent 
difficulties staging stenotic or bulky lesions.  At the time of these investigations, phased array 
coils were being developed which superseded the need to use the endorectal coils as the 
resolution was so good when using the high resolution parameters (Brown et al., 2004). 
 32 
The development of the high resolution phased array surface coil systems which combine a 
high spatial resolution with a large field of view has allowed improved and more detailed 
evaluation of the relevant anatomy. 
MRI is able to interpret the relationship of the tumour to the surrounding structures and the 
bowel wall as these layers can usually be clearly identified (see figures 1.2-1.4); 
Figure 1.2: Thin section, T2 weighted, axial MR Images of a rectal cancer (outlined in 
white)  
It can be seen that the invasive margin is at 9’oclock and therefore careful inspection of this 
area should be performed. 
 
  
 
Figure1.3: The mesorectal fascia is shown by the white arrows. 


Figure 1.4: Schematic representation of the layers of the bowel wall 


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The MERCURY study (Mercury Study Group, 2006, Mercury Study Group, 2007) 
demonstrated that MRI is feasible and reproducible in a multi-centre setting and showed 
equivalence with histopathology in pre-operative prediction of tumour spread.  The study 
demonstrated accurate measurement of depth of extramural spread. 
Brown et al. compared the accuracy of high resolution MRI with digital rectal examination and 
EUS in identifying favourable, and locally advanced rectal cancers in 98 patients undergoing 
TME. They demonstrated the superiority of MRI on both cost and clinical effectiveness in 
selecting appropriate patients for neoadjuvant therapy (Burton et al., 2006, Brown et al., 2004). 
The limitation of the current staging process is that prognosis is determined by the 
histopathological staging systems. While there is now good evidence that MRI is able to 
identify many of the prognostic features that are used to stage patients, there have been no 
studies looking at the long term prognosis based upon the preoperative assessment of these 
features. 
The aim of this thesis is to identify which of these factors are important and can they be used 
for the pre-operative identification of high risk patients. 
1.4 Prognostic Features 
 Margin involvement 
 EMVI 
 Lymph node involvement 
 Pelvic side wall involvement 
 Extent of extramural invasion 
Many studies have shown that depth of extramural invasion, nodal involvement and 
involvement of the circumferential resection margin are independent histopathological markers 
for poor prognosis, and it has been shown that these factors can be accurately identified by 
MRI (Cawthorn et al., 1986, Czito and Willett, 2007).  As yet there have been no studies 
linking MRI identification of prognostic features and outcome. 
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1.4.1 Margins 
Circumferential resection margin involvement (tumour within 1mm from the resection margin) 
has been shown to be associated with a higher risk of pelvic recurrence and poor survival based 
upon pathological involvement of the margin (Birbeck et al., 2002).  MRI has been shown to be 
accurate in predicting involvement of the CRM, as the mesorectal fascia is clearly visualised. 
Figure 1.5: High resolution T2-weighted axial MRI through rectal tumour  
showing the fascia propria of the mesorectum (red arrowheads) which corresponds to the 
surgical circumferential resection margin. 
 
 
 
1.4.1.1 Evidence for the Use of a 1mm Margin on Pathology 
The prognosis in rectal cancer is directly related to the extent of extramural spread into the 
mesorectum (Adam et al., 1994) and the ability to achieve clearance at the CRM (Cawthorn et 
al., 1990, Hall et al., 1998, Birbeck et al., 2002). Birbeck in 2002 showed that CRM status may 
be used as an immediate predictor of survival after rectal cancer surgery and serves as a useful 
indicator on the quality of surgery.  They concluded that CRM involvement by tumour  is the 
only pathological variable that independently influences both survival and local recurrence.  
Ultimately it confers a poorer prognosis, doubling the risk of death and with a 3.5 times the risk 
of local recurrence compared to patients with non involved margins. 
Numerous other pathological studies have demonstrated the poor prognosis associated with 
tumour within 1mm of the CRM.  Quirke et al. demonstrated a local recurrence rate of 64% 
compared to 9 % with margins >1mm and they later also demonstrated a poor survival in this 
group of patients (Birbeck et al., 2002, Adam et al., 1994, Quirke et al., 1986). Wibe et al. 
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(2002) demonstrated 22% local recurrence and 63% survival compared to 5% LR and 81% 
survival with margins > 1mm. 
The Dutch TME trials demonstrated an increased risk of local recurrence with margins less 
than or equal to 2mm (Nagtegaal et al., 2002a) and margins of less than or equal to 1mm were 
associated with increased risk of distant metastases.  This increased local recurrence in the 
patients in the 1-2mm group was not replicated in the other studies.  
1.4.1.2 MRI Evidence 
 
MERCURY was able to show that MRI accurately predicts the potential surgical resection 
margins, in a reproducible manner (Purkayastha et al., 2007, Mercury Study Group, 2006, 
Mercury Study Group, 2007).  This has been confirmed with a meta-analysis comparing MRI 
with histology after TME (Purkayastha et al., 2007).  This study established that high-
resolution MRI can accurately predict tumour involvement of the CRM with a sensitivity and 
specificity of 94% and 85% respectively and concluded that this is reproducible across different 
centres. 
In 2001 Beets Tan et al. published a paper in the Lancet describing a study that looked at 76 
patients and the best margin to use on MRI to identify those patients at risk of margin 
involvement.  This study suggested that a margin of at least 5mm was required to predict a 
clear circumferential margin on histopathology (Beets-Tan et al., 2001). 
However, Brown et al. in a prospective study assessed 98 patients preoperatively for CRM 
status and compared this with postoperative histopathology.  Using a margin of 1mm this study 
demonstrated MRI prediction of CRM involvement with 92 percent agreement (Brown et al., 
2003). 
It can be seen therefore, that over the years there has been some question as to what is the best 
margin to use for MRI assessment of the CRM. 
Obviously the quality of surgery does also play a significant part in the prediction of a positive 
CRM, in other words MRI will only predict a positive resection margin for those patients 
undergoing total mesorectal excision (TME).  With inadequate surgery giving an incomplete 
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mesorectum, the accuracy of preoperative identification of the margins would be negated.  
Nagtegaal et al. looked in detail at 180 patients entered into the Dutch rectal cancer study and 
found that 24% of patients had incomplete mesorectum.  Patients in this group were at 
increased risk for local and distant recurrence (Nagtegaal et al., 2002b). 
Studies have demonstrated that involvement of the peritoneal surface is a significant adverse 
factor in the prognosis of rectal cancer and this is something that should be looked for on the 
preoperative scan (Heald et al., 1982, Shepherd et al., 1995, Sigurdsson et al., 2009). Peritoneal 
Involvement is defined as nodular extension of tumour at the peritoneal reflection with 
inflammatory reaction, mesothelial hyperplasia, and or ulcerations or tumour cells 
demonstrated free in the peritoneum (Shepherd et al., 1997). 
Shepherd et al. (1995) looked at 209 resections for rectal cancer. In this study it was recorded 
that local peritoneal involvement was shown in 25.8% of the resected specimens.  Of theses, 
12.4% also had tumour cells apparently free within the peritoneum on histological examination.  
Local peritoneal involvement was more common in women than in men and was correlated 
with increasing tumour size, lymph node involvement and tumour site.  On univariate analysis 
it was significantly associated with an adverse prognosis in curative resections.  They noted 
that there were a group of patients with local peritoneal involvement and mesorectal margin 
involvement who did not exhibit subsequent local recurrence.  Half of these patients will have 
died from metastatic disease; however there are still patients who survived without 
demonstrable local recurrence.  This indicates that there are clearly other important factors 
involved. 
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1.4.2.2 MRI evidence 
EMVI can be readily identified on MRI; it is shown by the expansion and irregularity of 
venules penetrating the outer muscularis layer of the rectal wall, adjacent and contiguous to the 
primary tumour. A vessel is defined as a tubular structure containing signal void on T2-
weighted images and shown in continuity on adjacent slices(Brown et al., 2003). 
Smith et al. (2008a) showed that the presence of EMVI on a preoperative MRI scan was 
associated with a fourfold higher risk of distant metastases and a reduction in relapse free 
survival at 3 years from 74% to 35%.  
1.4.3 Pathology evidence of Mesorectal Lymph Nodes 
The prognosis of patients with rectal cancer is known to be influenced by the number of 
involved lymph nodes (Dukes, 1932, Adam et al., 1994, Dukes and Bussey, 1958) and the 
presence of tumour containing lymph nodes near to the mesorectal fascia increases the risk of 
recurrence (Caplin et al., 1998, Gunther et al., 2002, Yano et al., 2006).  Lymph node 
involvement is an independent adverse prognostic factor and is associated with reduced overall 
survival (Wolmark et al., 1986). 
 More recently studies have demonstrated that node negative colorectal cancer patients in 
whom only a small number of lymph nodes are included in the resected specimen have a 
prognosis exactly  comparable to patients with positive nodes (Herrera and Villarreal, 1992). 
There are several possible explanations for this: are the lymph node metastases being missed on  
histopathology, was the surgery incomplete in mesorectal resection or is this a reflection of the 
biology of the tumour, with patients in whom there are lots of nodes exhibiting a better immune 
response resulting in a higher benign to malignant lymph node ratio? 
In patients undergoing TME surgery, nodal status is much less likely to predict local recurrence 
however the risk remains for patients with 4 or more nodes (N2 disease). Hermanek et al. 
(2010) showed a 33% local recurrence rate for N2 nodal disease compared with just 10% for 
N0 or N1.  Therefore, identification of N2 lymph node involvement should be an important 
influence in guiding preoperative and post operative treatment strategies. 
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1.4.3.1 MRI Assessment of Lymph Nodes 
Currently the identification of preoperative lymph node status has implications for the 
treatment decisions for the patient.  Identification of the number of involved nodes and the 
presence of  nodes close to the mesorectal excision margin will increase the risk of recurrence 
unless the surgical plane is adjusted (Adam et al., 1994, Jass et al., 1987). 
The inability of pre-operative staging techniques to identify malignant nodes is one of the 
significant challenges of this preoperative staging technique. However, involved nodes may 
only contain microscopic foci of invasion and may be normal sized.  Brown et al. analysed 437 
lymph nodes harvested from TME specimens and matched the MRI images with the 
histopathology specimens.  This demonstrated that the diameters of benign and malignant 
nodes were similar (Brown et al., 2003).  A histological survey of over 12000 lymph nodes 
supported this finding and showed considerable overlap between normal and involved nodes 
(Gunther et al., 2002). 
Brown et al. showed that greater accuracy was achieved using criteria based upon an irregular 
border and mixed signal intensity (Brown et al., 2003).  This paper looked at 437 lymph nodes 
harvested from surgery. One hundred and two lymph nodes were too small (<3mm) to be seen 
on MRI, 2 of these contained metastases. Sixty-eight percent of 22 patients with nodal 
metastases had uninvolved nodes that were the same size as the involved nodes and therefore 
size was felt to be a poor predictor.  They demonstrated a superior accuracy using irregular 
border or mixed signal intensity as factors, with a sensitivity of 85% (51/60) and a specificity 
of 97% 216/221. 
MRI cannot necessarily distinguish between lymph nodes replaced by tumour or a separate 
extramural tumour deposit in the mesorectum.  However, since patients with discontinuous 
tumour deposits have a much worse prognosis it is important to identify these features 
preoperatively (Singh et al., 2000, Ueno et al., 1998). 
1.4.4 Pelvic Sidewall Lymph Nodes 
The presence of pelvic sidewall nodes is worth noting.  In the UK pelvic sidewall nodal 
dissection is not routinely performed, however these nodes are probably included in the field 
when preoperative radiation is given.  In Japan, pelvic side wall dissection has been applied 
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since the late 1970’s. Sugihara performed a retrospective multicentre study to clarify the 
indication and benefit of pelvic sidewall dissection in rectal cancer.  He looked at 1977 patients 
with rectal cancer of which 930 underwent pelvic sidewall dissection without adjuvant 
radiotherapy.  He concluded that positive lateral lymph node was the strongest predictor in both 
survival and local recurrence and therefore that pelvic sidewall dissection may be indicated for 
patients with T3-T4 lower rectal cancers because of the greater probability of positive lateral 
lymph nodes. 
Yano and Moran (2008) reviewed the literature in 2007 and concluded that it is crucial to 
assess for the presence of pelvic sidewall nodes. 
1.4.4.1 Extent of Extramural Invasion – Pathological evidence. 
This has been discussed in the sections above regarding Dukes’ staging and TNM staging. 
To summarise, T staging has been consistently shown to predict outcomes in patients with 
rectal cancers (Gardner et al., 1987, Hojo, 1986, Moreaux, 1989). 
To investigate further the wide range of survivals in the Dukes B stage patients, Merkel et al. 
(2001) analysed 853 patients from the Erlangen Registry for Colorectal Carcinomas with stage 
I-III rectal cancer that underwent radical surgery alone. The category pT3 was subdivided 
according to the histological measurement of the maximal tumour invasion beyond the outer 
border of the muscularis propria: pT3a (up to 5 mm) and pT3b (more than 5 mm). Locoregional 
recurrence rates were 10.4% for pT3a and 26.3% for pT3b (P<0.0001). The cancer-related 5-
year survival rates were 85.4% for pT3a and 54.1% for pT3b (P<0.0001). An extended pT 
classification (pT1, pT2, pT3a, pT3b, pT4) improved prediction of outcome in rectal carcinoma 
patients (Merkel et al., 2001). 
Other series also showed that patients with disease limited to the bowel wall carried an 
excellent outcome with 5 year survival of 80-95% following anterior resection (Weitz et al., 
2005). 
1.4.4.2  MRI Detection of T Stage 
As discussed earlier in this chapter, the development of the pelvic surface phased array coils 
enabled high resolution coils to capture images of the rectal wall.  Brown et al. (1999) studied a 
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prospective series of 28 patients and demonstrated good correlation with histology.  Twenty 
one of twenty four patients with tumour infiltrating over 5mm into the perirectal fat were 
correctly identified.  In most cases there was direct agreement with the extramural depth 
measured on MRI and the corresponding histopathological measurements (Brown et al., 1999). 
This was validated in a prospective  series of 98 patients  showing agreement of 94% for T 
substage (Brown et al., 2003). 
In 2006, the MERCURY study showed that the technique of high resolution MRI was feasible 
and reproducible in a multicentre setting and showed equivalence in measurements of 
extramural depth of invasion compared with the histological gold standard (Mercury Study 
Group, 2006). 
The question raised is whether this assessment can be translated into a valid prognostic 
prediction. 
This review raises the following questions: 
What are the main factors that can be identified on MRI that will influence prognosis? 
What combination of factors carries the worse/best prognosis? 
Can MRI staging accurately identify patients in different prognostic groups? 
What is the best margin to enable identification of a predicted involved CRM? 
1.5 Treatment Options 
Following MRI assessment of the tumour stage, patients have several options depending upon 
the stage of disease.  Over the past 20 years, there have been improvements in the management 
of rectal cancer in terms of postoperative death (falling from 10% to 2%), locoregional failure 
(dropping from 30%-40% to less than 15%), sphincter conserving surgery rates (increasing 
from 20% to 60%) and survival, with advances made in the understanding of the biology of this 
type of tumour as well as staging and the use of combined therapies (Ortholan et al., 2006). 
Very early tumours (invasive adenocarcinoma spreading into, but not beyond the submucosa – 
i.e. T1) can be considered for local resection.  All other tumours should be considered on the 
following basis: 
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Patients should be discussed at a Multidisciplinary Team (MDT) meeting to decide whether 
they should proceed straight to surgery or whether they should receive preoperative 
neoadjuvant therapy.  Currently patients with T1/T2 or early T3 tumours tend not to be offered 
preoperative therapy.  Patients with more advanced tumours are offered either a one-week 
approach using 25 Gy radiotherapy in 5 fractions (SCPRT) or, more commonly, long-course, 
concurrent chemoradiation (CRT).  CRT is used in an attempt to induce maximum tumour 
regression prior to surgery when the tumour either involves, or is close to the mesorectal fascia.  
All patients with potential margin involvement on MRI should be offered chemoradiotherapy, 
since it has been shown that implementation of this treatment programme has led to a decrease 
in the margin positivity rates (Sasapu et al., 2006). 
The use of SCPRT is more contentious.  Some centres use it routinely and others never use it 
(Dahlberg et al., 1998).  In some patients the use of neoadjuvant chemoradiotherapy may not 
offer any significant benefit and indeed any benefit may be outweighed by the significant 
morbidity (Heald and Ryall, 1986).  The evidence base for SRT will be reviewed in more detail 
in section 1:5:3. 
1.5.1 Local Recurrence (LR) 
LR is a major problem in the treatment of rectal cancer. It is the end point by which surgery is 
judged, t is a cause of morbidity which can severely impair the quality of life and usually leads 
to death.  It often causes intractable pain, intestinal obstruction, perforation and septic 
complications (Camilleri-Brennan and Steele, 2001). Recurrence typically occurs within the 
first 2 years after primary surgery and without treatment is associated with an exceptionally 
poor prognosis (Heriot et al., 2008, Ogunbiyi et al., 1997). 
Local recurrence may arise as a result of involvement of the lateral/circumferential margin, the 
presence of distal mesorectal spread and involvement of the distal resection margin. 
Approximately 50% have pelvic disease or are associated with operable metastatic disease and 
so are potentially operable (McDermott et al., 1985, Rao et al., 1981, Pilipshen et al., 1984). 
There has been a significant reduction in local recurrence since the introduction and widespread 
use of total mesorectal excision (TME) and neoadjuvant treatments with figures reduced to 5-
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15 % compared to 30-40% previously (Kapiteijn et al., 2001, MacFarlane et al., 1993, Martling 
et al., 2000, Hansen et al., 2007, Wibe et al., 2002). 
The most important surgical factor is considered to be achieving an R0 resection, however it is 
clear there are other factors involved in this process and this thesis sets out to explore the 
significance of the factors that can be identified preoperatively on the prognosis of patients 
(Wiig et al., 2008, Heriot et al., 2008, Sagar and Pemberton, 1996, Boyle et al., 2005). 
A multicentre cohort study from Norway taking patients from 1986-1988 (prior to TME) 
showed that the estimated 5-year survival rate after diagnosis of local recurrence was 7.7 
percent, but a further prospective cohort study of 577 patients  showed 5-year survival rates of 
14.9 percent.   Of these patients 185 had undergone curative resections (32.1 %) 97 had an R0 
resection and 88 R1, with 5 year survival of 55 and 20 percent respectively.  This study 
confirmed that obtaining an R0 resection is the most important prognostive factor in treating 
recurrent rectal cancer (Hansen et al., 2007, Norstein and Silen, 1997). 
 Several studies have attempted to identify the risk factors for local recurrence in patients with 
colorectal cancer after curative resection (Obrand and Gordon, 1997, Malcolm et al., 1981, 
Kraemer et al., 2001, Read et al., 2002, Fujita et al., 2003, Olson et al., 1980, Phillips et al., 
1984, Quirke et al., 1986, Birbeck et al., 2002, Hermanek, 1991). The main factors identified 
are as follows: size of the primary, CRM involvement, location of the tumour (height from anal 
verge), EMVI, tumour differentiation, nodal status and extent of extramural spread). Yun et al. 
(2008) performed a retrospective review of 1838 patients who underwent curative resection. 
They identified that pathological T stage, N stage and lymphovascular invasion were all 
adverse risk factors for local recurrence (Yun et al., 2008). 
1.5.2 Surgery 
Transanal Endoscopic Microsurgery (TEM) 
This technique was first described in 1985 by Buess et al. (1985).  It is reserved for those 
lesions that are suitable for local excision (T1 lesions) thus requiring accurate staging to allow 
selection. Early rectal tumours may be locally excised by this technique with low morbidity and 
mortality (Bach et al., 2009, Cataldo et al., 2005). It is performed through a 40 mm operating 
rectoscope with carbon dioxide insufflation to obtain vision.  Operating instruments are 
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introduced through sleeves and the tumour is excised using bipolar diathermy.  The preparation 
and positioning is the same as for transanal excision.  TEM is usually reserved for tumours in 
the extra-peritoneal rectum due to the risk of perforation and technical difficulties.  This limits 
the technique to lesions up to 20 cm on the posterior wall, 15 cm laterally and 12 cm on the 
anterior wall. The most distal lesions can be unsuitable as it is difficult to maintain an adequate 
seal around the resectoscope and insufflation pressure is lost.  TEM can give a magnified view 
of the operating field, enabling precise excision of the tumour with a more accurate view of the 
oncologically safe margin.  Complications are infrequent but include bleeding, intraperitoneal 
perforation, fistula formation, incontinence and wound breakdown.  Local disc excision of the 
primary tumour with a margin of normal tissue allows preservation of the rectum however, 
there is the risk is of leaving behind microscopic lymph node metastases.  The probability of 
tumour spread to the mesorectal nodes and the rate of local failure can be estimated on the 
histopathological examination of the excised specimen (Bentrem et al., 2005, Endreseth et al., 
2005, Bach et al., 2009, Nascimbeni et al., 2002). Low risk lesions – pT1 Sm1 lesions without 
lymphovascular invasion and up to 3cm in diameter- have recurrence rates of <5% and require 
no further treatment (Bach et al., 2009). The majority of cases have a 10-30% risk of recurrence 
and a proportion will need conversion to radical TME surgery (Bach et al., 2009). 
A meta-analysis of the role of TEMS in excision of T1 rectal cancers compared to radical 
surgery was undertaken in 2011 looking at 397 patient outcomes. This demonstrated that 
TEMS was safer with lower morbidity, shorter hospital stay and no mortality. Although the 
recurrence rate was significantly higher in the TEMS group this did not translate to survival 
differences at 5 years (Wu et al., 2011). 
There are substantial variations in outcomes between the sub-groups of T1 tumours and Bach et 
al. (2009) looked at 487 patients from 21 centres in an attempt to stratify cases on their 
histopathology. Using a Cox regression model to analyse the factors most associated with local 
recurrence at 3 years.  They identified that the level of submucosal invasion (sm level) was a 
strong predictor of recurrence with sm2-3 showing similar recurrence rates to T2 lesions. Local 
recurrence rates were the lowest in pT1 sm 1 lesions without lymphovascular invasion if <3cm 
and were similar to radical surgery. 
 46 
It is known that the risk of nodal spread increases with the level of invasion (Saraste et al., 
2013, Yamamoto et al., 2004, Hida et al., 1999) and further intervention may be required if 
poor prognostic factors are present in the TEMS specimen.  Nevertheless, radical surgery 
following TEMS has been shown to be safe and to give similar oncological outcomes to those 
proceeding straight to primary surgery.  In a series of 105 patients undergoing TEM for T1 
rectal cancer the local recurrence rate was 6% for low risk T1 lesions and 39% in the high risk 
group.  If this high risk group then went onto definitive surgery the recurrence was reduced to 
6% (Borschitz et al., 2006). 
Whilst local excision alone may be curative for the majority of early tumours, a recurrence rate 
of 10-30% amongst the higher risk tumours is unacceptable.  At the time of writing there is no 
means to precisely identify the cases that are likely to recur following local excision. 
WHAT is the role for MRI in selecting this group of patients? 
Mesorectal Excision 
It is now accepted that optimal surgical technique involves total mesorectal excision (TME) 
(Heald, 1998).  Removal of the rectum and its draining lymph nodes as a distinct anatomical 
package has been shown to reduce local recurrence rates.  The surgery involves the use of sharp 
dissection under direct vision allowing complete excision of the tumour with its surrounding 
mesorectal envelope.  There is a layer of endopelvic fascia that encases the mesorectum and 
parietal endopelvic fascia over the sacrum.  By dissecting in this area, the technique allows 
preservation of the pelvic autonomic nerves, reducing the risk of urinary or sexual dysfunction. 
Radical surgery for rectal cancer has good results with low levels of local recurrence and good 
long term survival.  Lowest recurrence rates and best survival have been consistently reported 
with TME (Enker et al., 1997, den Dulk et al., 2008, MacFarlane et al., 1993, Sebag-
Montefiore et al., 2009, Heald et al., 1998).  However, the morbidity and mortality rates remain 
high and anorectal and genitourinary dysfunction, common (MacFarlane et al., 1993, Bryant et 
al., 2012, Akesson et al., 2012, Valenti et al., 2007). 
 47 
Local recurrence rates of 30-40% have been reported following “conventional” rectal surgery 
and the introduction of TME has certainly improved these figures with recurrence rates down to 
between 5-15% (Heald et al., 1998, Martling et al., 2000, Visser et al., 2007). 
1.5.3 Radiotherapy 
Adenocarcinoma of the rectum is radiosensitive. The first randomised trial investigating the use 
of radiotherapy was reported in 1959 (Stearns et al., 1959) and the benefit of radiotherapy 
administered pre or post operatively has been established in several randomised trials 
(Cedermark et al., 1995, Goldberg et al., 1994, Nesbakken et al., 2002, Gerard et al., 1988). 
Pre-operative radiation therapy decreases local recurrence and increases survival in patients 
with all stages of rectal cancer (Marsh et al., 1994, 1996, Kapiteijn et al., 2001, Sebag-
Montefiore et al., 2009). 
Only one trial has directly compared pre and post operative radiotherapy and this clearly 
showed that the former was superior in terms of local control and side effects (Frykholm et al., 
1993).  This was confirmed in a meta-analysis of 22 randomised trials, concluding that 
preoperative radiotherapy is superior to post operative radiotherapy in terms of cancer specific 
death and reduction of local recurrence (Kapiteijn et al., 2001, Colorectal Cancer Collaborative, 
2001). 
In the Dutch Colorectal Cancer Study, patients were randomised to the use of preoperative 
short-course radiation or surgery alone.  The local recurrence rate was significantly lower in the 
radiotherapy group, however no survival benefit could be demonstrated (Heald et al., 1998, 
Kapiteijn et al., 2001).  The conclusion concurred with previous reports that TME can 
significantly decrease the risk of local recurrence but that this effect was enhanced by the use of 
short term preoperative radiotherapy.  They demonstrated a significant benefit with 
preoperative radiotherapy in patients with TNM stage II and stage III disease.  However, 
individual surgeons have reported local recurrence rates in patients undergoing curative 
surgery, below 5%, using TME surgery without adjuvant therapy (Martling et al., 2000). 
The Stockholm TME teaching initiative showed a decrease of local recurrence from 15% to 6% 
in the group who underwent TME surgery combined with radiotherapy (Martling et al., 2000). 
Visser et al. (2007) showed a significant decrease in local recurrence and a non-significant 
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trend for improved relative survival at 5 years. Several randomised studies have found lower 
rates of local failure with preoperative radiotherapy than with surgery alone (Camma et al., 
2000).  The Swedish study alone demonstrated a survival advantage in patients with resectable 
rectal cancer given pre-operative radiotherapy.  This study randomised 1168 patients to surgery 
alone or following a 1-week course of radiotherapy and demonstrated an improved 5 year local 
recurrence rate (23% to 9%) and improved 5 year survival (58% from 48%),(1997).  However, 
this trial was conducted prior to the widespread use of TME surgery.  A meta-analysis in 2000, 
of patients with resectable rectal cancer concluded that preoperative radiotherapy significantly 
improved overall and cancer-specific survival compared with surgery alone (Camma et al., 
2000, Kapiteijn et al., 2001). The magnitude of the benefit is relatively small and criteria are 
needed to identify patients most likely to benefit from adjuvant radiotherapy. 
 CR07 described a benefit of preoperative short course radiotherapy over selective post 
operative chemoradiotherapy (Sebag-Montefiore et al., 2009).  Of note, not all patients in this 
study were staged preoperatively with MRI. 
With the significant reduction in local recurrence, survival of patients with curative resection 
becomes dependent on the presence of systemic disease.  Radiation therapy is considered to be 
beneficial only in local control and is thought to have no effect on the prevention of systemic 
spread. Improved survival rates will depend on the use of chemotherapy.  Overall in the 
modern “TME” era the benefit is relatively small and criteria are needed to identify those 
patients most likely to gain from neoadjuvant radiotherapy. An unselective approach would 
mean some patients would be unnecessarily subjected to a treatment with significant morbidity.  
This can include rectal toxicity, urinary and sexual dysfunction.  Impotence rates of 5-92% 
have been reported following radiotherapy for rectal cancer.  Studies of patients from the 
Norwegian Rectal Cancer Registry collected data on patients investigating the late side effects 
of rectal cancer, one looked specifically for the side effects in women with a questionnaire to 
patients that demonstrated increased risk of sexual dysfunction in the irradiated group and the 
other study noted there were similar long term effects on sexual function in the male population 
(Bruheim et al., 2010). 
Several studies have highlighted the considerable long term effects on anorectal function, in 
particular bowel frequency and incontinence associated with a decreased quality of life, both in 
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short course and long course chemoradiotherapy (Braendengen et al., 2011, Ho et al., 2011, 
Peeters et al., 2005, Birgisson et al., 2005, Birgisson et al., 2007, Dahlberg et al., 1998, Pollack 
et al., 2006, Frykholm et al., 1993, Holm et al., 1996). This was summarized in a review article 
by Birgison in Sweden.  This paper presented a comprehensive overview of the literature. Most 
of the information was obtained from randomized controlled trials comparing preoperative 
short course therapy with surgery alone. This study included at least 30 randomised trials but 
only a few had reported the late adverse effects. They summarized the numerous late adverse 
effects due to RT for rectal cancer as: gastrointestinal disorders, neurological problems, anal, 
rectal, urinary and sexual dysfunction, pelvic or hip fractures, thromboembolic diseases and 
secondary cancers. They did note that fewer adverse effects were noted in later studies which 
reflects the newer improved irradiation techniques and smaller irradiated volumes (Birgisson et 
al., 2007). 
This emphasizes the need to select accurately those patients who would actually benefit from 
the treatment and allow others to proceed with primary surgery (Bakx et al., 2006, Peeters et 
al., 2005, Bruheim et al., 2010). 
1.5.4 Chemoradiotherapy 
Concomitant chemotherapy has been used to augment the local response by radiosensitising the 
tumour within the pelvis. 
Locally advanced tumours (those reaching to and beyond the mesorectal fascia) and node-
positive tumours will not be curatively resectable using TME.  Long course neoadjuvant 
therapy has emerged as the preferential treatment of patients with anticipated involved CRM on 
MRI in order to downstage/downsize the tumour and to obtain a tumour free resection margin 
(Bosset et al., 2005, Ruo et al., 2002). 
Large randomised trials have shown that neo-adjuvant therapy improves local tumour control 
even further regardless of optimised surgical techniques (Kapiteijn et al., 2001). 
There is also increasing evidence that the degree of response to treatment has an overall effect 
on the prognosis of the patient. In those patients with a marked response to preoperative 
chemoradiotherapy, the long term outcome is more favourable (Chua et al., 2010). In contrast 
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those patients that fail to respond to one treatment protocol should be identified early on so that 
treatment can be modified (Sauer et al., 2004).  
Preliminary results of the EORTC Trial 22921 indicated that the addition of chemotherapy to 
preoperative radiotherapy induced down-sizing, downstaging, and significant changes in 
histological characteristics of rectal tumours. Long term results with 10.4 years median follow-
up showed that 5-FU (fluorouracil) based adjuvant chemotherapy after preoperative chemo-
radiotherapy for patients with cT3-resectable and T4 M0 rectal cancer did not improve survival 
or disease-free survival (Bosset et al., 2005, Bosset et al., 2014).  The Authors suggest that new 
treatment strategies incorporating neoadjuvant chemotherapy are required.  Would the 
outcomes vary if the patients had been better stratified for risk? 
The published results of the EXPERT study have shown intensification of systemic therapy 
with neoadjuvant combination chemotherapy before standard treatment, is feasible in poor-risk 
potentially operable rectal cancer, with acceptable safety and promising long-term outcomes 
(Pahlman and Glimelius, 1990, Chua et al., 2010). 
1.5.5 Pre or Post Operative Treatment? 
In the United States there had been a preference for post operative adjuvant therapy once the 
stage has been confirmed with histopathology.  However, in 2001 Frykholm et al. (2001) 
published a small randomized controlled trial of patients with fixed rectal cancers who were 
randomized to preoperative radiotherapy or chemoradiotherapy. This trial showed a significant 
improvement in resectability and reduction in local failure with preoperative CRT (Frykholm et 
al., 2001). 
Sauer et al. (2004) prospectively randomized a group of patients into preoperative versus 
postoperative chemoradiotherapy.  They found a marked decrease in five year incidence of 
local relapse (6 vs 13%) and a decrease in toxic effects with preoperative therapy.  There was 
no improvement in survival (Sauer et al., 2004).  This study did not use MRI to stage patients.  
The patients were staged by EUS and CT to rule out TNM stage 1 tumours and distant 
metastases. Therefore, no assessment was made of the CRM or other prognostic features.  
Eighteen percent of patients in the postoperative treatment group, determined preoperatively to 
have tumour penetration through the bowel wall or lymph node metastases were found to be 
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overstaged on pathological examination.  This German rectal cancer study recommended 
preoperative chemoradiotherapy as the preferred treatment for locally advanced rectal cancer. 
Preoperative radiotherapy has also been shown to be more effective than postoperative 
treatment (Strassburg et al., 2007). 
 The Polish trial comparing short term preoperative DXT to chemoradiation in patients with 
locally advanced rectal cancer showed no difference in local recurrence risk, despite the fact 
that there was more downsizing after prolonged treatment (BUJKO 2004 radiotherapy). 
 The EORTC trial (Bosset et al., 2014),  was a 4 arm randomized trial to investigate the value 
of preoperative chemoradiotherapy vrs preoperative radiotherapy alone and the value of 
adjuvant chemotherapy versus none, with respect to overall and progression free survival in 
patients with potentially resectable T3-T4 tumours.  Disease staging was by clinical 
examination, rigid sigmoidoscopy, CXR and abdominopelvic CT, EUS was optional. This 
study concluded that only patients who were downstaged by preoperative chemoradiotherapy 
would benefit from adjuvant Chemotherapy.  They suggested that there was a group of patients 
with good prognostic factors who responded well to both pre and post operative therapy, thus 
highlighting the need to clearly identify this group. 
Gunderson et al. (2008) performed a pooled analysis of phase III North American trials.  He 
determined three risk groups, intermediate (T1-2N1, T3N0), moderately high (T1-2N2, T3 N1, 
T4N0) and high (T3N2, T4N1, T4N2).  Patients with a single high risk factor were shown to 
have better OS, and DFS and disease control compared to patients with more than one.  This 
study concluded that those patients found to be in the moderate or high risk group after surgery 
should have adjuvant chemotherapy but that for those with intermediate stage disease the use of 
preoperative chemoradiotherapy in all patients may be excessive. 
Differences in different staging techniques hinder adequate comparison of trial results and the 
majority of the trials used clinical staging or EUS.  None of these trials used standardized MRI 
to accurately stage patients preoperatively. 
Neoadjuvant therapy has advantages in that there is; 
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 greater radiosensitivity of the tumour cells – the sensitivity to radiation is diminished 
post operatively as the cells on the tumour bed are poorly oxygenated. 
 increased rate of complete tumour resection through tumour regression (downsizing and 
down staging) 
 increased rate of sphincter preserving resections, 
 reduced risk of intra-operative tumour cell dissemination – if the tumour bed was 
sterilised preoperatively this risk would be lowered, 
 lower recurrence rate,  
 improved compliance and 
 reduced acute and chronic toxicity - small bowel is less at risk preoperatively as it 
should be out of the pelvis. 
To offset the advantages, there is the possibility to overtreat patients and this therapy is not 
without morbidity.  Long-term bowel dysfunction is seen more frequently in irradiated patients 
than in patients undergoing TME alone (Marijnen et al., 2002). 
There have been several advances over recent years in the treatment of metastatic disease both 
with chemotherapy and with surgical resection for metastases.  Combination chemotherapy 
with oxaliplatin and irinotecan and the targeted agents e.g. Bevacizumab which is a vascular 
endothelial growth factor specific antibody that has a direct and rapid antivascular effect on 
human tumours (Willett et al., 2004), and cetuximab (epidermal growth factor receptor (EGFR) 
inhibitor).  It may well be that this will provide improved treatment options for certain patients.  
This again highlights the need for an accurate preoperative staging system. 
1.6 Special Considerations 
1.6.1 The Prognostic inhomogeneity of T3 Carcinomas 
As discussed earlier, numerous studies have outlined the inhomogeneity of T3 tumours 
(Nesbakken et al., 2002, Merkel et al., 2001).  Patients in the ERCRE series with rectal 
carcinomas invading beyond the border of the muscularis propria of 5mm or less had a more 
favourable prognosis than those with invasion beyond 5mm.  This applies both to the rate of 
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locoregional recurrence and to cancer-related survival (Marr et al., 2005, Jatzko et al., 1999).  
Patients with T3 tumours (80% of rectal tumours) show the widest range in survival.   
Merkel et al. (2001) showed significant differences in survival for the T3 group of tumours 
depending on the degree of extramural spread.  The 5 year survival rates were 85.4% for pT3a 
tumours reducing to 54.1% for pT3b tumours, regardless of lymph node involvement.  They 
concluded that the subdivision of pT3 tumours allows those patients who would not benefit 
from adjuvant treatment (i.e. pT3a NO) to be selected out. This thesis explores the subdivision 
of T3 tumours on MRI staging. 
1.6.2 Low Rectal Cancer 
It has been noted in several studies that there is a difference in outcome (local recurrence and 
survival) between patients with high and low rectal cancers with the latter  having a much 
worse prognosis (Faerden et al., 2005, Heald et al., 1997, Enker et al., 1997, Wibe et al., 2004, 
Marr et al., 2005). Patients treated by abdominoperineal excision (APE) have a higher rate of 
CRM involvement, a higher local recurrence and a poorer prognosis than those undergoing 
anterior resection (AR). The frequency of CRM involvement in the APE specimens is related to 
the removal of less tissue at the level of the tumour in APE and wherever possible a more 
radical operation should be considered for all low rectal cancer tumours (Hida et al., 1999). 
Several studies have demonstrated that MR imaging of anal sphincter infiltration is possible.  
Urban et al. (2000) undertook a prospective study of 61 patients with low rectal or middle third 
tumours and demonstrated a specificity of 98% and sensitivity of 100% in detecting the 
relationship of the tumour to the sphincter muscles (Cawthorn et al., 1990, Urban et al., 2000). 
Peschaud et al. (2005) warn that MRI can overestimate CRM involvement in low and anterior 
tumours and so tumour location should be considered as a stratification factor for future clinical 
trials  regarding the value of MRI in the management of rectal cancer (Sengul et al., 2006, 
Peschaud et al., 2005, Salerno et al., 2006). 
It is has been shown that lower rectal cancers have increased metastases to iliac lymph nodes 
compared with upper third rectal cancers, 20% vrs 8% for T3 tumours (Hida et al., 1999, Kim 
et al., 2003). 
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1.6.3 Mucinous Tumours 
Mucinous adenocarcinomas have an abundance of extracellular mucin (>50%), and are 
associated with a poor prognosis, especially when located in the rectum (Sengul et al., 2006, 
Salerno et al., 2006).  MRI can readily identify these tumours (Brown et al., 2004b,Kim et al. 
2003] and studies have shown that they have a lower response to pre-operative chemo-
radiotherapy (Brown et al., 2004). 
Summary 
In this background review it has been established that rectal cancer poses several challenges to 
the MDT.  The surgery is demanding, particularly in male patients with a large tumour and a 
narrow pelvis, and should only be performed by surgeons adequately trained in TME surgery.  
It is important that all patients should have a pre-operative MRI scan to accurately stage the 
tumour and then be discussed in the context of a multi-disciplinary meeting to decide upon the 
most appropriate management. 
There is no doubt that for some patients pre operative therapy will result in an improved 
outcome.  There are still, however, a large group of patients who fall right in the middle of 
traditional staging categories and it is clear that there are a number who are undergoing more 
intensive therapy than is required for their tumour.  Preoperative radiotherapy does have a 
significant morbidity and indeed mortality and to allow patients with good prognosis to avoid 
this treatment would be of great benefit.  By developing this pre operative staging system we 
hope to enable disease specific therapy to be instituted. 
To date MRI-based staging has been focused primarily on the assessment of the potential 
CRM, with downstaging therapies offered to patients with threatened or involved margins. This 
has led to a successful reduction in the proportion of patients having R1 resections, and thereby 
has reduced the rates of local recurrence.   Detailed preoperative staging using high resolution 
MRI enables the selection of patients with other poor prognostic features that may benefit from 
preoperative therapy for tumour regression. 
Unfortunately, however, patients continue to develop distant metastases, and this is the 
commonest cause of death for patients with colorectal cancer. Post-operative adjuvant 
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chemotherapy regimens have certainly increased disease-free survival and reduced overall 
mortality, but not by much. There are compelling oncological theories why giving 
chemotherapy prior to surgery might be even more beneficial, but such a strategy is unlikely to 
gain widespread popularity until the value has been proven in randomised controlled clinical 
trials. The importance of developing pre-operative staging methods that might permit reliable 
identification of poor-prognosis colorectal tumours is paramount. Until the pre-operative 
staging has been shown to be reliable, it is not appropriate to initiate a pre-operative 
chemotherapy trial. 
1.7 Conclusions 
This thesis sets out to explore the prognostic significance of the factors that can be identified in 
the preoperative setting with the aim of optimising treatment for patients at high risk of disease 
recurrence and minimising morbidity for the patients in which this is of no benefit.  
The main questions arising from this review are: 
 Can MRI staging demonstrate preoperative prognostic features? 
 Which MRI features are important in prognosis? 
 What margin is best able to predict prognosis based on MRI assessment? 
 Can MRI be used to select patients that would be suitable for TEMS?  
 How are patients best selected for the different treatment groups?  
 Can MRI identify those at most risk of local or distant recurrence? 
1.8 Can MRI identify the poor prognosis patients with T3 tumours? Aims 
The overriding aim of this work is to investigate in greater detail the factors that influence 
prognosis for patients over and above the well recognised pathological factors. How can 
patients possibly be accurately selected for the different treatment groups if only the post 
operative histology to identify those at most risk of recurrence. What are the factors that give 
such wide ranging outcomes for patients grouped in the same pathological stages? 
This thesis is the first study linking MRI identification of prognostic features and outcome.  It 
is hoped that as a result of this work the multidisciplinary teams will be able to institute disease 
specific therapy to enable better targeting of both treatment and follow up systems.  
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1.8.1 Chapter Aims 
Chapter 2: Description of the methodology employed. 
Chapter 3: The aim of this study in the MERCURY cohort was to evaluate the effectiveness of 
MRI in stratifying patients with early rectal tumours and to assess whether closer analysis of 
the depth of invasion for these early tumours will enable more accurate preoperative staging.  
Chapter 4: This chapter set out to investigate the outcomes in patients identified preoperatively 
has having low risk tumours. Is it correct to select some patients to proceed to surgery alone? 
Chapter 5: The aim of this study was to assess which cut-off (1, 2 or 5 mm) was the best 
predictor of local recurrence based on preoperative MRI assessment of the circumferential 
resection margin (CRM).  Can a margin of 1mm accurately predict the circumferential margin? 
Chapter 6: The aim of this study was to assess the importance of the preoperative MRI 
assessment of circumferential resection margin in rectal cancer in terms of disease free survival 
and local recurrence.  Does preoperative identification of this well known pathological factor 
influence outcome despite the treatment given? 
Chapter 7: This study investigated which of the preoperative factors hold the most significant 
influence on outcome and what combination carries the worst prognosis? What are the factors 
involved in promoting disease recurrence outside of the traditional pathological factors. 
By exploring the outcomes based upon the preoperative imaging this work has enabled 
identification of the important radiological markers of poor disease with the hope that this can 
produce a more tailored, disease specific therapy for patients with rectal cancer. 
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Chapter 2 - General Methods 
In this chapter, an overview of the materials and methods that were employed for evaluating the 
aims of the thesis are presented. Further details particular to the specific aims of each part of 
the study are furnished in the individual chapters. The design of the radiological proforma, the 
follow-up database, data collection and data interpretation, were all undertaken personally 
except in specific instances, where help was rendered by other individuals.  The image 
interpretations were performed by the individual radiologists with myself observing and aiding 
in recording the scores. Their valuable and specific contributions of these individuals are cited 
in the chapters and also in the acknowledgments.  
The Original MERCURY study was undertaken by the radiologists, pathologists, surgeons, and 
nurse specialists who were members of the MERCURY Study Group and were responsible for 
conception and design of the study and collection of data (see bmj.com for details). The 
following hospitals took part in this study: Pelican Cancer Foundation, Royal Marsden 
Hospital; St Helier NHS Trust; Mayday University Hospital; North Hampshire Hospital; Leeds 
Hospitals Teaching Hospitals, Leeds General Infirmary; St James’s University Hospital; 
Norwegian Radium Hospital; Frimley Park Hospital; Ashford St Peters Hospital; Krankenhaus 
im Friedrichshain; Llandough Hospital; Karolinska University Institute. The Pelican Cancer 
Foundation supported the trial throughout. 
2.1 Patients and Materials 
2.1.1 Data Collection 
The patients involved in this study were taken from the MERCURY rectal cancer study.  
Patients presenting consecutively with biopsy proven rectal adenocarcinoma were included in 
the study.  Patients were taken from 11 hospitals in European centres from 2002-2003.  Patients 
had to be over 18 years of age and able to give written informed consent. 
Patients were excluded if they were pregnant or had a previous history of pelvic malignancy, 
pelvic radiotherapy, or pelvic floor surgery for faecal incontinence or rectal prolapse. Patients 
were also excluded if they were unable to undergo magnetic resonance imaging because of 
metal fragments or implanted metal devices within the body.  
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374 patients who underwent surgical resection for a proven adenocarcinoma in the MERCURY 
study have consented to clinical follow-up as part of the ongoing MERCURY follow-up project 
and were included in this study.  
Imaging workshops were held before the study started to ensure standardisation of scan 
techniques, image interpretation, and reporting.  A dedicated proforma was constructed to 
allow collection of all the relevant radiological prognostic factors.  
Eleven of the original radiologists (with 5-20 years experience in gastrointestinal and magnetic 
resonance imaging) agreed to take part in the follow up. All scans were reported using the 
dedicated proforma (see Table 2.1).  This data was then entered into a database to allow 
correlation with clinical follow-up. 
2.1.2 Imaging Technique 
Pre-operative MRI scans – all patients underwent 1.5 T MRI staging pre-operatively. These 
scans were then anonymised and stored on DICOM format for analysis by participating 
radiologists using the dedicated proforma.  These criteria/imaging characteristics were 
validated against pathological data and previously reported studies. 
The protocol employed a thin 3mm section turbo spin-echo T2-weighted technique using a 
surface pelvic phased array coil. For all tumours, scans were performed perpendicular to the 
long axis of the tumour. Coronal imaging was performed for all tumours arising at, or below, 
the levator muscle origins. Images were stored in DICOM format on CD.  A 1.0T/1.5T system 
is used with phased array coils. These coils maintain the high signal required but will obtain 
greater coverage than the endorectal coils.  For a 1.5T magnetic resonance imaging scanner, 
four sequences were used: 
1. After a coronal localiser, sagittal scans were required from inner pelvic sidewall to sidewall 
using a 24cm field of view, 5mm contiguous/interleaved slices (no gap), TR>2500 and <5000, 
TR=85. These acquisitions were used to plan thin section oblique axial images. 
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2. Axial T2FSE acquisitions of the anatomic pelvis by using a 24cm field of view, a 
5millimetre contiguous section thickness, 4000/85, 512 x 256 matrix, an echo train length of 
eight, no fat saturation, a 32kHz bandwidth, and two signals acquisitions (2NEX). 
3. The sagittal T2 weighted images obtained were then used to plan T2-weighted thin-section 
axial images through the rectal cancer and adjacent peri-rectal tissues. These images were 
performed perpendicular to the long-axis of the rectum. These were obtained by using a 16cm 
field of view, a 3mm section thickness, no intersection gap, 4000/85, a 256 x 256 matrix, an 
echo train length of eight, no fat saturation, a 32kHz bandwidth and four acquisitions (4 NEX). 
4. For low tumours these sequences were repeated with imaging in the coronal plane. For a 
1.0T magnetic resonance imaging Scanner, the sequences were similar with a modification of 
the imaging parameters to obtain an adequate SNR. The high resolution images are obtained 
with 20cm field of view, 3mm section thickness, no intersection gap, a 256 x 256 matrix, a TR 
>2500 (<5000), and a TE > 80.For patients with low rectal cancers, high spatial resolution 
coronal imaging will optimally show the levator muscles, the sphincter complex, the 
intersphincteric plane and the relationship to the rectal wall. 
No bowel preparation, air insufflation or intravenous anti-spasmodic agents were used.   
2.1.3 Interpreting the Images 
The radiologist was first asked to describe the height of the tumour, ideally from the anal verge 
as this is a useful reference point for surgeons (see proforma – Table 2.1). 
Traditionally the rectum has been divided into thirds, as outcomes appear to relate to the height 
of the tumour: 
Upper - the lowest edge of the tumour being above 10 cm from the anal verge.  The anterior 
wall of the upper rectum is covered by the peritoneal reflection – knowledge with regards to the 
position of the tumour at this site must facilitate a careful search for peritoneal perforation of 
these tumours due to the importance of trans-coelomic spread (Salerno et al., 2009, Salerno et 
al., 2006, Shepherd et al., 1995). 
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Middle – lowest point between 5cm and 10cm.  At this point the rectum is entirely encircled by 
mesorectal fat and the vast majority of patients with tumours at this level will undergo a total 
mesorectal excision (TME) with sphincter sparing surgery (Brown et al., 2004). 
Lower – tumour below 5cm from the anal verge, the area of rectum and mesorectum below the 
origin of the levators where the mesorectum tapers sharply, making interpretation at this level 
more challenging. 
T Stage 
The tumour was then given a T stage. 
Noting the morphological description was helpful in identifying the invasive portion of the 
tumour thereby indicating the area that giving rise to most concern. 
MRI is able to interpret the relationship of the tumour to the surrounding structures and the 
bowel wall. These layers can usually be clearly identified (see figures 2.1-2.7). 
On T2-weighted images, the muscularis mucosal layer is demonstrated as a fine low signal 
intensity line with the thicker, high signal submucosal layer seen beneath this. 
The muscularis propria can often be depicted as two distinct layers -the inner circular layer and 
the outer longitudinal layer. The outer muscle layer has an irregular, grooved appearance with 
interruptions due to vessels entering the rectal wall. 
The perirectal fat appears as high signal surrounding the low signal of the muscularis propria 
and contains signal void vessels. The mesorectal fascia is seen as a fine low signal layer 
enveloping the perirectal fat and rectum and it is this layer that defines the surgical excision 
plane in TME anterior resections (Brown et al., 2004). 
MRI diagnosis of a T3 lesion is based upon the presence of tumour signal extending into the 
perirectal fat with a broad based bulging or nodular configuration in continuity with the 
intramural portion of the tumour. It is important to note the continuity with the intramural 
component as there can be disruption to the outer longitudinal layer as a result of small vessels 
penetrating the wall, not necessarily invaded by tumour. 
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Figure 2.1: T staging MRI (T2 weighted axial image) and corresponding line diagram. 
The tumour has effaced the submucosal layer which can be seen immediately adjacent to the 
tumour (see arrow). However the muscularis propria comprising the inner and outer circular 
longitudinal muscle layers are seen fully preserved.  
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Figure 2.2: A T2 weighted axial MRI showing an annular tumour with invasion entering 
the outer muscle layer but not extending beyond this, i.e. T2 

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Figure 2.3: A T2 weighted axial MRI showing an annular tumour with extension less than 
1mm beyond the muscle coat (see arrow) – T3a 
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Figure 2.4: A T2 weighted image with posterior annular tumour where the invasive 
portion at 6 o’clock demonstrates extension <5mm beyond the outer muscular coat. (T3b) 
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Figure 2.5: A T2-weighted coronal MR image of a low rectal cancer demonstrating 
invasion of the intersphincteric plane on the left. 
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Figure 2.6: Diagram representing the different levels of the anorectum 
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Figure 2.7: A T2 weighted axial image demonstrating extramural venous invasion with 
extension into the lateral rectal vein. 
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Figure 2.8: A T2 weighted axial image showing a benign lymph node 
This is smooth bordered with homogenous signal intensity (measuring 7mm). 
The benign nature of this node was confirmed on histopathology. 
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Figure 2.9: A T2 weighted axial image showing an obviously malignant node with 
irregular border and mixed signal intensity. 

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Figure 2.10: Thin section T2 weighted axial MR Images of a rectal cancer. 

a – A T4 invasive tumour with extension                b – The mesorectal fascia is shown in 
 through the peritoneal reflection.   white arrows. 

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strategy to reduce the likelihood of an R1 resection. Treatment options included extending the 
surgical resection to remove structures beyond the mesorectal fascia enbloc, short course (5×5 
Gy) radiotherapy, long course radiotherapy or chemoradiotherapy. 
2.1.8 Histopathological Assessment 
Sixteen specialist gastrointestinal histopathologists (with 5-25 years’ experience) reported the 
original specimens. Pathology workshops were held before the study to standardise 
pathological examinations and naked eye and microscopic assessment of specimens.  This 
information has been compiled onto a dedicated database allowing collation of all the follow-
up data. 
2.1.9 Surgical Intervention 
Prospective data has been collected for all patients regarding the precise nature of the surgery 
and post operative treatment. 
2.1.10 Follow-up 
Patient records were obtained retrospectively to collect the following data for all patients:  
disease relapse, sites and timing of disease relapse, treatment for relapse and survival at 5 years. 
This data was entered onto an Excel spreadsheet to allow statistical calculations. 
2.1.11 Statistics 
The Statistics methods are described in more detail for each individual chapter. In general, the 
5 yr survival rates were calculated for the individual radiological prognostic markers. Chi-
squared analyses were used to calculate which differences were statistically significant, then all 
variables were entered into the Cox stepwise proportional hazards model, using sequential steps 
for multivariate analysis.   
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Table 2.1: Recording findings in rectal cancer 
Patient Name Date: 
Date of Birth Hospital Number 
Exam performed elsewhere Yes No If yes, where? 
Exam technically satisfactory (3 mm) Yes No 
Image quality Optimal Sub-Optimal 
Pathology identified Yes No 
Has the patient received radiotherapy? Yes No 
Has the patient had a previous rectal MRI? Yes No 
If Yes, date of previous examination 
Morphological description of tumour: 
e.g. polypoidal, annular, ulcerating. 
Site of invasive border, nature of invasive border e.g. smooth, nodular infiltrating. 
Mucinous tumour? 
Nodal spread 
No visible nodes = N0 
Homogeneous signal intensity smooth bordered node = N0 
1–3: Mixed signal intensity or irregular bordered lymph node or tumour deposit = N1 
4 or more: Mixed signal intensity or irregularly bordered node or tumour deposit = N2 
T staging 
Tumour not seen (Tx) Invades submucosa (T1) 
Invades muscularis propria (T2) Beyond muscularis propria < 1 mm (T3a) 
Beyond muscularis propria 1–5 mm (T3b) Beyond muscularis propria > 5–15 mm (T3c) 
Beyond muscularis propria > 15 mm (T3d) Perforation of peritoneal covering (T4b) 
Tumour invasion into adjacent organ (T4a) 
Maximum depth of extramural spread beyond muscularis 
propria______________(mm) 
Extramural venous invasion 
No tumour signal in vessels 
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Tumour signal intensity expanding small non-characterisable veins 
Tumour signal intensity expanding large anatomical veins (e.g., superior rectal vein) 
Potential Circumferential Margins (above distal levator insertion) 
Measure minimum distance of: 
Main tumour to mesorectal fascia 
Malignant lymph nodes or tumour deposit 
EMVI 
CRM status 
Distance to mesorectal fascia ≤ 1 mm = potential CRM involved 
Distance to mesorectal fascia > 1 mm = potential CRM clear 
Staging tumours at/below the distal levator insertion 
1. Tumour on MRI images appears confined to bowel wall but not 
through full thickness (with intact outer muscle coat) 
2. Tumour on MRI replaces the muscle coat but does not extend into the intersphincteric 
plane 
3. Tumour on MRI invading into the intersphincteric plane 
4. Tumour invading into external anal sphincter 
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Table 2.2: Specific staging system employed 
Parameter  TSE/FSE 
Standard 5mm sagittal 
and axial scans 
High resolution 
oblique axial and 
coronal scans for low 
tumours 
TR 5080 (sag) 5362 
  4018 (ax)   
TE 132 (sag) 100 
  80 (ax)   
No of slices 23 (20 ax) 16 
Thickness/gap 3 (sag) 3/0.3 
  5/1 (ax)   
Interleaved No Yes 
ETL 23 16 
Matrix in phase direction 512   
Matrix in phase encoding   256 
Phase encoding direction AP FH 
Field of view(mm) 250 160 
Phase 250   
Frequency 250   
No of acquisitions 3 (sag) 6 
 2 (ax)   
Flow compensation Yes   
Sat bands Anterior/superior None 
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Chapter 3 - The Ability of MRI to Identify Early T Stage 
Tumours 
Aims: The detection of early rectal cancer is on the increase since the introduction of bowel 
cancer screening in 2006.  The aim of this study in the MERCURY cohort was to evaluate the 
effectiveness of MRI in stratifying patients with early rectal tumours and to assess whether 
closer analysis of the depth of invasion for these early tumours will enable more accurate 
preoperative staging. 
Methods: A cohort of patients was collected from the MERCURY Study. A single observer 
scored a total of 105 patients, looking in particular at depth of invasion. All early tumours with 
histopathological measurements of extramural depth (T1, T2, and T3a) and preoperative MRI 
were included in this analysis.  
Results: Using a cut off of 3 mm (thickness of muscularis propria visible at outer border) to 
identify a tumour that is not through the bowel wall, gives a sensitivity of 44.1% and a 
specificity of 86.5%. 
Of the tumours that were pT1 on histopathology, MRI identified 12/24 as either T1 or T1/2 
(50%). Of the pT3a tumours, MRI identified 3 of these tumours as being T1 or T1/2 (3/36) with 
33 being identified as T2 or greater. When the MRI determines a T1/T2 tumour, the proportion 
of pT2 compared with pT1 increases since the MRI shows tumour effacing the full thickness of 
the submucosa and therefore the likelihood of early T2 infiltration is greater.   If MRI stages 
these tumours as T1N0 then the prediction of node negative status is 13/16 (81% However with 
increasing depths of tumour invasion visualised on MRI the risk of nodal involvement 
increases. So that MRI T1/T2 or T2 N0 is associated with a nodal involvement rate of 14/39 
(36%). 
Conclusion: The majority of trials regarding TEMS call for a more reliable preoperative 
staging technique and this study suggests that currently MRI should be used only as an adjunct 
to other techniques in this particular setting. 
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3.1 Introduction 
Early rectal cancer (ERC) is defined as invasive adenocarcinoma spreading into, but not 
beyond, the submucosa, that is a T1 tumour in the tumour node metastasis (TNM) classification 
(Taylor et al., 2008, Sobin and Wittekind, 1997). These tumours have a smaller chance of 
metastasizing to local lymph nodes than adenocarcinoma invading deeper into the submucosa 
owing to the paucity of lymphatics within colorectal mucosa (Nascimbeni et al., 2002, 
Blumberg et al., 1999, Brodsky et al., 1992). It is recognised that, amongst these, the most 
superficial T1 tumours have the least chance of metastasizing to local lymph nodes compared 
with the more deeply invading T1 tumours where the rich lymphatic and venous plexuses 
within the submucosa provide a mechanism for tumour spread beyond the rectum.  Currently 
only about 10% of patients presenting with rectal cancer are diagnosed with early disease, 
however, a greater proportion of rectal tumours are being uncovered at an earlier stage and this 
is likely to continue following the start of the UK screening programme (Atkin et al., 2002, 
Jepson et al., 2005, McClements et al., 2012, Robb et al., 2013, Weller et al., 2007).  Therefore, 
greater emphasis is being placed on treatment options that do not involve radical surgery and 
the possibility of a stoma. 
The gold standard for rectal cancer surgery is TME which enables the primary tumour and its 
draining lymph nodes to be excised in a single package and the procedure has been accredited 
with the near elimination of local recurrence in the pelvis. However even radical TME 
resection of pT1N0 disease does not absolutely guarantee a cure and recurrence rates of 1.7 
percent have been seen in this group (Peeters et al., 2007). 
In selecting patients for local excision, it is currently understood that T1 sm1/sm2 can be safely 
removed without further therapy since the likelihood of local relapse and tumour recurrence is 
low in these patients (Bach, 2009, Bach et al., 2009). However, it is considered that other 
patients with T1 and T2 tumours may, after careful selection, be suitable for local excision by 
the TEMS technique. Since the current gold standard for such patients is TME surgery, this 
should only be undertaken in the context of a clinical trial.  
The NCRI trial will be recruiting MRI T1/T2 N0 tumours and patients will be randomised 
between radical TME surgery versus TEMS procedure with short course radiotherapy.  In 
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assessing early rectal cancer radiologically it is important to recognize the morphologic features 
and the anatomic margins that need to be identified if the tumour is to be considered for local 
excision.  The ability to precisely T stage tumour depth within and beyond the rectal wall is 
reliant on depiction of the intermediate signal intensity tumour against low signal intensity 
muscularis propria. Accurate staging is dependent upon recognizing and understanding the 
patterns of spread. Tumours are either polypoidal with a clear stalk, or flat/sessile polyps with a 
central depression that forms the invasive border. 
The hypothesis in this study from the MERCURY group was that careful assessment of the 
degree of preservation of muscularis, deep to the invasive border of the tumour may be used as 
an adjunct to traditional staging assessment of the T stage.  
Local excision involves removing a full-thickness portion of the rectum containing tumour with 
circumferential 1 cm margins.  For mid to distal rectal tumours, this is classically performed as 
a transanal excision, whilst more proximal tumours can be approached with transanal 
endoscopic microsurgery.   
Since the depth of tumour penetration through the rectal wall directly correlates with the risk of 
nodal metastases  and therefore local recurrence (Nascimbeni et al., 2002)(Tables 3.1 and 3.2) 
the proponents of local excision have developed the following criteria for tumours amenable to 
local excision: 
(a) Early T stage (T1 or T2) N0 M0 
(b) Low grade tumours without lymphovascular invasion 
(c) Less than 4cm in size 
(d) Less than 40% rectal wall circumference 
(e) Less than 10cm from the anal verge (Diaz-Gonzalez et al., 2007) 
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Table 3.1: Risk of nodal involvement by TNM tumour stage 
 T1 T2 T3 T4 
 
 
0-12 12-28 36-66 53-79 
 
 
Table 3.2: Risk of nodal metastasis on SM level   
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Figure 3.1: Classification of tumours 
Tumours are divided into SM1, invasion of the upper third of the submucosa, Sm2, of the 
middle third and SM3 of the lower third. 
 
 
An American retrospective review of 7,543 colorectal cancers found that 650 (8.6%) were T1 
adenocarcinomas and of these 353 patients had a sessile T1 adenocarcinoma removed via 
surgical resection. Twenty percent were found to be Sm1, 34% were Sm2 and 43% were Sm3. 
lymph node positivity was 3% for Sm1, 8% for Sm2 and 23% for Sm3 (Nascimbeni et al., 
2002). 
The aims of this study were to assess imaging criteria that could enable more accurate 
discrimination between T1, T2 and T3a tumours.  
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3.2 Materials and Methods 
A cohort of patients was collected from the MERCURY Study and reviewed by a single 
reviewer. The technique for acquisition of the scans has previously been described. Complete 
digital images were available on these patients.  
For the purposes of this analysis, all histopathological tumours with less than T3a disease that 
had undergone primary surgery or primary surgery immediately after short course radiotherapy, 
were identified and re-examined.  All MRI staged tumours considered to be T1 or T2 and node 
negative were also included.  
A total of 105 patients were available for study. 
3.2.1 Criteria of Tumour Measured 
The following characteristics were included when examining the tumours on MRI: 
 Diameter of the tumour - polypoidal/sessile/ulcerating 
 Thickness of muscularis propria at outer border of tumour - position within the bowel 
wall 
 mm of spread beyond the bowel wall - nodal involvement – benign/malignant. 
 
Nodal status was based on border and signal 
MRI Staging:  
MRI T1: submucosa visible beneath invading edge of tumour 
MRI T1/T2: intermediate signal intensity visible in submucosa layer only but no 
visible submucosal layer seen at advancing edge 
MRI T2:  tumour extending into muscularis propria but some muscularis 
propria signal visible deep to this 
 
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Figure 3.2: Muscular layers 
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Figure 3.3: Detailed anatomy of bowel wall and tumour seen on high-resolution MRI 
 
 
3.3 Results 
Table 3.3: Summary of tumours 
Position of tumour No of cases (n) 
Anterior 20 
Left lateral 9 
Right lateral 9 
Posterior 43 
Circumferential 24 
 
Table 3.4: Diameter of tumour in mm 
Diameter of tumour 
(mm) 
No of cases (n) 
0-10 0 
11-20 16 
21-30 26 
31-40 33 
>41 30 
Total 105 
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Table 3.5: Comparison of MRI and histopathology 
 Histopathology Staging 
MRI Staging pT1 pT2 pT3a Totals 
T1 6 9 1 16 
T1/2 6 13 2 21 
T2 6 11 10 27 
T2/3 5 4 14 23 
T3a 1 8 9 18 
Total 24 45 36 105 
 
Table 3.5 illustrates the strengths and limitations of MRI in T staging tumours less than pT3a.   
Of the tumours that were pT1 on histopathology, MRI identified 12/24 as either T1 or T1/2 
(50%). 
Of the pT3a tumours, MRI identified 3 of these tumours as being T1 or T1/2 (3/36) with 33 
being identified as T2 or greater.   
When the MRI determines a T1/T2 tumour, the proportion of pT2 compared with pT1 increases 
since the MRI shows tumour effacing the full thickness of the submucosa and therefore the 
likelihood of early T2 infiltration is greater.   
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Table 3.6: Thickness of muscularis propria visible at outer border of tumour 
 
 Histopathology Stage No of cases (n) 
Deepest distance of 
penetration from 
base of tumour (mm) 
pT1 pT2 pT3a  
<1 6 13 18 37 
2 10 11 12 33 
3 4 8 2 14 
4-6 4 14 3 21 
Total 24 46 35 105 
 
Figure 3.4: ROC curve of these values against identification of tumours that are not 
through the wall 
 
 
Fitted ROC Area 0.693; Accuracy 59.0%; Sensitivity44.1%; Specificity 86.5% 
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By using the deepest distance from the base of the tumour to identify tumours not through the 
bowel wall, the area under the curve is 0.693.  Using a cut off of 3 mm is considered positive to 
give a tumour that is not through the bowel wall.  This gives a sensitivity of 44.1% and a 
specificity of 86.5%.  This meant there would have been 5 cases that were through the bowel 
wall not identified and 38 cases that were not through, that were missed. 
 
Table 3.7: Breakdown of the values for individual tumours. 
MRI  
 Histology  T staging 
 pT1 pT1/2 pT2 pT2/3 pT3a 
T1 Deepest distance from base of tumour (mm) 
2 1 0 1 0 0 
3 2 0 2 0 0 
4 0 0 3 0 0 
5 1 0 2 0 1 
6 2 0 1 0 0 
T1/2 Deepest distance from base of tumour (mm) 
0 0 0 1 0 0 
1 0 0 0 0 1 
2 5 0 1 0 0 
3 0 0 5 0 1 
4 0 0 2 0 0 
5 1 0 4 0 0 
T2 Deepest distance from base of tumour (mm) 
0 1 0 1 0 0 
1 0 0 0 0 1 
1 0 0 4 0 2 
2 2 1 3 0 4 
3 2 0 1 0 1 
4 0 0 2 0 2 
T2/3 Deepest distance from base of tumour (mm) 
0 4 0 2 0 9 
1 0 0 0 0 1 
1 1 0 1 0 2 
2 0 0 0 1 2 
T3a Deepest distance from base of tumour (mm) 0 1 0 8 0 9 
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3.3.1 Examples to Illustrate Under/Overstaging 
pT3a understaged as T1/2 by MRI 
MRI understaged a total of 3 patients as T1 or T1/2 who were histopathologically T3a. 
Typically these cases showed microscopic focal T3a penetration which could not be resolved 
on even high resolution imaging (figure 3.5).  
 
Figure 3.5: Example of aT3 tumour which was unresolvable even on a high resolution 
image. MR image and corresponding histopathological slide 
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Figure 3.6: Difficulties in imaging early stage tumours 
axial view 
 
 
Figure 3.6 illustrates the challenges faced by pathology and imaging in staging early tumours. 
The MRI in this example has been obtained using a scan plane that is not exactly perpendicular 
to the tumour. This, almost certainly contributes to examples of overestimation of depth of 
spread. The corresponding pathology however shows only a small fragment of the tumour 
embedded for histopathological review. It is possible that under sampling of the specimen may 
also lead to minor discrepancies in staging between pathology and imaging.  
Of the 105 MRI studies reviewed 10 (10%) were deemed technically inadequate. In two cases 
this resulted in major over or understaging.  This is illustrated in Figure 3.7. 
 
There were a few examples where technically inadequate images meant an accurate staging 
diagnosis could not be made. In these cases often the radiologist may over- rather than 
understage a tumour. In most cases discrepancies between histopathology and MRI were 
minimal (Figure 3.7). 
 
  
 
Figure 3.7: Technically inadequate images 
Shows an example of histology and MRI scan for a pT2 tumour staged as T3a by MRI. The 
margin in MRI (Figure 3.7a) shows impingement through the bowel wall as marked by arrow. 
There is evidence of tumour signal intensity extending through the muscle layer into the 
perirectal fat with obliteration of the interface between muscle and perirectal fat.  In Figure 
3.7b and Figure 3.7c the histology section shows the tumour is very close to breaching the 
muscularis propria and could be considered borderline between pT2 and pT3a. 

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3.3.2 Nodal Staging 
Table 3.8 illustrates the false negative and false positive rates for nodal status in early stage 
tumours sensitivity and specificity of MRI at correctly identifying positive lymph nodes, 
particularly in early staged tumours.  
Table 3.8: False negative and positive rates 
MRI Nodal 
involvement 
MRI 
Staging 
Histology N staging Grand 
Total N0 N1 N2 
NO T1 13 3  16 
 T1/2 14 3  17 
 T2 19 3  22 
 T2/3 12  1 13 
 T3a 3 4  7 
NO Total  61 13 1 75 
YES T1/2 4   4 
 T2 1 4  5 
 T2/3 10   10 
 T3a 8 2 1 11 
YES Total  23 6 1 30 
Grand Total  84 19 2 105 
Positive predictive value=23%, negative predictive value=81% 
Sensitivity =33% specificity =73%.  Accuracy =65% 
Table 3.8 collates information regarding nodal involvement in addition to T staging. This is of 
the utmost importance for the TEMS procedure as studies have shown nodal involvement 
heavily influences outcome, and therefore obtaining an accurate negative nodal involvement is 
needed. If MRI stages these tumours as T1N0 then the prediction of node negative status is 
13/16 (81%). However with increasing depths of tumour invasion visualised on MRI the risk of 
nodal involvement increases, as expected. Ultimately in TEMS procedures there needs to be 
good specificity.  
3.4 Discussion 
This study highlights the challenges and pitfalls faced by radiologists in the interpretation of the 
early stage tumours on MRI. 
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The morbidity associated with radical surgery is well documented and if a less invasive 
technique can offer similar oncological outcomes then clearly this would be preferable (Temple 
et al., 2005).  Some forms of bowel, sexual and urinary dysfunction are common, despite nerve 
saving techniques (Hendren et al., 2005).  The Dutch TME trial showed that some degree of 
newly developed urinary and faecal incontinence was present in 33.7% and 38.8% of patients, 
respectively (Wallner et al., 2008). This has stimulated interest in local excision procedures for 
patients who are not fit for radical surgery or those who do not wish to go through with major 
surgery, when understanding the consequent risk of morbidity and mortality.   
Bach et al. (2009) constructed a predictive model for local recurrence based upon prospectively 
collected data on the national TEMs database.  He highlighted that patient selection for TEM 
should be based upon suitable tumour biology and that treatment with TEM may provide 
excellent local control in the treatment of pT1 tumours with favourable histopathological 
features.  This is consistent with other published data (Borschitz et al., 2006).  This data also 
highlighted that there is a serious risk of under treatment of Sm2-3 and pT2 tumours and that 
TEM alone could not be recommended for this group of patients.  In this study of 424 patients, 
44.3 percent of pT1 and 31.2 per cent of pT2 lesions were thought to be benign.  This 
emphasizes the current inability to accurately identify these patients.  In the first half of the 
study patients were locally staged with pelvic CT and during the second half, with MRI. 
Our study has shown definite limitations for using preoperative MR imaging to stratify patients 
for TEMs surgery. MRI clearly has a role in identifying potential candidates for local excision, 
i.e. those who have clear CRM, no other suspicious features and look to be early tumours, but it 
is essential that once these patients are selected they should undergo imaging with EUS, to 
further improve the local staging. A pathway using both techniques as an adjunct to the 
treatment pathway would be most useful. 
From a histopathological point of view, it is clear that the risk of nodal invasion in patients with 
sm3 or higher tumours is so great that currently they should undergo TME surgery after local 
excision. It is notable that there were no examples of T1 tumours with depth of invasion <sm3 
in the MERCURY study and this calls into question the rationale for local excision in rectal 
cancer patients in clinical practice. Nevertheless, there has been recent interest in using the 
TEMs procedure in selected individuals, particularly those not fit for TME surgery and there is 
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interest in developing a strategy that enables patients with T1 or T2 to undergo TEMS +/- 
adjuvant therapy for potential high risk features. Such an approach could be justified if an 
imaging technique could reliably avoid this treatment being employed for T3 tumours our study 
has shown the limitations of using MRI alone and the difficulty with accurate lymph node 
assessment. 
In patients with midrectal and upper third Sm3 T2/T3a tumours the gold standard for care is 
TME surgery, which results in effective cure.  For patients with lower third rectal tumours 
treatment decisions are slightly more difficult.  A pT1 Sm3 tumour is associated with the risk 
of lymph node metastasis.  If a sphincter preserving local excision is undertaken, a subsequent 
TME or APE may result in no tumour or lymph nodes being found in the specimen and a full 
thickness excision may compromise subsequent successful TME or APE surgery.  If the patient 
is recommended for an APE, they may elect to receive radiotherapy for the nodal risk and close 
marking of the primary tumour site and mesorectum by interval follow-up MRI to identify 
regrowth.  A low pT2/T3a tumour considered to be encroaching upon potential resection 
margins (anterior or abutting intersphincteric planes) may be offered radical radiotherapy or 
chemoradiotherapy followed by surgery (if fit) or watchful waiting. 
Local excision (TEMS Procedure) above the lower third posteriorly is investigational and MRI 
should be used to ensure that the deep fascia propria is not compromised by this procedure. 
Our analysis confirms the histopathological study observations of increased nodal involvement 
with increased depth of spread and the finding of a T1 or T1/T2 is associated with a 
histological node positive prevalence of 18% (this has been reported by histopathologists for 
sm3 tumours) irrespective of the MRI assessment of nodal involvement. This needs to be taken 
into consideration in planning future TEMS trials. For more extensive T2/T3a the prevalence of 
nodal involvement rises. 
3.5 Conclusions 
MRI does have a role in the identification of early tumours however currently only as an 
adjunct to other more accurate techniques.   
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The advantage of using MRI over other techniques in the assessment of early tumours is that 
images are reproducible, cases can be reviewed by a number of radiologists and allows a search 
to be made for other poor prognostic features, in particular, to verify the safety of the 
circumferential resection margin. 
Some of the inaccuracies of MRI staging were related to difficulty in image interpretation. 
These were often caused by factors such as; poor positioning in scanner, movement artefact and 
inadequate slice sections (axial vs coronal).  If the radiologist is aware of these potential 
problems then steps can be taken to avoid them. 
Most trials regarding TEMS call for a more reliable preoperative staging technique and this 
study emphasises the use of caution in using MRI alone in this setting.  Many studies have 
highlighted the use of EUS in the early stage tumours and once an early tumour has been 
identified on MRI then further adjunctive assessments should be used. Ashraf et al reviewed 
the accuracy of EUS in the TEMS database and demonstrated throughout the UK the results 
were disappointing (Ashraf et al., 2012). There appeared to be considerable overstaging using 
this technique with a general accuracy of only around 50%.  They suggested that this may be 
due to a peritumour inflammatory or fibrotic response, which also has an impact on the MRI 
assessment. 
Our study shows that using this technique with MRI assessment shows some promise in aiding 
the identification of the early tumours and would certainly have a role to play in an algorithm 
of management of these patients. Further studies looking at interobserver data would be helpful  
In summary: 
Preoperative assessment of sessile or polypoidal cancers requires detailed evaluation of the 
central depressed portion of the tumour and the degree of preservation of the submucosa and 
muscularis propria at the advancing edge. Multiplanar assessment is essential and if the 
submucosa is evident on any single view at the base of the stalk or at the central invasive base 
of a sessile tumour, - then this enables consideration to the diagnosis of a T1 lesion amenable to 
local excision. . Assessment of the T stage tumour depth within and beyond the rectal wall is 
achieved by assessing the extent of the intermediate signal intensity tumour and its extent of 
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spread into the submucosa, muscularis and beyond. An attempt should be made  to determine   
the precise depth of extension into the submucosa  but crucially a measurement of the thickness 
of any preserved submucosa is more  relevant; a thickness of >3mm in any plane increases the 
likelihood of detection of a Sm1 or Sm2 lesion which should be cured by a local excision . The 
lack of any measurable high signal intensity layer in any plane imaged between the advancing 
edge of the tumour and the low signal intensity of the muscularis propria suggests the high 
probability of a T1Sm3 or early T2 tumour. It should be emphasised that the distinction 
between a T1Sm3 and an early T2 is prognostically and clinically irrelevant since it means that 
a local excision without removal of the full thickness of the underlying muscularis propria will 
result in a positive deep margin of <1mm. 
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Chapter 4 - MRI identification of Good Prognosis Rectal 
Cancer 
Aim: To assess local recurrence, disease free survival and overall survival in MRI predicted 
good prognosis tumours treated by surgery alone. 
Background: The routine policy in most centres involved in the MERCURY study was 
primary surgery alone in MRI predicted Stage II or less and in MRI “good prognosis” Stage III 
with selective avoidance of neoadjuvant therapy.   
Patients and Methods: Data was collected prospectively on all patients included in the 
MERCURY study who were staged as MRI defined “good” prognosis tumours. “Good” 
prognosis included MRI predicted safe circumferential resection margins, with MRI predicted 
T2/T3a/T3b (less than 5 mm spread from muscularis propria); regardless of MRI N stage.  No 
patients received pre-operative radiotherapy.  Overall survival, disease free survival and local 
recurrence were calculated.  
Results: Of 374 patients followed up in the MERCURY study, 122 (33%) were defined as 
“good prognosis” stage III or less on MRI. Overall, and disease free survival for all patients 
with MRI “good prognosis” stage I,II and stage III disease at 5 years was 68% and 85% 
respectively. The local recurrence rate for this series of patients predicted to have a good 
prognosis tumour on MRI was 3%.   
Conclusions: The preoperative identification of good prognosis tumours using MRI will allow 
stratification of patients and better targeting of pre-operative therapy. This study confirms the 
ability of MRI to select patients who are likely to have a good outcome with primary surgery 
alone.  
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4.1 Introduction 
Internationally, preoperative treatment strategies for rectal cancer show considerable variation 
though many advocate routine pre-operative chemoradiotherapy (CRT) to all clinically staged 
II and stage III rectal cancers  (Diaz-Gonzalez et al., 2007).  With the lack of robust staging 
techniques, this inevitably results in over treatment of some stage I patients. 
The US standard of care has been to give postoperative CRT and chemotherapy to patients with 
stage II and III disease, based on the NIH consensus statement in 1990 and the results of the 
Krook and O’Connell studies (1990, Krook et al., 1991, O'Connell et al., 1994). Recently Sauer 
et al. used similar eligibility criteria and demonstrated pre-operative CRT to be better than post 
operative CRT (Sauer et al., 2004). In resectable disease, the Dutch and CR07 studies have 
shown a benefit in reduction of local recurrence (LR) when short course preoperative 
radiotherapy is used in addition to mesorectal excision. However, the investigators recognised 
that there was substantial over-treatment of many patients, exposing them to the long term 
toxicity of radiotherapy, and that there was a need to define subsets of patients in whom TME 
alone is adequate loco-regional treatment (Sebag-Montefiore et al., 2009, Peeters et al., 2007).  
Furthermore, analysis of pooled data from a large number of patients treated by surgery alone, 
without preoperative therapy, reported a wide ranging survival from 37-79%, depending on the 
pathological stage, thus indicating scope to refine patient selection (Gunderson et al., 2004). 
This study evaluated the outcome of a subset of patients who were predicted preoperatively on 
MRI to have a good prognosis tumour and were treated by surgery alone. 
The aim was to evaluate whether MRI can enable identification of a group of stage II and stage 
III patients with good prognosis rectal cancer that can avoid preoperative therapy.    
The centres participating in the MERCURY study did not routinely offer neoadjuvant treatment 
to all preoperatively identified stage II or less and some stage III patients, provided that the 
circumferential margin was radiologically more than one mm from the nearest outermost edge 
of extramural tumour and there were no other major adverse features.  The purpose of this 
study was to assess the implications of this in terms of local recurrence, disease free, and 
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overall survival using a policy of avoidance of preoperative therapy in MRI predicted good 
prognosis stage III disease or less.  
4.2 Patients and Methods 
This study examined all tumours taken from the MERCURY study, with MRI-predicted 
T2/T3a/T3b (i.e., extramural spread < 5mm), regardless of MRI nodal stage, and without other 
adverse features, managed by surgery alone. Five year follow up was collected and OS, DFS 
and LR were calculated for this group of patients. Recruitment is summarized in Figure 4.1.  
Figure 4.1. Flowchart summarising recruitment for the follow-up study. 
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4.2.1 Radiological Assessment: 
Patients underwent magnetic resonance imaging of the pelvis using a high-resolution protocol 
and images were reported using the dedicated proforma by the trial radiologists who were 
blinded to histopathological results (Mercury Study Group, 2006). Computed tomography (CT) 
was used to stage metastatic disease, both at diagnosis and at annual follow-up. 
 
4.2.2 MRI Definitions 
We defined MRI good prognosis as follows: 
Patients who were predicted to be CRM clear on preoperative MRI  (tumour >1mm to the 
mesorectal fascia), showed no evidence on MRI of extramural venous invasion, were early 
MRI T stage i.e. T2 or less, T3a, T3b (spread less than 5 mm from bowel wall) regardless of N 
stage (Mercury Study Group, 2006, Hermanek and Junginger, 2005, Hermanek et al., 1989b, 
Smith et al., 2008a, Willett et al., 1999, Willett et al., 2007, Merkel et al., 2001, Cawthorn et 
al., 1990). 
For low rectal tumours good prognosis was defined as MRI stage 1 or 2 low rectal, namely 
tumour not encroaching into the intersphincteric plane or levators (Salerno et al., 2009). 
Each centre was allowed to apply their local treatment policy which was primarily determined 
by the MRI assessment of the CRM status. For all centres a policy of offering preoperative 
chemoradiotherapy or radiotherapy to potentially CRM positive patients was followed. For 
some centres preoperative chemoradiotherapy was also offered to patients with evidence of 
extramural venous invasion, T3 tumour spread >5mm or tumour extension into the 
intersphincteric plane. Figure 4.2 summarises treatment according to MRI prognosis. 
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Figure 4.2. Treatment plans according to MRI prognosis  
 
 
 
4.2.3 Treatment, Surgery and Histopathological Assessment 
The pre-operative treatment allocated to patients at the time of the original presentation was 
recorded. Total mesorectal excision was performed in all the patients according to a 
standardised technique (Heald and Ryall, 1986).  Training for proforma reporting was provided 
for participating pathologists.  Histopathology assessment was undertaken at each centre by 
specialist GI histopathologists (with 5-25 years experience). The standard definitions for 
histological involved margins were used (1mm or less of tissue between the tumour and the 
margin) (Quirke et al., 1986). All patients included in this analysis underwent primary surgery.  
Postoperative therapy was given according to local unit policy, predominantly single agent 
fluoropyrimidine for node-positive disease.  No patients in the study received post operative 
radiotherapy. 
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4.2.4 Quality Control 
In this prospective study, quality assurance was undertaken in the form of pathology and 
radiology workshops to ensure standardisation of techniques and interpretation (Mercury Study 
Group, 2006).   
4.2.5 Reproducibility of MRI Staging Assessment 
To determine the reproducibility of identifying good versus poor prognosis tumour based on T 
stage and extramural venous invasion, paired observers, blinded to outcomes and pathology, 
and were asked to re-score the MRI scans of all patients originally enrolled into the 
MERCURY trial. Inter-observer agreement for T3b or less (good prognosis) versus T3c or 
more and, EMVI negative versus EMVI positive was calculated with the chance corrected 
agreement given as the kappa statistic, based on marginal homogenised data. Confidence 
intervals of kappa were calculated by the method of Donner and Eliasziw (1992). 
4.2.6 Follow-up 
Patients were followed according to local protocols, namely three-month intervals for two years 
and then at six-month intervals for five years. Clinical follow up comprised physical 
examination, routine blood tests and yearly CT of the thorax, abdomen and pelvis. 
Histopathological confirmation of local or distant recurrence was sought when appropriate or 
based on clinical or radiological enlargement of a recurrent mass. The details of surgery, 
including the dates, operation performed and quality of the specimen were recorded 
prospectively; the date of last follow-up, and the date and cause of death were also collected. 
The presence of distant metastatic disease or local recurrence at the time of death was recorded 
as a rectal cancer-specific death. 
4.2.7 Statistical Analysis 
Patient characteristics were presented using descriptive statistics. Patterns of failure, either 
local or distant, were compared with radiological assessment, treatment, surgery and 
pathological assessment including quality of the specimens. 
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Survival analysis was performed by the Kaplan–Meier method. For survival analysis, ‘time till 
event’ (failure time) and censored observations were defined as follows: Overall survival (OS) 
was the time from date of first MRI till death from any cause.  Patients who were alive or did 
not develop disease during the study time period (at last follow-up) were recorded as censored 
observations. Disease-free Survival (DFS) was measured from date of preoperative MRI until 
progression at any site or death from any cause; patients who were alive and disease free were 
censored at last follow-up or death.  
Time to local recurrence (TTLR) was measured from date of first MRI until local progression; 
patients with no recurrence were censored at the date of last follow-up or death.   
Univariate analysis of the association between ‘time till event’ and the known preoperative 
clinical variables (age, sex, height of tumour from anal verge, type of preoperative treatment, 
and type of operation (anterior resection or abdominoperineal excision (APE)), was performed.  
Multivariate analysis using Cox proportional hazards model was carried out to identify 
independent predictors of outcome. All factors in the univariate analysis were included in the 
multivariate model using a method of forced entry. Five-year survival times (and 95% CI) were 
calculated.  Adjusted hazard ratios (HR) were reported in the final analysis.  Significance was 
set at P<0.05.  Statistical analyses were performed using SPSS statistics v17.0. (SPSS Inc, 
Chicago, IL) 
4.3 Results 
4.3.1 Patients 
A total of 122 patients from the 11 hospitals were staged as good prognosis on MRI.  The 
baseline characteristics of the 122 patients in the study population are summarised in Table 4.1.  
The median age of patients was 69.5 (33-88 years) and there were 71 (58.2%) males and 51 
(41.8%) females. 
The overall LR for this group was 3.3% (4 of 122) with 5-year OS 68.2 (95% CI, 60.3%-
77.0%) and 5-year DFS of 84.7 % (95% CI, 76.0% - 90.4%) Figure 4.3 shows the Kaplan-
Meier survival curves for the MRI defined good prognosis group. 
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Table 4.1: Characteristics of the study population 
 
Demographics - 
 
 
N= 122 
patients 
  
Sex     
Male 
 
71 
 
   
Female 51    
Operation     
Anterior resection 102    
APE 13    
Hartmann’s 6    
Other 1    
Height of Tumour      
Low rectal (<5cm) 20    
Mid rectal (5-10cm) 62    
Upper rectal (10-15cm) 40    
MRI TN stage   Total  
Stage I T2N0 57 57  
Stage II  T3a N0 24   
 T3b N0 19 43  
Stage III  T2 N1  7    1 =CRM+ve on path 
 T3a N1 6   1=CRM +ve on path 
 T3b N1 7   2=CRM+ve on path 
 T3b N2 2 22  
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Figure 4.3. Kaplan-Meier survival curves for total good prognosis group. Overall survival 
(A) and Disease-free survival (B). 
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4.3.2 MRI and Histopathology Status 
The histopathology results for these patients are shown in Table 4.2. Four patients (3.3%) were 
considered CRM positive on final pathology. There was no local recurrence at 5 years in those 
patients with margin involvement. Of the 4 patients who had  pCRM involvement: 1 patient 
was T2N1on MRI , T3b N1 on histopathology, 1 patient was T3a N1 on MRI, T3b N2 on 
histopathology, and 2 patients were T3b N1 on MRI and T3b and T3c N1 on histopathology. 
Table 4. 2: Final pathology for the study patients (n=122) 
Path TN Stage  Total  
Variable Frequency (%)   
Path CRM clear 118 (96.7)  
 involved  4 (3.3)  
Stage I or less   Actual no of LR 
pT0N0 7 (5.7)  0 
pT1N0 8 (6.6)  0 
pT2N0 34 (27.9) 49 1 
Stage II    
pT3aN0 20 (16.4)  0 
pT3bN0 7 (5.7)  0 
pT4N0 2 (1.6) 29 1 
Stage III    
pT1N1 1 (0.8)  0 
pT2N1 9 (7.4)  0 
pT2N2 1 (0.8)  0 
pT3aN1 8 (6.6)  1 
pT3bN1 9 (7.4)  0 (2=CRM +ve) 
pT3bN2 7 (5.7)  1(1=CRM +ve) 
pT3cN0 3 (2.5)  0 
pT3cN1 4 (3.3)  0(1=CRM +ve) 
pT4N1 2 (1.6) 44 0 
 Total 122  
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4.3.3 Inter-Observer Agreement 
The Kappa value for agreement between radiologists on T stage was 0.56 (95% CI 0.48-0.64), 
showing moderate to substantial agreement. The Kappa value for EMVI was 0.41 (95% CI 
0.31-0.49). Furthermore, radiologists agreed on good prognosis T stage in 95% of cases (95% 
confidence interval 88%-98%) and for absence of EMVI in 90% (95% confidence interval: 
83%-95%) 
4.3.4 Events During Follow-up 
As of December 2008, surviving patients had been followed for a median of 61.5 months and 
overall outcomes at 5 years are summarised in Table 4.3. Of the 40 deaths that occurred during 
follow-up, 17 (42%) were cancer related and 23 (57.5%) from other causes; in 3 (7.5%) cases 
the cause of death was unknown. Local recurrence occurred in 4 of the 122 (3.3%) patients, of 
these, 1 had local recurrence alone.  There were 7 patients who despite initial biopsy findings 
were found to be pT0 on final histopathology. If the 7 patients with T0 were excluded, the local 
recurrence rate would be 4/115, 3.5%. A total of 14 patients had distant recurrence alone.  
 
Table 4. 3 -Outcome of MRI predicted good prognosis patients 
MERCURY – 
MRI predicted good prognosis 
patients 
Local 
recurrence 
 5 year Overall survival 5 year Disease free 
survival 
Total pts (n=122) 
 
3.3% 68.2 (95% CI: 60.3-77.0%) 84.7% (95% CI: 76.0-
90.4%)  
T3a/b N0, N1 and N2  (n=58) 1.7%  67.9% (95% CI: 53.9-78.5%) 81% (95% CI: 66.1-
89.8%)  
T1,2 or 3b, N positive disease 
(n=22) 
0%  81% (95% CI: 48.7-78.2%) 95% (95% CI: 69.5-
99.3%). 
 
4.3.5 Local Recurrence, Disease-Free Survival, and Overall Survival 
For patients staged as MRI good prognosis T3 stage tumours, (n=58) (< 5mm extramural 
spread, regardless of nodal status), there was 1(1.7%) local recurrence, 11 (19%) relapses and 
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20 (34.5%) deaths. The overall survival at 5 years was 67.9% (95% CI: 53.9-78.5%) in this 
group. Disease free survival was 81% (95% CI: 66.1-89.8%). 
There were 43 MRI defined good prognosis stage II patients, 1 patient developed (2.3%) local 
recurrence, 10 (23.3%) relapses and 16 (37.2%) deaths.  The overall survival at 5 years was 
65.7% (95% CI: 48.7-78.2%) with disease free survival of 76% (95% CI: 56.7-87.6%). 
There were 22 MRI defined good prognosis stage III patients with no local recurrences at 5 
years.  The 5 year overall survival was 81% (95% CI: 48.7-78.2%) with disease free survival of 
95% (95% CI: 69.5-99.3%). 
4.3.6 Results of Univariate and Multivariate Analysis 
Table 4.4 summarises the results of univariate and multivariate analysis of the influence of 
other potential factors on overall survival, disease free survival time to local recurrence in 
patients with MRI predicted good prognosis disease.  Univariate analysis was performed on the 
following potentially confounding factors:  tumour height from the anal verge (less than or 
equal to 5cm or greater than 5cm), age >65, sex and type of operation. 
The only preoperative factor significant for overall survival on univariate analysis was age >65. 
None of the other factors were significant in this group of patients on univariate analysis for 
overall survival, disease free survival or local recurrence. On multivariate analysis, age >65 and 
type of operation remained significant for overall survival.  
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Table 4.4 Outcomes for MRI-predicted Good Prognosis patients and the effect of 
univariate and multivariate analysis on local recurrence, 5-year Overall survival and 
Disease-free survival. 
MERCURY –MRI 
predicted Good 
Prognosis Patients 
 
Local 
Recurrence 
 5-year Overall 
Survival 
 5-Year 
Disease-free 
Survival 
 
Total Patients (n=122) 3.3%  68.2% (95% 
CI, 60.3% - 
70%) 
 84.7% (95% 
CI, 76.0%-
90.4%) 
 
T3a/b N0, N1 and N2 
(n=58) 
1.7%  67.9% (95% 
CI, 53.9%-
78.5%) 
 81% (95% CI, 
66.1%-89.8%) 
 
T1,2 or 3b, N positive 
disease (N=22) 
0%  81% (95% CI, 
48.7%-78.2%) 
 95% (95% CI, 
69.5%-99.3%) 
 
Univariate analysis       
Preoperative Factor Local 
Recurrence 
 Overall 
Survival 
 Disease –free 
Survival 
 
 Hazard Ratio P Hazard Ratio P Hazard Ratio P 
Height of Tumour (low) 1.546 (0.161–
14.863) 
0. 
706 
0.646 (0.253–
1.651) 
0.362 1.938 (0.682–
5.505) 
0.214 
Type of operation (APE) 0.050 (0.000–
7361.65) 
0.622 1.499 (0.97–
2.317) 
0.068 1.384 (0.432–
4.436) 
0.584 
 
Age (>65), y  
0.783 (0.107–
5.392) 
0.760 2.854 (1.352–
5.986) 
0.004 1.009 (0.394–
2.585) 
0.985 
Sex (male) 0.244 (0.025–
2.345) 
0.222 1.230 (0.649–
2.334) 
0.526 0.932 (0.368–
2.365) 
0.883 
 
Multivariate analysis 
 
      
Preoperative Factor Local 
Recurrence 
 Overall 
Survival 
 Disease –free 
Survival 
 
 Hazard Ratio P Hazard Ratio P Hazard Ratio P 
Height of Tumour (low) 2.580 (0.268–
24.829) 
0.412 0.457 (0.171–
1.220) 
0.118 1.917 (0.598–
6.152) 
0.274 
Type of operation (APE) No events n/a 2.128 (1.049–
4.317) 
0.036 1.031 (0.270–
3.936) 
0.964 
Age (>65), y 0.821 (0.114–
5.899) 
0.845 2.967 (1.407–
6.255) 
0.004 0.968 (0.375–
2.501) 
0.947 
Sex (male) 0.244 (0.025–
2.374) 
0.224 1.120 (0.585–
2.146) 
0.733 0.955 (0.376–
2.428) 
0.923 
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Table 4.5: The following table shows the results for this subgroup of MERCURY based 
upon MRI staging, compared with outcomes according to pathological staging for other 
recently reported series.  
 Stage II   LR Treatment received DFS OS 
MERCURY T3a/b N0 
(n=43) 
2.3% TME surgery + No preoperative 
therapy  
76% 65.7% 
GUNDERSON 
(range with diff 
treat groups) 
T3 N0 9% 
(5-14%) 
Non TME surgery + selective 
adjuvant therapy 
75% 
(65-84) 
65%  
(51-75) 
CR07 
(3yr local 
recurrence rates) 
All stage II 1.9%   TME surgery + preoperative 
radiotherapy 
Not 
published 
Not 
published 
6.4% TME surgery + selective post 
operative radiotherapy 
DUTCH TME All stage II 5.3%  
 
TME surgery + preoperative 
radiotherapy 
Not 
published 
Not 
published 
7.2% TME surgery + selective post 
operative radiotherapy 
 Stage III  LR Treatment received DFS OS 
MERCURY T2N1,T3a/b 
N1, T3b N2 
(n=22) 
0% TME surgery + No preoperative 
therapy  
95% 81% 
GUNDERSON T1-2 N1 
T3 N1 
T3 N2 
7% 
12% 
14% 
Non TME surgery + adjuvant 
therapy 
79% 
60% 
44% 
73% 
48% 
36% 
CR07 
(3yr local 
recurrence rates) 
 All stage III 7.4% 
 
TME surgery + preoperative 
therapy 
Not 
published 
Not 
published 
15.4% TME surgery + selective post 
operative radiotherapy 
DUTCH TME All stage III 10.6% 
 
TME surgery + No preoperative 
therapy 
Not 
published 
Not 
published 
20.6% TME surgery + selective post 
operative radiotherapy 
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4.3.7 Outcomes According to Pathology 
In the patients who were good prognosis pT3 stage (n=51) there was 1(2%) local recurrence, 10 
(19.6%) relapses and 20 deaths (39.2%).  Overall survival at five years was 63.7% (95% CI: 
48.7-75.4%); disease free survival was 76.6% (95% CI: 60.5-86.8%). Only 8/122 (6.5%) 
patients with MRI good prognosis stage I/II or III had 4 or more positive nodes on 
histopathology assessment (N2) 
4.4 Discussion 
This study has demonstrated that pre operative MRI can select good prognosis rectal cancer 
patients, accounting for one third of the patients recruited to the MERCURY study over a 
twenty month period, in eleven institutions. Furthermore in a multicentre setting, with optimal 
preoperative selection and good quality TME surgery, local recurrence rates of 1.7% are 
achievable in MRI defined T3a/b with any nodal status and is independent of known variables 
such as type of surgery and height of tumour.   This represents a group of patients who in many 
centres, would otherwise have routinely been offered neoadjuvant radiotherapy or 
postoperative radiotherapy. 
The overall and disease free survival and local recurrence rates in this series compare 
favourably with other studies (Sebag-Montefiore et al., 2009, Gunderson et al., 2004). For 
example, patterns of relapse for good prognosis stage II and stage III tumours in prior surgical 
series have ranged from 20-40%(Pahlman and Glimelius, 1995). These studies predated TME 
surgery and MRI staging.  Current experience reflects a change in surgical practice towards 
more standardised TME surgery as a result of training initiatives such as the English TME 
multidisciplinary team  development program (2004, Jessop et al., 2006).The study centres 
participating did not, as a routine, offer neoadjuvant therapy to “good” prognosis T3 tumours 
regardless of nodal status. These results have validated this approach and is, for the majority of 
centres, their ongoing treatment policy. 
The study was undertaken in 11 different hospitals that ranged from busy general hospitals to 
specialised university teaching hospitals. The prior experience of radiologists in undertaking 
MRI staging of rectal cancer ranged from none to 7 years. However, using a standardised 
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technique and reporting reinforced by training workshops – good reproducibility was achieved 
as shown by the moderate to substantial agreement between radiologists. 
The current classification of patients as stage II and stage III encompasses a rather 
heterogeneous group of tumours that does not take into account the extent of local spread of the 
primary tumour.  Others have highlighted this shortcoming and have proposed that patients can 
be subdivided on the basis of histopathological features including depth of spread (Willett et 
al., 1999, Merkel et al., 2001, Cawthorn et al., 1990). In their original study, Gunderson et al. 
(2008) highlighted the need for a robust means of preoperative identification of patients in the 
stage II or stage III category that had a relatively low risk of local and distant relapse.  There is  
good consensus that T2/N1/N2 and T3 N0 patients have a relatively low risk of local and 
distant relapse if only they could be identified with certainty preoperatively(Gunderson et al., 
2008). This data shows that such patients can be identified pre operatively, as can a group of T3 
N1 tumours that have a low risk of local recurrence and relapse.   
In Gunderson’s published series, involvement of the CRM was not reported either 
preoperatively or on histopathology and this may account for the high local recurrence rates 
seen in this data.  The CR07 and Dutch TME results suggest that local recurrence rates in 
mobile cancers are substantially reduced if patients with rectal cancer are treated with pre 
operative short course radiotherapy (Marijnen and van de Velde, 2001, Peeters et al., 2007, 
Sebag-Montefiore et al., 2009). In both CR07 and the Dutch TME trial preoperative staging 
using MRI was not used to determine which patients were most at risk of local failure, though 
pathological analysis of the resected specimen could identify subgroups with maximal 
beneficial effect from neoadjuvant therapy (Sebag-Montefiore et al., 2009, Marijnen and van de 
Velde, 2001).  Patients with CRM positive disease were not excluded from these studies since 
they were not identified preoperatively, yet it is known that these patients benefit from long 
course chemoradiotherapy to reduce local recurrence (Burton et al., 2006, Chua et al., 2010). In 
the present study, patients with potentially involved circumferential resection margins were 
identified using MRI preoperatively and treated aggressively.  This represents a significant 
difference in patient selection when compared with previous series (Sebag-Montefiore et al., 
2009, Gunderson et al., 2004, Gunderson et al., 2002, Kapiteijn et al., 2001, 1997). 
 106 
Data would suggest that up to 20% of patients will have potential CRM involvement on 
preoperative MRI and should therefore be given preoperative chemoradiotherapy.  It is likely 
that this accounts for the low CRM positivity rates on histopathology and subsequent low local 
recurrence rates in this group of patients.  There is good evidence from pathology studies that 
T3c and above tumours do significantly worse and this thesis will look into this further, along 
with some of the other poor prognostic factors that can be identified on MRI. Therefore, based 
on this experience and with the assumption of good quality TME with assessment of safe CRM, 
a preoperative MRI stratification is proposed as outlined in figure 4.2.  Of note, this data is 
based upon high quality imaging, interpretation, surgery and detailed pathological audit. 
Equally the implementation of this stratification would require high quality audit to confirm 
that our findings in a study population can successfully be translated to clinical practice. 
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Chapter 5 - MRI Prediction of Surgical Margin Status in 
Rectal Cancer 
Background: A pathologically involved margin in rectal cancer is defined as tumour within 1 
mm of the surgical resection margin.  There is no standard definition of a predicted safe margin 
on magnetic resonance imaging (MRI).  
Aim: The aim of this study was to assess which cut-off (1, 2 or 5 mm) was the best predictor of 
local recurrence based on preoperative MRI assessment of the circumferential resection margin 
(CRM). 
Methods: Data were collected prospectively on the distance between the tumour and 
mesorectal fascia for patients with documented radiological margin status in the MERCURY 
study.  Positive margin and local recurrence rates were compared for MRI distances from the 
tumour to the mesorectal fascia of  1 mm or less, more than 1 mm up to 2 mm, more than 2 mm 
up to 5 mm and more than 5 mm.  The Cox proportional hazard regression method was used to 
determine the effect of level of margin involvement on time to local recurrence.  
Results: Univariate analysis showed that, relative to a distance measured by MRI of more than 
5 mm, the hazard ratio (HR) for local recurrence was 3.90 (95 per cent confidence interval 1.99 
to7.63; P < 0.001) for a margin of 1 mm or less, 0.81 (0.36 to 1.85; P = 0.620) for a margin of 
more than 1 mm up to 2 mm, and 0.33 (0.10 to 1.08;  P = 0.067)  for a margin greater than 2 
mm up  to 5 mm.  Multivariate analysis of the effect of MRI distance to the mesorectal fascia 
and preoperative treatment on local recurrence showed that a margin of 1 mm or less remained 
significant regardless of preoperative treatment (HR 3.72, 1.43 to 9.71; P = 0.007). 
Conclusion: For preoperative staging of rectal cancer, the best cut-off distance for predicting 
CRM involvement using MRI is 1 mm. Using a cut-off greater than this does not appear to 
identify patients at higher risk of local recurrence. 
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5.1 Introduction 
Tumour within 1 mm of the circumferential resection margin (CRM) on the resected specimen 
in rectal cancer surgery has been shown to be a powerful predictor of local recurrence and poor 
survival (Quirke et al., 1986, Birbeck et al., 2002, Cawthorn et al., 1990, Wibe et al., 2002, 
Nagtegaal and Quirke, 2008, Adam et al., 1994). A key advantage of preoperative assessment 
using high-resolution magnetic resonance imaging (MRI) is the ability to measure the distance 
from the outer edge of the tumour to the mesorectal fascia (Mercury Study Group, 2006, Beets-
Tan et al., 2001, Martling et al., 2003). 
There is some variation in the definition of MRI prediction of CRM involvement, which has led 
to differences in selection criteria for preoperative chemoradiotherapy.  Previous work showed 
a correlation between a measured MRI distance of greater than 5 mm to the mesorectal fascia 
and subsequent negative CRM on histopathology. This has resulted in preoperative 
chemoradiotherapy or long-course radiotherapy being offered to all patients with tumours 
extending to within 5 mm of the mesorectal fascia (Beets-Tan et al., 2001). The MERCURY 
study showed that histopathologically negative margins could be predicted using a 1-mm cut-
off and demonstrated that this was reproducible across 11 different centres with 18 different 
radiologists (Mercury Study Group, 2006). There is therefore, debate about the optimal cut-off 
distance for prediction of CRM involvement on MRI in patients with rectal cancer.  It is 
unclear whether a distance from the tumour to the CRM of more than 1 mm is of prognostic 
importance.  
The outcomes of patients followed up in the MERCURY study were analysed to determine: the 
relationship between distance from tumour to the mesorectal fascia and subsequent positive 
histopathological CRM involvement using cut-offs of 1, 2 and 5 mm; and whether more 
patients with subsequent local recurrence were identified by increasing the cut-off to 2 or 5 
mm, for all patients and the subset who had primary surgery alone without preoperative 
radiotherapy or chemoradiotherapy. 
5.2 Methods 
Study recruitment is summarized in figure 5.1. Follow-up was available for 374 (96.9 per cent) 
of 386 patients with complete histopathological and radiological data at the close of the study.  
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Figure 5.1: Study flow chart. MRI, magnetic resonance imaging 
 
 
5.2.1 Radiological Assessment 
Patients underwent MRI of the pelvis using a high-resolution protocol(Mercury Study Group, 
2006). Computed tomography (CT) was used to stage metastatic disease, both at diagnosis and 
annual follow-up.  The study was undertaken in 11 European hospitals; 18 radiologists at the 
trial centres (with 5–20 years’ experience in gastrointestinal imaging and MRI) reported on the 
scans before surgery and, as this was a prospective study, were blinded to the histopathology 
findings. The height of tumour from the anal verge was recorded. Data were recorded for 
distance of tumour, mesorectal lymph node metastases, extramural tumour nodules and 
extramural venous invasion (EMVI) to the potential resection margin.  The presence of any one 
or more of these features at the margin cut-offs of 1, 2 and 5 mm was classified as potential 
circumferential margin involvement.  If patients received preoperative therapy, where possible, 
the post-therapy, preoperative MRI CRM assessment was used for this analysis.  
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Positive margin rates (defined histologically using Quirke and Dixon’s definition of CRM 
involvement as tumour within 1 mm of the surgical resection margin) were compared with 
assessment of the potential surgical CRM, namely the mesorectal fascia, on the magnetic 
resonance image, for different cut-off distances (Quirke and Dixon, 1988). 
Treatment, Surgery and Histopathological Assessment 
Total mesorectal excision (TME) was planned in all patients according to a standard technique 
(Heald and Ryall, 1986).  Twenty-three surgeons took part in the study and all were trained in 
TME. Histopathological assessment was undertaken at each centre by specialist gastrointestinal 
histopathologists (with 5–25 years’ experience). The standard definitions for histologically 
involved margins were used (1 mm or less between the tumour and the margin)(Quirke and 
Dixon, 1988). The policy in the units was to offer postoperative single-agent fluoropyrimidine 
for stage III disease.  No patient received postoperative radiotherapy. 
Patients were assigned to appropriate treatment groups depending on their preoperative 
assessment. Each centre applied its local preoperative treatment policy: short-course 
radiotherapy, long-course radiotherapy, chemoradiotherapy or primary surgery, with a strategy 
that included long-course preoperative radiotherapy with or without chemotherapy for patients 
with potential CRM involvement identified by MRI.  Study patients were considered for 
preoperative therapy if MRI identified tumour 1 mm or closer to the CRM.  Surgical options 
included standard TME surgery or extended TME (TME with adjacent visceral resection). 
5.2.2 Quality Control 
In this prospective study, quality assurance was undertaken in the form of pathology and 
radiology workshops before recruitment commenced. Quality assurance for radiology reporting 
was undertaken by workshops for standardization of scanning techniques (Mercury Study 
Group, 2006, Brown et al., 2005, Taylor et al., 2008), image interpretation and reporting 
criteria. All scans were reported prospectively using a dedicated pro forma (Mercury Study 
Group, 2006).  Pathology workshops were also held before the study to standardize pathology 
examinations, using both the naked eye and microscopic assessment of the specimens.  
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5.2.3 Follow-Up 
Patients were followed according to local protocols. Typically this comprised clinic assessment 
every 3 months for 2 years and at 6-month intervals for 5 years. Clinical follow-up comprised 
physical examination, routine blood tests, and annual CT of the thorax, abdomen and pelvis.  
Local recurrence was defined as clinically or histopathologically verified recurrent disease in 
the pelvis. Histopathological confirmation of local recurrence was sought when appropriate or 
based on clinical or radiological enlargement of a recurrent mass. Details of surgery, including 
dates, operation performed and quality of the specimen were recorded prospectively; the date of 
last follow-up, and the date and cause of death were also collected. The presence of distant 
metastatic disease or local recurrence at the time of death was recorded as a rectal cancer-
specific death. 
5.2.4 Statistical Analysis 
Time to local recurrence was defined as the interval between first MRI and local progression. 
Patients with no recurrence were censored at the date of last follow-up or death. A univariate 
analysis of the association between time to local recurrence and margin involvement (recorded 
as distance in millimetres from the mesorectal fascia) and preoperative treatment was 
performed. The Cox proportional hazard regression method was used to determine the effect of 
level of margin involvement (1 mm or less, more than 1 mm up to 2 mm, more than 2 mm up to 
5 mm, more than 5 mm) on time to local recurrence. Hazard ratios and 95 per cent confidence 
intervals are reported. Multivariate analysis was performed to account for any potential 
confounding effect of preoperative treatment on distance from tumour to CRM. The level of 
significance was set at P < 0.050. Analysis was performed using PASW® Statistics 18 (SPSS, 
Chicago, Illinois, USA) and R 2.9.2(Everitt and Hothorn, 2006). 
5.3 Results 
Patient demographics are outlined in Table 5.1. At December 2008, surviving patients had been 
followed for a median of 62 months. 
  
 112 
Table 5.1: Demographic and clinical data 
 
 No. of patients 
(n = 374) 
Age (years) 
< 65 
   ≥ 65 
 
159 (42.5) 
215 (57.5) 
Sex ratio (M : F) 223 : 151 
Treatment 
   Long-course RT +  surgery 
   Short-course RT + surgery 
   Chemotherapy + RT + surgery 
   Surgery alone 
   Chemotherapy + surgery 
 
53 (14.2) 
47 (12.6) 
55 (14.7) 
216 (57.8) 
3 (0.8) 
Tumour height (cm)*    
> 5 
   ≤ 5 
 
261 (69.8)  
113 (30.2) 
Operation 
   Anterior resection and other 
   Abdominoperineal excision 
 
288 (77.0) 
86 (23.0) 
MRI UICC stage 
   I 
   II 
   III    
 
87 (23.3) 
105 (28.1) 
182 (48.7) 
Pathological UICC stage 
   I 
   II 
   III    
 
100 (26.7) 
117 (31.3) 
157 (42.0) 
Values in parentheses are percentages. *From anal verge. RT, radiotherapy; MRI, magnetic 
resonance imaging; UICC, International Union Against Cancer.  
 
5.3.1 Magnetic Resonance Imaging Cut-Off in Relation to Histopathology and 
Local Recurrence 
Histopathological CRM status and local recurrence in relation to 1-, 2- and 5-mm cut-offs of 
margin distance on MRI are summarized in figure 5.2 and table 5.2.Figures 5.3 and 5.4show 
examples of magnetic resonance images and corresponding histopathological findings.    
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Table 5.2: Rates of pathological circumferential resection margin positivity and local 
recurrence in relation to margin cut-off using magnetic resonance imaging for all patients 
and those who had surgery alone 
 
MRI margin N Pathology-positive 
CRM 
Local recurrence 
All patients  374 53 (13.9) 35 (9.4) 
   ≤ 1 mm   64 (17.1) 34 (53) 13 (20) 
> 1, ≤ 2mm  83 (22.2) 6 (7) 7 (8) 
> 2, ≤ 5 mm  83 (22.2) 7 (8) 3 (4) 
> 5 mm  144 (38.5) 6 (4.2) 12 (8.3) 
Surgery alone  216 24 (11.1) 16 (7.4) 
   ≤ 1 mm  11 (5.1) 9 (82) 2 (18) 
> 1, ≤ 2 mm  39 (18.1) 3 (8) 4 (10) 
> 2, ≤ 5 mm 50 (23.1) 7  (14) 3 (6) 
> 5 mm  116 (53.7) 5 (4.3) 7 (6.0) 
Values in parentheses are percentages. MRI, magnetic resonance imaging; CRM, 
circumferential resection margin. 
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Figure 5.2: Time to local recurrence in relation to tumour distance from mesorectal fascia 
measured by magnetic resonance imaging (MRI) 
 
Figure 5.3: Rate of pathological circumferential resection margin involvement and local 
recurrence in relation to tumour distance from mesorectal fascia measured by magnetic 
resonance imaging (MRI) 
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Figure 5.4: a. Axial T2-weighted magnetic resonance imaging in a 66-year-old woman 
with a mid-rectal cancer.  
The tumour has extended to within 1 mm of the mesorectal fascia (arrow). b. The 
corresponding histopathology section confirms tumour involvement of the circumferential 
resection margin 
 
 
 
Cut-off of 1 mm  
Sixty-four (17.1 per cent) of 374 patients were identified as having a potentially positive 
margin on MRI using the 1-mm cut-off, that is tumour at or within 1 mm of the mesorectal 
fascia.  Thirty-four (53 per cent) of these 64 patients had an involved CRM on pathology and 
13 (20 per cent) developed local recurrence. The local recurrence rate in those with a clear 
CRM was 7.1 per cent (220 of 310). 
Cut-off of 2 mm  
Some 147 (39.3 per cent) of 374 patients would have been identified as having a potentially 
positive margin on MRI using a 2-mm cut off; of these, 83 (56.5 per cent) had tumour located 
at more than 1 mm up to 2 mm from the mesorectal fascia. The pathological CRM was 
involved in six (7 per cent) of these 83 patients and seven (8 per cent) developed local 
recurrence. 
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Cut-off of 5 mm  
Two hundred and thirty (61.5 per cent) of 374 patients would have been identified as having a 
potentially positive margin on MRI using a 5-mm cut-off. Of these, 83 (36.1 per cent) had 
tumour located at more than 2 mm up to 5 mm from the mesorectal fascia. Therefore, if a cut-
off of 5 mm or less was used rather than 1 mm or less, a further 166 patients would have been 
identified as having potential margin involvement.  Thirteen (7.8 per cent) of 166 had a 
pathologically positive CRM and ten (6.0 per cent) developed local recurrence. 
5.3.2 Cox Proportional Hazards Analysis According to Margin Measured by 
Magnetic Resonance Imaging 
Relative to a margin measured by MRI of more than 5 mm, the hazard ratio (HR) for local 
recurrence was 3.90 (1.99 to 7.63; P < 0.001) for a margin of 1 mm or less, 0.81 (0.36 to 1.85; 
P = 0.620) for a margin of more than 1 mm to 2 mm, and 0.33 (0.10 to 1.08; P = 0.067) for a 
margin of greater than 2 mm to 5 mm.   
5.3.3 Univariate and Multivariate Analyses According to Preoperative Treatment 
Univariate analysis showed that, relative to chemoradiotherapy, the hazard ratio for local 
recurrence with long-course radiotherapy was 0.75 (0.29 to 1.98; P = 0.560), that for short-
course radiotherapy was 0.22 (0.05 to 0.98; P = 0.050) and that for surgery alone was 0.41 
(0.19 to 0.90; P = 0.030). There was no significant effect of treatment type on time to local 
recurrence in multivariate analysis.  
Multivariate analysis of margin and treatment type showed that a distance between the tumour 
and mesorectal fascia of 1 mm or less remained significant, regardless of preoperative 
treatment (HR 3.72, 1.43 to 9.71; P = 0.007). 
5.3.4 Outcomes in Patients Undergoing Primary Surgery Alone 
Some 216 of 374 patients underwent surgery alone and local recurrence developed in 16 (7.4 
per cent). Two of these patients had a predicted CRM of 1 mm or less, four had a predicted 
CRM of 1–2 mm and three had a predicted CRM of 2–5 mm. In the remaining seven patients 
the distance was predicted to be greater than 5 mm.   
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Taking into consideration the 216 patients who underwent primary surgery without 
preoperative or postoperative radiotherapy in the MERCURY study, if all patients with a 
tumour distance to the CRM of 5 mm or less rather than less than 1 mm or less were offered 
preoperative radiotherapy, 89 of 216 additional patients would have been treated to potentially 
prevent seven local recurrences. The local recurrence rate in patients undergoing primary 
surgery with a tumour distance to the CRM of 1–5 mm on MRI was 7.8 per cent, not 
significantly different from that in patients with a distance of more than 5 mm (6.0 per cent) (P 
= 0.607). 
5.4 Discussion 
Pathological involvement of the CRM in rectal cancer has been shown to be a powerful 
predictor of local recurrence and distant failure, regardless of treatment given. The standard 
definition for involvement of this margin is the finding of tumour within 1 mm from the 
resection margin. The ability to accurately identify involvement of the resection margin before 
surgery provides the clinician with an opportunity to institute therapy that may enable 
downstaging of the tumour. 
This study has shown that, regardless of treatment received, a cut-off of 1 mm or less for 
pathological involvement of the CRM, based on the distance between the tumour and 
mesorectal fascia measured by MRI is a good predictor of subsequent local recurrence.  
The rate of pathological CRM positivity was 53 per cent in the group with a margin of 1 mm or 
less defined by MRI, and fell to 7–8 per cent when the tumour distance to the mesorectal fascia 
was greater than 1 mm but no more than 5 mm. 
TME surgery has significantly reduced local recurrence rates in patients with rectal cancer 
(Wibe et al., 2004, Martling et al., 2000), and this study illustrates the safety of predicting the 
TME plane before surgery using MRI. In addition, optimal preoperative imaging and treatment 
of patients suspected to be at risk of a positive margin (margin 1 mm or less) has reduced the 
overall percentage of patients with margin involvement on histopathology to 13.9 per cent in 
the MERCURY study (Mercury Study Group, 2006).  In this study, the 5-year local recurrence 
rate for patients deemed CRM-positive on MRI using a cut-off of 1 mm or less was 20 per cent, 
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compared with 4–8 per cent in those with larger margins, giving a significantly worse hazard 
ratio.  
In a previous radiological study it was observed that a tumour-free margin of at least 1 mm 
could be predicted with a high degree of certainty when the measured distance on MRI was at 
least 5 mm, and a margin of at least 2 mm when the distance was 6 mm(Beets-Tan et al., 2001). 
With precise, standardised radiological definitions and consistent use of a high-resolution 
technique, the present study has now shown that it is possible to define a safe margin with 
greater certainty based on this multicentre experience.  CRM status is not the only factor 
involved in the prediction of local recurrence and it is well recognized that some patients 
develop local recurrence despite having an uninvolved margin (Wibe et al., 2002, Quirke et al., 
2009, Merkel et al., 2001). This data shows that up to 8 per cent of patients will develop local 
recurrence despite a clear margin.  It is therefore likely that other factors may play a small but 
important role in such patients. Further studies are needed to determine whether features such 
as tumour category, EMVI and lymph node status play a role in the development of local 
recurrence in CRM-negative patients after good quality TME surgery, and which of these 
patients can be identified by preoperative MRI (Mercury Study Group, 2007, Taylor et al., 
2008, Brown et al., 2003, Brown, 2004, Smith et al., 2008b, Yano and Moran, 2008).  This will 
be explored in a later chapter. 
One possible limitation of this study is that it compared outcomes in patients undergoing 
different treatments, for example primary surgery, short-course radiotherapy, and long-course 
radiotherapy with and without chemotherapy. However, multivariate analysis of preoperative 
treatments did not demonstrate any differences in CRM involvement and local recurrence 
between the treatment groups. Strengths of this observational study were that is was based on 
high quality imaging, TME surgery and audited pathological data. 
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Figure 5.5: a. Axial T2-weighted magnetic resonance imaging in a 71-year-old man with a 
low rectal cancer.  
The tumour has breached the muscularis propria anteriorly but the distance to the fascia is 2 
mm (diamond). b. The corresponding histopathology section confirms that the tumour is clear 
of the circumferential resection margin. 
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Chapter 6 - Preoperative MRI Assessment of 
Circumferential Resection Margin in Rectal Cancer 
Predicts Disease Free Survival and Local Recurrence 
Aims and Background: Preoperative high resolution MRI assessment of circumferential 
margin (CRM) involvement is of unknown prognostic relevance. This follow up study of 374 
rectal cancer patients reports the relationship between preoperative assessment of MRI staging 
of CRM, AJCC TNM stage, and clinical variables with overall survival (OS), disease free 
survival (DFS) and time to local recurrence (LR). 
Patients and Methods: Patients underwent high resolution protocol pelvic MRI.  A tumour 
distance to the mesorectal fascia of ≤1mm was recorded as an MRI involved CRM. 
Multivariate analysis used Cox proportional hazards model to determine the relationship of 
MRI assessment of CRM on survivorship after adjusting for preoperative covariates 
Results: Surviving patients were followed for a median of 62 months. OS at 5 years was 62.2 
% in patients with MRI clear CRM compared with 42.2% in patients with MRI involved CRM 
(P=0.01), HR = 1.97 (1.27-3.04), P<0.01). The 5 year DFS was 67.2% (95% CI: 61.4-73%) for 
MRI clear CRM compared with 47.3% (95% CI: 33.7-60.9 %) for MRI involved CRM 
(P=0.003); HR=1.65 (1.01-2.69) P<0.05).  Local recurrence HR for MRI involved CRM was 
3.50 (1.53-8.00); P<0.05). MRI involved CRM was the only preoperative staging parameter 
that remained significant for OS, DFS and LR on multivariate analysis. 
Conclusion: High resolution MRI preoperative assessment of CRM status is superior to AJCC 
TNM based criteria for assessing risk of LR, DFS and OS. Furthermore, MRI CRM 
involvement is significantly associated with distant failure; therefore colorectal cancer teams 
could intensify treatment and follow-up accordingly to improve survival outcomes 
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6.1 Introduction 
Tumour within 1mm of the surgical circumferential resection margin (CRM) as judged by the 
pathologist is a crucial, potentially preventable factor that predicts both local recurrence and 
poor survival. Sharp dissection along the mesorectal fascia produces an intact ‘specimen 
package’ comprising rectal tumour with the surrounding ‘mesorectum’ containing fat, 
connective tissue, local tumour deposits and lymph nodes. So, if complete removal of the 
tumour with a clear CRM is achieved, this should largely eliminate the risk of local recurrence.  
It would be advantageous to predict local recurrence risk by preoperative imaging. This would, 
firstly, enable more intensive preoperative treatments and secondly, provide a surgical road-
map to avoid breaching tumour. Although computed tomography (CT), endoluminal ultrasound 
(EUS) and magnetic resonance imaging (MRI) have shown acceptable accuracy for Tumour 
and Node staging, neither CT nor EUS are capable of assessing the potential CRM (Bipat et al., 
2004).  Current practice involves offering similar preoperative treatments to EUS/CT staged 
T3/T4 (AJCC stage II) and all node positive tumours (Stage III) (Sauer et al., 2004, Guillem et 
al., 2008). These comprise up to 80% of rectal cancers undergoing major resection; ranging 
from tumours that barely breach the rectal wall to gross extension beyond the mesorectal fascia. 
It could therefore, be argued that more selective treatment to target patients specifically at risk 
of local recurrence would improve outcomes.   
High-resolution magnetic resonance imaging can precisely delineate both local tumour extent 
and its relationship to the mesorectal fascia (Mercury Study Group, 2007, Blomqvist et al., 
1999, Brown et al., 2003, Martling et al., 2003, Mercury Study Group, 2006).  Although this   
is established the long term prognostic importance is unknown and there is no evidence to 
indicate whether or not MRI CRM status is independent of standard preoperative staging 
variables such as AJCC TNM stage which, arguably, could be equally well assessed using 
EUS.  
This study investigates the relationship between preoperative staging assessment of MRI CRM, 
AJCC TNM Stage I, II or III (Edge et al., 2010), clinical and histopathological variables and 
prediction of clinical outcomes: overall survival, disease free survival and time to local 
recurrence. 
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6.2 Patients and Methods 
6.2.1 Radiological Assessment: 
Eighteen study radiologists (with 5-20 years experience in MRI) evaluated scans before 
surgery, blinded to histopathology findings. 
 The MRI predicted AJCC TNM  stage and tumour height from anal verge were recorded;  
closest distance of tumour to the mesorectal fascia on baseline and post-treatment scans were 
measured to predict CRM status in all patients (mrCRM);  if a scan showed tumour ≤1mm from 
the mesorectal fascia, this was recorded as potentially involved CRM (mrCRM involved) 
(figure 6.1). Predicted clear mrCRM was defined if the distance of tumour to the mesorectal 
fascia was greater than 1mm. For lower third rectal tumours, mrCRM involvement was defined 
as tumour ≤1mm of the levator muscle. If tumour was present at or below the level of the 
puborectalis sling, mrCRM was predicted as involved if there was invasion into the 
intersphincteric plane or beyond mrCRM status at baseline and following treatment was 
recorded prospectively by each participating radiologist. If a post-treatment scan was not 
performed, baseline mrCRM was entered as the mrCRM status. 
  
 
Figure 6.1: A T2-weighted axial thin section magnetic resonance imaging and the 
corresponding gross tissue slice.  
This scan depicts a low rectal tumour with involvement of the potential CRM (white arrow) 
and the corresponding gross tissue slice. (Black arrow) 
 
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6.2.2 Treatment, Surgery and Histopathological Assessment 
Preoperative treatments allocated to patients at original presentation were recorded. Each centre 
applied their local treatment regimes but all had a policy of offering long course preoperative 
therapy for patients with mrCRM involvement. Surgical options included standardised 
technique of TME surgery or extended TME i.e.  TME with adjacent visceral resection (Heald 
and Ryall, 1986). 
The surgical TME specimen was T and N staged and assessed for involvement of the CRM 
(defined as tumour at 1mm or less from the radial resection margin, pCRM). Mesorectal 
specimen quality was prospectively graded for presence of defects or tears, by study 
pathologists using a three point grading system as described by Quirke et al. (1986), Quirke et 
al. (2009) and Nagtegaal et al. (2002b).  
6.2.3 Follow Up 
Patients were followed according to local protocols. Typically, this comprised three-monthly 
clinic assessment for two years and six-monthly clinic assessment for five years. Clinical 
follow up comprised physical examination, routine blood tests and yearly CT of thorax, 
abdomen and pelvis. Confirmation of local recurrence and distant recurrence was sought by 
biopsy when appropriate or based on progressive enlargement of recurrence. Surgery date, 
operation performed and specimen quality were recorded prospectively; the date of last follow-
up, date and cause of death were also collected. The presence of distant metastatic disease or 
local recurrence at time of death was recorded as rectal cancer-specific death.  
6.2.4 Statistical Methods and Analysis 
The study ended in October 2003 at all participating hospitals. All eligible and consenting 
patients with complete covariate data were included. Patient characteristics were presented 
using descriptive statistics. Patterns of failure, either local or distant, were compared with 
radiological staging, treatment, surgery and pathological assessment including specimen grade.  
The odds ratio, confidence limits and relative risk for mrCRM involvement resulting in pCRM 
involvement and local recurrence was calculated using the Cox-Hinkley-Miettinen-Nurminen 
method (Miettinen and Nurminen, 1985). 
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For survival analysis, ‘time till event’ (failure time) and censored observations were defined as 
follows: Overall survival (OS) was time from first MRI till death from any cause.  Patients who 
were alive or did not develop disease during the study (at last follow-up) were recorded as 
censored observations.  Disease free survival (DFS) was measured as duration in months from 
first MRI to date of loco-regional recurrence, distant metastases or to date of death from 
colorectal cancer; observations were censored at date of death due to non-colorectal cancer. 
Non colorectal cancer related events such as death or recurrence from second malignancies 
were not included as events. 
Time to local recurrence (LR) was measured from first MRI date until local progression; 
patients with no recurrence were censored at the date of last follow-up or death.  Patients 
without complete covariate data were excluded from survival analyses. 
Survival curves for OS, DFS and LR were calculated using the Kaplan Meier product limit 
method; differences between survival curves for mrCRM clear versus mrCRM involved were 
tested for significance using the Mantel-Cox log rank test. 
Univariate analysis was performed for the association between ‘time till event’ and known 
preoperative clinical variables (age, sex, type of preoperative treatment, MRI assessment of: 
tumour height, mrCRM and MRI predicted TNM stage group (I, II or III)], and postoperative 
variables (operation: anterior resection or abdominoperineal excision (APE), pCRM, and 
histopathology TNM stage group).  
Multivariate analysis using Cox proportional hazards model was performed to identify 
independent predictors of survival. All factors in the univariate analysis were included in the 
multivariate model using a ‘forced entry’ method.  Five-year survival times (and 95% CI) were 
calculated.  Cox proportional hazard (PH) models were used to determine the effect of both 
mrCRM and pCRM on survivorship after adjusting for pre and postoperative covariates 
respectively.  The PH assumption was assessed numerically using scaled Shoenfeld residuals. 
Adjusted hazard ratios (HR) were reported in the final analysis.  Significance for all tests was 
set at P<0.05.  Statistical analyses were performed using SPSS v18.0 for windows. 
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6.3 Results 
6.3.1 Patient Characteristics 
Baseline characteristics of 374 patients from 11 hospitals followed up are presented in Table 
6.1.  
The median age of patients was 63 years range (29-89 years). Of these, 216 (57.8%) patients 
underwent primary surgery, 108 (29%) received preoperative chemoradiotherapy or long-
course radiotherapy and a further 3 patients receiving neoadjuvant combination chemotherapy 
alone. Table 2 summarises treatments, baseline, post treatment mrCRM status, pCRM status 
and events during follow-up. The MRI positive predictive value for CRM involvement was 
53%, the negative predictive value was 94%, sensitivity was 64%, specificity, 91%, accuracy, 
87%. The odds ratio (OR) for mrCRM involvement resulting in positive pathologic CRM was 
17.36, (95% CI: 8.87 to 33.99), P < 0.001. The relative risk for mrCRM involvement versus 
mrCRM clear resulting in positive pathologic CRM was 8.67 (95 % CI: 5.30 to 14.19), P < 
0.001. At baseline, 98/374 (26%) of patients were considered to have potentially involved 
margins, 81 (83%) of whom received preoperative chemoradiotherapy or long-course 
radiotherapy to downstage the tumour; in 60/81 (74%) tumour regression resulted in pCRM 
negative and a consequent reduction in local recurrence to 7/60 (12%). For those patients that 
were mrCRM positive initially and remained positive on final pathology following CRT- local 
recurrence was observed in 8/21 (38%), this amounted to relative risk for local recurrence in 
favour of mrCRM downstaging by preoperative therapy of 0.30, (95 % CI: 0.12 to 0.74), 
P=0.009. 
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Table 6.1: Baseline characteristics by MRI CRM and pathology CRM (N=374) 
Variable 
  
  
Frequency  
(%) 
5-yr  overall 
survival rate 
(95% CI) 
  
MRI Predicted Pathology 
CRM 
neg  % 
CRM  
pos % 
CRM  
Neg % 
CRM  
Pos % 
    310  82.9% 64 17.1% 321 85.8% 53 14.2% 
Age (yrs) <65 158 (42.2) 69.7 (62.1-77.3) 129 81.6% 29 18.4% 138 87.3% 20 12.7% 
≥65 216 (57.8) 50.7 (43.7-57.7) 181 83.8% 35 16.2% 183 84.7% 33 15.3% 
Sex Male 223 (59.6) 52.6(45. 6-59.6) 179 80.3% 44 19.7% 189 84.8% 34 15.2% 
Female 151 (40.4) 67.7 (59.9-75.5) 131 86.8% 20 13.2% 132 87.4% 19 12.6% 
Treatment Long course 53 (14.2) 53.6 (39.6-67.6) 22 41.5% 31 58.5% 39 73.6% 14 26.4% 
Short course RT 47 (12.6) 58.6 (44-73.2) 41 87.2% 6 12.8% 41 87.2% 6 12.8% 
Chemo & RT 55 (14.7) 50 (36.4-63.6) 39 70.9% 16 29.1% 46 83.6% 9 16.4% 
Surgery only 216 (57.8) 61.9 (54.9-68.9) 205 94.9% 11 5.1% 192 88.9% 24 11.1% 
Neoadjuvant 
Chemo 
3 (0.8) - 3 100.0% 0 0.0% 3 100.0% 0 0.0% 
Specimen 
quality 
Muscularis propria 20 (5.3) 30 (9.6-50.4) 11 55.0% 9 45.0% 11 55.0% 9 45.0% 
Intramesorectal 67 (17.9) 60.1 (47.5-72.7) 61 91.0% 6 9.0% 55 82.1% 12 17.9% 
Mesorectal 233 (62.3) 61.5 (54.9-68.1) 209 89.7% 24 10.3% 212 91.0% 21 9.0% 
Missing 54 (14.4) - 29 53.7% 25 46.3 43 79.6% 11 20.4% 
Tumour height > 5cm 261 (69.8) 57.6 (51.2-64) 225 86.2% 36 13.8% 231 88.5% 30 11.5% 
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≤ 5cm 113 (30.2) 59.8 (50.4-69.2) 85 75.2% 28 24.8% 90 79.6% 23 20.4% 
Operation Sphincter 
preserving TME 
288 (77.0) 61.2 (55.2-67.2) 253 87.8% 35 12.2% 261 90.6% 27 9.4% 
AP excision 86 (23.0) 48.8 (37.6-60) 57 66.3% 29 33.7% 60 69.8% 26 30.2% 
MRI AJCC 
TNM Code 
Stage I 87 (23.2) 62 (51.2-72.8) 86 98.9% 1 1.1% 83 95.4% 4 4.6% 
Stage II 105 (28.1) 58.7 (48.9-68.5) 82 78.1% 23 21.9% 91 86.7% 14 13.3% 
Stage III 182 (48.7) 57.2 (49.6-64.8) 142 78.0% 40 22.0% 147 80.8% 35 19.2% 
 Pathology 
AJCC TNM 
Code  
Stage I 100 (26.7) 82.2 (74.4-90) 93 93.0% 7 7.0% 100 100.0% 0 0.0% 
Stage II 117 (31.3) 52.6 (43 -62.2) 90 76.9% 27 23.1% 100 85.5% 17 14.5% 
Stage III 157(42.0) 48.3 (39.9-56.7) 127 80.9% 30 19.1% 121 77.1% 36 22.9% 
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Table 6.2: Treatments given, baseline and post treatment MRI assessments of predicted CRM status, pathological CRM status 
and events during follow-up according to treatment category and CRM status 
Baseline 
mrCRM status 
Clear n=276 
Involved n=96 
Preoperative (post neoadjuvant 
therapy) 
mrCRM clear 
N=310 
Preoperative (post neoadjuvant 
therapy) 
mrCRM involved 
N=64 
Total 
Treatment 
Given 
pCRM 
clear 
LR DF pCRM 
involved 
LR DF pCRM  
clear 
LR DF pCRM 
involved 
LR DF LR (%) DF (%) 
Long course 
RT 
N=53  
mrCRM 
clear n=10 
 9 0 3 0 0 0 0 0 0 1 0 0 0 (0%) 3 (30%) 
mrCRM 
involved 
n=43 
13 2  5 0 0 0 17 1 4 13 4 4 7 (16%) 13 
(30%) 
ChemoRT 
N=55 
  
mrCRM 
clear n=18 
17 1  7 1 1 0 0 0 0 0 0 0 2 (12%) 7 (38%) 
mrCRM 
involved 
n=37 
 21 2  7 0 0 0 8 2 1 8 4 1 8 (22%) 9 (24%) 
Neoadjuvant  
Induction Chemo 
N=3 
  
mrCRM 
clear n=2 
2 0  1 0 0 0 0 0 0 0 0 0 0 (0%) 1 (50%) 
mrCRM 
involved 
n=1 
1 0  0 0 0 0 0 0 0 0 0 0 0 (0%) 0 (0%) 
Primary surgery 
N=216 
mrCRM 
clear n= 205 
190 11  42 15 3 2  14 (7%) 44 
(21%) 
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 mrCRM 
involved 
n=11 
 2 0 0 9 3 5 3(27%) 5 (45%) 
25 x 5Gy RT with 
immediate Surgery 
N=47 
mrCRM 
clear  = 41 
38 2  9 3 0 1  2 (5%) 10 
(26%) 
mrCRM 
involved =6 
 3 0 1 3 0 1 0(0%) 2 (33%) 
Grand Total 
374  
291 18 74 19 4 3 30 3 6 34 11 11 36 
(9.6%) 
94(25%) 
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6.3.2 Events During Follow-Up 
Median follow up of surviving patients was 62 months. Of 159 deaths during follow-up, 
108 (68%) were rectal cancer related and 40 (25%) from other causes. In 11 (6.9%) cases 
the cause of death was unknown. Local recurrence alone occurred in 14 (3.7%) patients and 
22 (5.9%) patients had both local and distant recurrence. A total of 93 (25 %) patients had 
distant recurrence only.  
6.3.3 Univariate and Multivariate Analysis of Preoperative Clinical and 
Imaging Characteristics 
Table 6.3 summarises the results of univariate and multivariate analysis for the association 
between OS, DFS and LR and preoperative clinical variables. MRI predicted a potentially 
involved CRM in 64 patients; of these 32/64 relapsed and 38 died.  OS at five years was 
62.2 % (95% CI: 56.4-68%) in patients with mrCRM clear margins compared with 42.2% 
(95%CI: 29.4-55%) in patients with mrCRM predicted involved margins (P=0.01) (Figure 
6.2). mrCRM involvement remained significant for poor OS on multivariate analysis HR = 
1.97 (95% CI: 1.27-3.04) (P<0.05).  
The five-year DFS was 67.2% (95% CI: 61.4-73%) for patients with mrCRM clear margins 
compared with 47.3% (95% CI: 33.7-60.9 %) in patients with mrCRM involved margins 
(P=0.003) (Figure 6.2).mrCRM involvement remained significant for poor DFS on 
multivariate analysis HR 165 (95% CI: 1.01-2.69), P<0.05. 
Of the 374 patients 22/310 (7.1%) patients with clear mrCRM developed LR compared 
with 13/64 (20%) with mrCRM involvement. The hazard ratio for LR in patients with MRI 
predicted CRM involvement was3.9 (95% CI: 1.99-7.62; P<0.0001) (Table 6.3). Only 
mrCRM involved remained significant for LR on multivariate analysis (HR= 3.50, 95% CI: 
1.53-8.00), P<0.01. 
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Table 6.3: Overall survival, Disease-free survival and time till local recurrence: HR and 95% CI and P-values for univariate 
and multivariate analyses of preoperative clinical staging factors using Cox regression model (N=374).  
P-value (Wald statistic): *P<0.05; **P<0.01; ***P<0.0001 SCRT=Short Course Radiotherapy, RT = Radiotherapy 
Variable Categories Overall survival Disease-free survival Time till local recurrence 
(Stratified on UICC) 
HR (95% CI); P-value HR (95% CI); P-value HR (95% CI); P-value 
Univariate 
analysis 
Multivariate 
analysis 
Univariate 
analysis 
Multivariate 
analysis 
Univariate 
analysis 
Multivariate 
analysis  
Age <65 years  1 1 1 1 1 1 
≥65 years 1.90 (1.36-
2.66)*** 
1.91 (1.37-
2.68)*** 
1.03 (0.73-
1.45) 
1.04 (0.73-1.47) 0.92 (0.48-
1.77) 
0.98 (0.50-1.89) 
Sex Male 1 1 1 1 1  
Female 0.65 (0.46-
0.9)* 
0.70 (0.50-0.98) 
* 
0.6 (0.41-
0.87)* 
0.64 (0.44-
0.94)* 
0.52 (0.25-
1.08) 
0.57 (0.27-1. 2) 
Treatment LCRT 1 1 1 1 1  
SCRT 0.82 (0.46-
1.46) 
1.14 (0.62-2.10) 0.6 (0.31-1.16) 0.87 (0.43-1.77) 0.29 (0.06-
1.38) 
0.63 (0.12-3.2) 
Chemo & RT 1.07 (0.63-
1.83) 
1.29 (0.74-2.24) 1.1 (0.62-1.89) 1.45 (0.82-2.60) 1.33 (0.51-3.5) 2.20 (0.82-5.89) 
Surgery only 0.75 (0.48-
1.17) 
0.99 (0.57-1.71) 0.68 (0.42-
1.09) 
1.31 (0.73-2.38) 0.55 (0.23-1.3) 1.98 (0.66-5.91) 
Height from 
anal verge 
>5cm 1 1 1 1 1  
≤5cm 0.90 (0.64-
1.27) 
0.87 (0.60-1.25) 1.27 (0.89-
1.81) 
1.35 (0.92-1.99) 1.97 (1.03-
3.8)* 
2.15 (1.06-4.37) 
MRI stage 
group (TNM 
version 5)   
MRI Stage I 1 1 1 1 1  
MRI Stage II 1.13 (0.73-
1.76) 
0.90 (0.57-1.44) 2.23(1.23-
4.06)** 
2.01(1.09-3.71) 
* 
1.87(0.58-
6.07) 
1.37(0.40-4.69) 
MRI Stage III 1.13 (0.76-
1.69) 
0.91(059-1.40) 2.69(1.54-
4.68)*** 
2.42(1.36-4.32) 
* 
2.8(0.98-8.2) 
P=0.054 
2.08(0.68-6.37) 
MRI CRM Negative 1 1 1 1 1 1 
Positive 1.99 (1.39-
2.89)*** 
1.97 (1.27-
3.04)* 
1.96 (1.31-
2.94)* * 
1.65 (1.01-2.69) 
* 
3.9 (1.99-
7.62)*** 
3.50 (1.53-
8.00)* 
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Table 6.4: Overall survival, Disease-free survival and time till local recurrence: HR and 95% CI and P-values for univariate 
and multivariate analyses of postoperative clinical staging factors using Cox regression model (N=374). 
P value (Wald statistic):*P<0.05; **P<0.01; ***P<0.0001 SCRT=Short Course Radiotherapy, RT=Radiotherapy 
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6.3.4 Univariate and Multivariate Analysis of Post Operative and 
Histopathological Characteristics 
Table 6.4 summarises the results of univariate and multivariate analysis of the 
association between OS, DFS and LR of post operative variables. For LR, the only 
factors that remained significant on multivariate analysis were abdominoperineal 
excision and pathology CRM status. 
Of the 53 patients who had pCRM involvement, there were 29/53 relapses and 35 
deaths.  OS at five years was 63.3 % (95% CI: 57.7-68.9%) in patients with clear pCRM 
and 30.2% (95% CI: 17-43.4%) in patients with pCRM involvement (P=0.001). For OS, 
the HR in patients with pCRM involvement, compared with pCRM clear patients, was 
2.77 (95% CI: 1.91 to 4.02; P<0.0001). The five-year DFS was 63.3% (95% CI: 57.7-
68.9%) in pCRM clear patients (P<0.001) (Figure 6.3) and 34% (95% CI: 17-43.4%) in 
patients with pCRM involvement. For DFS, the HR in the latter group was 1.96 (95% 
CI: 1.31 to 2.94; P<0.01). 
Of the 374 patients,21/321 (6.5%) patients with clear pCRM developed local recurrence 
compared with 14/53 (26.4%) patients with involved pCRM. The HR for pCRM 
involved patients, as compared with the clear pCRM patients, was6.66 (95% CI: 3.41 - 
13.0; P<0.0001). 
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Figure 6.2: Results and Kaplan-Meier plots for Overall survival, Disease-free 
survival and time till local recurrence according to CRM status 
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6.3.5 Comparison of MRI and Histopathology Assessment of Outcomes 
According to CRM Status 
In 34 patients MRI predicted, and subsequent pathological assessment confirmed 
involved CRM. The five-year OS for this group was 21.6% (95% CI: 6.8-36.4%)and, 
the five-year DFS  was 25.1% (95% CI: 7.7 - 42.5%).  The 5-year LR rate was 32.3% 
(95% CI: 19.7-50.3%) (11/34). 
In contrast 30 patients had mrCRM involvement, but clear pCRM. The five-year OS for 
this group was 66% (95% CI 48.4-83.6), for  DFS 69.9 percent (95% CI: 51.9-87.9) and 
the LR rate was 10% (95% CI: 3.1-26%) (3/30). Of patients who had clear mrCRM but 
involved pCRM (n=19), there were 4 (21.1%) LRs, 4 (21.1%) with metastatic disease 
and 10 (52.6%) died.  Of these, 8 were positive margins from APE (42.1%), including 4 
tumour perforations.  
6.3.6 Plane of Surgery 
Of the 374 specimens, 320 (86%) were prospectively evaluated to determine the plane 
of surgical excision achieved.  Of the 320 graded specimens, 233 (73%) were in the 
mesorectal plane, 67 (21%) were intramesorectal and 20 (6.3%) were muscularis 
propria plane.    
6.4 Discussion 
This is the first, prospective, multi-centre study to evaluate the prognostic relevance of 
rectal cancer MRI preoperative staging and shows that both mrCRM and pCRM status 
(using a cut off of ≤1mm) are both equally good predictors for LR, DFS and OS.  A 
strategy of pelvic radiotherapy to reduce LR based on pre-operative assessment of 
AJCC TNM stage may therefore not be optimal as these factors do not adequately 
predict LR risk.  Only mrCRM status remained independently significant for LR 
regardless of other known preoperative variables.   
The overall LR rate was small, observed in only 36/374 patients (9.6%)  much lower 
than previously published results.  Nevertheless, LR for CRM involvement was 20% for 
MRI predicted and 27% for pathology confirmed cases compared with only 7% LR if 
the CRM was clear by either MRI or pathology. The highest LR and poorest survivals 
were in patients with both MRI predicted and pathology confirmed CRM with a 25% 
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DFS and 32% LR rates. Future clinical trials should re-appraise the intensity of adjuvant 
therapy and surveillance for this high risk group of patients.  The higher LR rates in 
previous studies relate to both a lack of high resolution MRI assessment of the predicted 
CRM and significantly higher proportions of poor quality TME specimens compared 
with only (6%) audited as muscularis propria plane in this MERCURY study. Therefore 
if the study findings are to be widely applied, treatment decisions based on preoperative 
high resolution mrCRM assessment may only be safely made if there is audited and 
histopathological evidence that good quality TME surgery is consistently undertaken. 
Poor survival outcomes with high distant failure rates were observed for mrCRM 
involvement despite 82% of these patients receiving preoperative therapy. Therefore, 
such patients may have better long-term outcomes from neoadjuvant combination 
chemotherapy prior to pelvic radiotherapy and that with both treatment of occult distant 
and local tumour regression from the CRM could be achieved. Whilst both digital rectal 
examination and EUS provides important clinical information, this study demonstrates 
that high resolution MRI CRM assessment identifies patients with particularly poor 
outcomes enabling teams to specifically direct treatment towards reducing local 
recurrence and improving survival.  
6.5 Supplementary Data 
6.5.1 MRI High Resolution Scan Parameters 
The protocol employed a thin 3mm section turbo spin-echo T2-weighted technique 
using a surface pelvic phased array coil and a small field of view (16 x 16cm). The 
machines and workstations used by each centre are shown in appendix 1. No bowel 
preparation, air insufflation or intravenous anti-spasmodic agents were routinely used. 
We did not use intravenous contrast enhancement as this has not found to have been 
helpful (Brown et al., 2005), nor did we use intrarectal contrast. 
For a 1.5T magnetic resonance imaging scanner, four sequences were used:  
After a coronal localiser, sagittal turbo (fast) spin-echo sequences from inner pelvic 
sidewall to sidewall using a 24cm field of view, 5mm contiguous/interleaved slices (no 
gap), TR>2500 and <5000, TR=85 were obtained. These acquisitions were used to plan 
thin section oblique axial images. 
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Axial T2 Turbo fast spin-echo acquisitions of the anatomic pelvis by using a 24cm field 
of view, a 5mm contiguous section thickness, 4000/85, 512 x 256 matrix, an echo train 
length of eight, no fat saturation, a 32kHz bandwidth, and two signals acquisitions 
(2NEX). 
The sagittal T2 weighted images obtained were then used to plan T2-weighted thin-
section axial images through the rectal cancer. These images were performed 
perpendicular to the long-axis of the rectum. These were obtained by using a 16cm field 
of view, a 3mm section thickness, no intersection gap, 4000/85, a 256 x 256 matrix, an 
echo train length of eight, no fat saturation, a 32kHz bandwidth and four acquisitions 
(giving a voxel size of 1mm3 and a pixel size of 0.6 x 0.6mm). These sequences were 
repeated with imaging in the coronal plane for all tumours arising at, or below, the 
levator muscle origin. 
For a 1.0T magnetic resonance imaging Scanner, the imaging parameters were modified 
to obtain an adequate SNR. The high resolution images are obtained with 20cm field of 
view, 3 mm section thickness, no intersection gap, a 256 x 256 matrix, a TR >2500 
(<5000), and a TE > 80. 
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Table 6.5: MRI vs. Pathology status and local recurrence outcomes 
 Pathology CRM 
Clear 
Path CRM 
involved 
Total 
MRI CRM Clear 291 19 310 
MRI CRM involved 30 34 64 
Total 321 53 374 
 Number of patients with local 
recurrence at 5 yrs 
Patients without 
local recurrence 
Total 
Pathology CRM 
involved 
15 38 53 
Pathology CRM clear 21 300 321 
MRI CRM involved 14  50 64 
MRI CRM clear 22  288 310 
 Point estimate 95% confidence limits 
Odds Ratio (OR) for 
local recurrence and 
pathology CRM status 
5.64 2.71 -11.77 (p<0.05) 
Odds Ratio (OR) for 
local recurrence and 
mrCRM status 
3.67 1.78 -7.58 (p<0.05) 
 Number of patients with local 
recurrence at 5 yrs 
Patients without local 
recurrence 
pN0 17 200 217 
pN1/2 19 138 157 
mrN0 13 179 192 
mrN1/N2 23 159 182 
 Point estimate 95% confidence limits 
Odds Ratio (OR) for 
local recurrence by pN 
status   
1.62   0.82 - 3.20  (n.s.) 
Odds Ratio (OR) for 
local recurrence by 
mrN status 
1.99 0.99 - 4.02 (n.s.) 
The data demonstrates that mrCRM and pCRM status are both strong predictors for 
local recurrence outcomes - this can be seen by the near-identical local recurrence rates 
observed in patients with predicted mrCRM status as pCRM status. Neither pathology 
nor MRI nodal status is associated with local recurrence.    
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Chapter 7 - Preoperative Prognostic Factors on MRI 
Predicts Outcome at 5 years in the MERCURY 
Study of Rectal Cancer 
Aims and Background: In rectal cancer, histopathological examination of the surgical 
specimen has always provided prognostic information.  The aim of this study was to 
determine whether high resolution MRI used preoperatively to identify certain potential 
prognostic factors, could predict outcome at 5 years. 
Methods: This study included all 374 patients involved in the MERCURY study. All 
patients underwent high resolution MRI and were scored by one of 18 radiologists for 
the following MRI features: circumferential resection margin status (CRM), T and N 
stage, extramural venous invasion (EMVI) and tumour height. The effect of the 
predictive factors on disease free survival (DFS) and local recurrence (LR) was 
assessed.  
Results: MRI assessment of: tumour height, CRM and EMVI were independent factors 
for LR on multivariate analysis regardless of preoperative treatment, age and sex of 
patient, depth of extramural spread and nodal status. Patients with no risk factors had a 
local recurrence rate of only 3.3% rising to 51% if all 3 factors were present HR = 24.17 
(95%CI 8.58-68.11) times risk of developing LR (p<0.001). 
DFS was strongly influenced by MRI extramural depth of tumour spread >5mm and 
EMVI.  DFS for patients with either extramural tumour spread >5mm or EMVI was 
significantly worse (Hazard ratio of 2.2, 95% CI 1.33-3.70, p =0.002 and 2.9 95% CI 
1.74-4.70, p< 0.001 respectively). 
Conclusions: This study demonstrates a clinically applicable MRI prognostic model for 
disease free survival and local recurrence. Preoperative imaging of EMVI, extramural 
depth of tumour spread and CRM status identifies patients who are at risk of local and 
systemic relapse, providing the multidisciplinary team with the opportunity to target 
preoperative therapy in high-risk groups.  
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7.1 Introduction 
Traditionally, rectal cancer staging has been based upon clinical examination and 
histopathological assessment of the resected specimen. TNM, AJCC and Duke’s staging 
all correlate with LR and survival (Heald and Ryall, 1986, Salerno et al., 2009, Dukes, 
1932, Sobin and Wittekind, 1997).  Whilst postoperative examination of the surgical 
specimen yields prognostic information that predicts clinical outcome, the opportunity 
to have optimised the preoperative treatment or surgical strategy is evidently lost. A 
validated preoperative prognostic system would facilitate patient stratification in 
clinical trials, help to determine both the need for and intensity of, neoadjuvant therapy.   
Further it would aid in surgical planning and determine the frequency of follow up.  
Until now there has been limited application of preoperative MRI staging to determine 
treatment strategy largely because of a paucity of information on the ability of MRI 
staging to determine high and low risk groups 
Of the known histopathological factors, pathological node and circumferential resection 
margin (CRM) status of the resected specimen are the dominant factors considered to be 
of sufficient prognostic importance to materially influence postoperative treatment 
decisions (Hermanek and Junginger, 2005, Harrison et al., 1994, Quirke et al., 1986, 
Birbeck et al., 2002, Cawthorn et al., 1990, Nagtegaal and Quirke, 2008, Rich et al., 
1983, Chapuis et al., 1985, Astler and Coller, 1954, Jass et al., 1987, Stocchi et al., 
2001, Mercury Study Group, 2006).  Currently adjuvant chemotherapy treatments are 
largely dictated by histopathological assessment of these features supplemented in some 
centres by appropriate molecular targeting and predictive markers of response to 
specific treatments. The main disadvantages of adjuvant therapy are delays to the onset 
of treatment and poor patient compliance following major surgical resection.  Many 
patients are either unable, or unwilling, to commence or complete therapy after surgery   
with its attendant complications and functional disturbances. 
 Prospective evaluation of high resolution MRI showed that MRI predicted depth of 
extramural spread, MR EMVI, nodal status, and potential mesorectal fascial 
involvement (the CRM in Total Mesorectal Excision)  could be correlated with 
corresponding histopathology (Rao et al., 2007, Mercury Study Group, 2006, Mercury 
Study Group, 2007, Brown et al., 2003, Salerno et al., 2009, Smith et al., 2008a, Taylor 
et al., 2008, Heald and Ryall, 1986).  
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It has also been shown that extramural spread on histopathology >5mm is associated 
with poor survival, that extramural venous invasion is associated with poor disease free 
survival and that tumour involvement of the CRM is associated with local recurrence 
(Dukes, 1932, Harrison et al., 1994, Hermanek and Junginger, 2005, Quirke et al., 1986, 
Sobin and Wittekind, 1997, Merkel et al., 2001, Talbot et al., 1980, Hermanek et al., 
1989b).  This crucial staging information has not yet been combined to develop a 
validated preoperative prognostic stratification. 
This study reports an analysis of MRI assessment of: depth of extramural spread (mm), 
EMVI, nodal status, CRM and height of tumour enrolled in this follow up study. The 
study reports on patients with a minimum of 5 years clinical follow up. The aim is to 
compare the current AJCC stratification applied to preoperative MRI with a staging 
system incorporating more detailed MRI staging factors hoping to optimally stratify the 
risk of recurrence in rectal cancer patients.  
7.2 Methods 
7.2.1 Patients 
Figure 7.1 summarises recruitment as previously outlined. A minimum of Five year 
follow up was completed for all patients in December 2008. Overall outcomes of 374 
patients are reported.  
  
 145 
 
Figure 7.1: Study flow chart. MRI, magnetic resonance imaging 
 
7.2.2 MRI Assessment 
All patients underwent high resolution MRI performed according to a standardised 
high-resolution protocol to assess the tumour using small field of view 3mm (high 
resolution) T2-weighted images as previously documented (Chapter 2).  MRI data was 
collected on the following features: Predicted mesorectal fascial involvement (mrCRM 
status using a definition of tumour <=1mm as an involved margin), mrT stage, depth of 
extramural spread, mrN stage, mrEMVI, and tumour height.  
Five year follow-up data was collected on local recurrence and distant failure as 
previously recorded. 
7.2.3 Statistical Methods 
Variables were categorised as low or high risk to enable binary comparison by 
multivariate analysis. The effect of the candidate predictive factors on disease free 
survival and local recurrence was assessed, using the Cox proportional hazards model.  
This was defined as the earliest event of, death, distant or local recurrence. 
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The following prognostic factors were assessed: 
1. MRI T stage – Subdivided either into low and high risk T substage based on depth of 
extramural spread as follows: mrT- T0 - no tumour, mrT1- tumour confined to 
submucosa, mrT2 -tumour confined to muscularis propria, mrT3a tumour spread 
beyond muscularis propria<1mm, mrT3b extramural spread 1-5mm, mrT3c >5mm 
and<15mm, mrT3d =>15mm. This stratification was used because  assessment of 
extramural spread >5mm has been established as a poor prognostic indicator in several 
pathology studies (Harrison et al., 1994, Cawthorn et al., 1990, Jass et al., 1987, Merkel 
et al., 2001). Furthermore, extramural depth of spread has been validated by the 
MERCURY study group when compared to corresponding histopathology 
measurements (Mercury Study Group, 2007). 
2. MRI Circumferential resection margin (CRM involved or clear) - Patients were 
defined at  high risk of CRM involvement if the  tumour extended to within 1mm of the 
mesorectal fascia or penetrated through it. In addition, any tumours arising at or below 
the level of the puborectalis muscle were also defined as high risk based on tumour 
extension into the intersphincteric plane or beyond (Salerno et al., 2009).  
3. MRI Nodal Stage - Low risk was defined as no suspicious nodes = mrN0, high risk as 
MRI predicted nodal involvement. Based on either, mixed signal intensity or irregular 
borders, mrN1 or N2 (Brown et al., 2003). 
4. MRI detected extramural venous invasion (mrEMVI present defined as high risk, or 
absent, low risk). Extramural venous invasion on MRI was defined as serpiginous, 
nodular or vascular expansion by tumour signal of extramural vessels  
5. MRI Height of tumour: defined as distance in mm from the lowest edge of the 
tumour to the anal verge   
6. Age (years)  
7. Gender  
8. Type of surgery -Anterior resection/other or abdominoperineal excision 
9. Type of preoperative therapy, = (none i.e. surgery alone, preoperative short course 
radiotherapy, long course chemoradiotherapy or long course radiotherapy 
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7.2.4 Statistical Analysis 
The construction of the prognostic model started with a univariate assessment of the 
effect of each factor.  Multivariate analysis was then performed using stepwise Cox 
proportional hazards regression modelling. The backward elimination procedure was 
followed whereby initially all candidate predictors (defined if p<0.1) were included 
simultaneously in the model and the least significant predictor variables successively 
removed with significance set defined as p≤0.05 (DaSL, 1989). Data analysis was 
performed using SPSS statistical package 18.  
The prognostic model was compared against the current standard AJCC classification: 
Stage 1: T1-T2N0M0, Stage II: T3/T4 N0 and Stage III: T any N1 or N2 for  
7.3 Results 
A total of 374 patients from 11 hospitals were recruited and results reported   
demographic characteristics are presented in Table 7.1.  Events during follow-up are 
shown in Table 7.2. 
As of December 2008, surviving patients had been followed for a median of 61.5 
months (range: 0 to 81 months). Of the 159 deaths during follow-up, 108 (68%) were 
related to rectal cancer and 40 (25%) to other causes. In 11 (6.9%) cases the cause of 
death was unknown.  LR alone occurred in 14/374 (3.7%) patients, 22 (5.9%) patients 
had both local and distant recurrences. A total of 93 (25 %) patients had distant 
recurrence only. The median survival for the whole group was 73.2 % (71.140 - 
75.286).  Five year disease free survival was 63.9% (58.5-69.3). 
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Table 7.1: Demographics 
Variable                                          Frequency (%)  
Age (years)   
<65 157 (42.3)  
≥65 214 57.7)  
Sex   
Male 223 (59.6)  
Female 151 (40.4)  
Treatment   
Long course RT 53 (14.2)  
Short course RT 47 (12.6)  
Chemo & RT 55 (14.7)  
Surgery only 216 (57.8)  
Chemo only 3 (0.8)  
Tumour height   
> 5cm 261 (69.8)  
≤ 5cm 113 (30.2)  
Operation   
Anterior resection and other 288 (77.0)  
AP excision 86 (23.0)  
AJCC Code MRI Pathology  
Stage I 87 (23.2) 100 (26.7) 
Stage II 105 (28.1) 117 (31.3) 
Stage III 182 (48.7) 157(42.0) 
N stage MRI Pathology 
Node positive 184 (49.2) 157(42) 
Node negative 190 (50.8) 217(58) 
T Stage MRI Pathology 
<T3c 248 (66.3) 262(70.1) 
T3c or greater 126 (33.7) 112(29.9) 
CRM MRI Pathology 
Involved 64 (17.1) 53(14.2) 
Clear 310(82.9) 321(85.4) 
EMVI MRI Pathology 
Positive 118 (31.6) 85(22.7) 
Negative 256 (68.4) 289(77.3) 
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Table 7.2: Follow-up events 
Prognostic Factors Number (%) 5 year DFS (95% CI)  5 yr LR (95% CI) 
Clinical factor    
AGE <70 158 (42.2) 63.9   (55.9-71.9) 10.6 (5.8-15.4) 
>70 216 (57.8) 63.9   (56.7-71.1) 12.4 (6.8-18) 
Sex – female 151 (40.4) 73.0   (65.4-80.6) 7.5  (2.9-12.1) 
Male 223 (59.6) 57.6   (50.4-64.8) 14.3 (8.9-19.7) 
MRI Prognostic factor    
Low risk <T3c 248 (66.3) 72.7  (66.5- 78.9) 7.8 ( 4.0-11.6) 
High risk T3c or worse 126 (33.7) 47.0  (37.4-56.6) 19.0 (11.0-27.0) 
Node negative 191 (51.1) 70.7  (62.7-78.7) 7.5 ( 3.3 -11.7) 
Node positive 183 (48.9) 57.2   (49.2-65.2) 15.7 (9.5-21.9) 
EMVI negative 256 (68.4) 76.2  (70.2-82.2) 6.0 (2.8-9.2) 
EMVI positive 118 (31.6) 37.4  (27.4 – 47.4) 24.5 (15.1-33.9) 
CRM –ve 310 (82.9) 67.2    (61.4-73.0) 8.7  (5.1-12.3) 
CRM +ve 64 (17.1) 47.3    (33.7-60.9) 26.3 (13.5-39.1) 
Height >5cm 261 (69.8) 66.9    (60.5-73.3) 9.1 (5.1- 13.1) 
Height ≤ 5cm 113 (30.2) 57.9    (48.1-67.7) 16.4 (8.8-24.0) 
Pathology prognostic 
factor 
   
Low risk <T3c 262 (70.1) 74.6    (68.8-80.4) 7.0  (3.4-10.6) 
High risk T3c or worse 112 (29.9) 38.2    (28.0-48.4) 22.6  (13.6-31.6) 
Node negative 217 (58) 77.2    (71.2-83.2) 8.5  (4.5-12.5) 
Node positive 157 (42) 45.4    (36.8-54.0) 16  (9.2- 22.8) 
EMVI negative 289 (77.3) 69.6    (63.8-75.4) 9.7  (5.9-13.5) 
EMVI positive 85 (22.7) 43.9    (32.1-55.7) 18.5 (8.1-28.9) 
CRM +ve 321 (85.8) 68.3    (62.7-73.9) 7.5  (4.3-10.7) 
CRM –ve 53 (14.2) 34.0    (19.0-49.0) 42.1 (24.7-59.5) 
Post operative factors    
Non APE 288 (77) 66.9  (60.9 - 72.9) 8.4 (4.8 -12.0) 
APE 86 (23) 54.0  (42.0 – 66.0) 21.7(11.7-31.7) 
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Treatment group    
Surgery alone 158 (42.2) 67.8 (60.8-74.8) 8.7 (4.5-12.9) 
Short course radiotherapy 47 (12.6) 66.2 (51.2-81.2) 5.0  (0-12.0) 
Chemoradiotherapy and 
Long course radiotherapy 
263 (70.3) 55.4  (45.4-65.4) 18.6 (10.0-27.2) 
 
7.3.1 MRI Factors 
MRI determined factors predictive for local recurrence. 
On univariate analysis the preoperative factors that were significant for time to local 
recurrence were; Height , HR 1.978 (95% CI 1.028-3.805), MRI CRM status HR 3.895 
(95% CI 1.989 -7.628), advanced mrT3 stage (>mrT3b) HR 2.966 (95% CI 1.535-
5.729), mrEMVI status, HR 4.173 (95% CI 2.130-8.175) and chemotherapy (3 patients 
did not  tolerate the radiotherapy) chemoradiotherapy and long course radiotherapy ,HR 
2.256 (95% CI 1.172-4.343), Table 7.3. 
Table 7.3: For univariate analysis on MRI factors for local recurrence 
Candidate Variable HR 1 HR Significance 95% CI for HR 
 Lower upper 
Age (>65) Under 65 0.921 0.805 0.478 1.772 
Sex F 1.927 0.078 0.928 4.000 
Height > 5cm 1.978 0.041 1.028 3.805 
MRI CRM -ve CRM 3.895 0.000 1.989 7.628 
Advanced T stage 
>T3b 
≤ T3b 2.966 0.001 1.535 5.729 
Nodal status Node -ve 1.913 0.062 0.969 3.778 
EMVI EMVI -ve 4.173 0.000 2.130 8.175 
Short Course 
Radiotherapy 
All other 
therapy 
0.390 0.195 0.094 1.623 
Chemoradiotherapy 
and long course 
radiotherapy 
All other 
therapy 
2.256 0.015 1.172 4.343 
Surgery alone All other 
therapy 
0.635 0.174 0.330 1.223 
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By Multivariate analysis the following factors were found to be significant for local 
recurrence 
Variable HR Significance 95% CI for HR 
Lower upper 
Height 1.962 .047 1.008 3.817 
MRI CRM 2.845 .003 1.425 5.678 
EMVI 3.867 .000 1.944 7.688 
 
Age, Sex, nodal status and surgery alone or preoperative short course radiotherapy were 
not significant on univariate analysis for LR. 
On multivariate analysis, the following three risk factors were significant: MRI Height 
of tumour, HR 1.962 (95% CI 1.008-3.817), MRI CRM, HR 2.845 (95% CI 1.425-
5.678), and mrEMVI, HR 3.867(95% CI 1.944-7.688). Figure 7.2 outlines the Kaplan 
Meir survival curves for patients with 0, 1, 2 or all 3 risk factors. 
There were statistically significant differences among the three MRI risk groups. There 
were 217/374 (58%) patients with one or more high risk factors.  Five year local 
recurrence rates for patients with no risk factors was 3.3%, 12.1% in patients with one 
risk factor, 33.4% with two risk factors and 51.1% in those with three risk factors 
Compared to patients with no risk factors, patients with one factor had 4.22 times risk 
(95% CI 1.41-12.64) of local recurrence (p=0.010), patients with 2 factors had 9.95 
times risk (95% CI 3.17 --31.29)(p<0.001) while patients that had all three risk factors 
had a 25.84 times risk (95% CI 6.87-97.2)  of developing local recurrence (p<0.001). 
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Figure 7.2: Kaplan Meier survival curve for Time to recurrence based on MRI 
prognostic factors 
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Disease free survival 
On univariate analysis the preoperative factors significant for disease free survival were; 
Sex, HR 1.673 (95% CI 1.15-2.43), MRI CRM status HR 1.962 (95% CI 1.31-2.94), 
advanced T3 stage (>T3b), HR 2.57(95% CI 1.81-3.64), Nodal status HR 1.668 (95% 
CI 1.17-2.37), EMVI status HR 3.12 (95% CI 2.21-4.41) and if the patient received 
preoperative Chemotherapy/chemoradiotherapy or long course radiotherapy HR 1.512 
(95% CI 1.05-2.19), Table 7.4. 
Table 7.4: MRI characteristics for univariate analysis on Disease-free survival 
 
Candidate Variable HR Significance 95% CI for HR 
lower upper 
Age (>65) 1.027 0.881 0.726 1.452 
Sex 1.673 0.007 1.152 2.429 
Height 1.269 0.189 0.889 1.813 
MRI CRM 1.962 0.001 1.308 2.944 
Advanced T stage 
>T3b 
2.571 0.000 1.817 3.639 
Nodal status 1.668 0.004 1.173 2.372 
EMVI 3.118 0.000 2.205 4.410 
Short Course Radiotherapy 0.881 0.671 0.492 1.579 
Chemoradiotherapy and long course 
radiotherapy 
1.512 0.028 1.045 2.188 
Surgery alone 1.313 0.125 0.928 1.858 
 
For Multivariate analysis the following factors were found to be significant: 
 
Variable HR Significance 95% CI for HR  
Lower upper 
Advanced T stage 2.012 0.000 1.402 2.886 
EMVI 2.602 0.000 1.815 3.731 
 
Age, height of tumour, type of operation, surgery alone and short course preoperative 
radiotherapy were not significant predictors on univariate analysis for DFS. 
On multivariate analysis, the preoperative factors predicting disease free survival were 
mrT3 poor (>5mm extramural spread), HR 2.01(95% CI 1.40-2.89) and mrEMVI, HR, 
2.60 (95% CI 1.82-3.73).  Figure 7.3 outlines the Kaplan Meir survival curves for 
patients with 0, 1 or both prognostic features.  
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Figure 7.3: Kaplan Meier survival curve for MRI prognostic factors (Disease-free 
survival) 
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both risk factors.  Compared to the low risk group, patients with either, EMVI had 2.22 
times risk (95% CI 1.33-3.70), p =0.002, or advanced T stage, 2.858 times the risk (95% 
CI 1.74-4.70), p< 0.001.  Combining both factors gave a hazard ratio of 5.24 (95% CI 
3.36-8.17), p<0.001. 
7.3.2 Pathology Factors 
Local recurrence 
On univariate analysis the preoperative factors that were significant for time to LR 
were; Path CRM status, HR 6.66 (95% CI 3.41-13.0) advanced T3 stage (>T3b), HR 
3.975 (95% CI 2.05-7.69), and operation APE, HR 2.947 (95% CI 1.53-5.69) Table 7.5. 
Table 7.5: Histopathology factors for univariate analysis for local recurrence 
 
Candidate Variable HR Significance 95% CI for HR 
Lower upper 
Age (>65) 0.921 0.805 0.478 1.772 
Sex 1.927 0.078 0.928 4.000 
Path CRM 6.660 0.000 3.413 12.996 
T stage (T3c or 
worse) 
3.975 0.000 2.054 7.692 
Nodal status 1.751 0.094 0.910 3.372 
EMVI 1.769 0.115 0.869 3.598 
Operation –APE 2.947 0.001 1.527 5.689 
Short Course 
Radiotherapy 
0.390 0.195 0.094 1.623 
Chemoradiotherapy 
and long course 
radiotherapy 
2.256 0.015 1.172 4.343 
Surgery alone 0.635 0.174 0.330 1.223 
 
For Multivariate analysis the following factors were found to be significant on 
Pathology: 
Variable HR Significance 95% CI for HR 
lower upper 
Path CRM 3.513 0.001 1.646 7.494 
Advanced T3c stage or worse 2.830 0.005 1.359 5.892 
Operation APE 2.515 0.008 1.266 4.996 
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Age, sex, nodal status and pathological EMVI were not significant on univariate 
analysis for local recurrence. 
On multivariate analysis, pCRM, HR 3.51 (95% CI 1.65-7.49), advanced T stage, HR 
2.83 (95% CI 1.36-5.89) and operation APE, HR 2.52 (95% CI 1.27-5.0) were found to 
be significant.  Figure 7.3 outlines the Kaplan Meir survival curves for patients with 0, 
1, 2 or all 3 prognostic features. 
There were statistically significant differences among the three risk groups (Figure 7.4).  
Five year LR rates for patients with no risk factors was 5.7%, 8.8% for patients with 
one risk factor, 31.4% for patients with 2 risk factors and LR at 38 months was 79% for 
patients with three pathology factors - positive margins on pathology, poor prognosis 
T3 and those who underwent an APE.  Compared to patients with no risk factors, 
patients with one factor had 1.89 (95% CI 0.77-4.64), times the risk of LR (p=0.168) , 
however patients with 2 factors had 6.90 times risk (95% CI 2.80-17.00), p<0.001, and 
patients that had all three risk factors having a 24.17 (95%CI 8.58-68.11) times risk of 
developing LR (p<0.001). 
On univariate analysis the postoperative histopathological factors that were significant 
for disease free survival were; Sex, HR 1.673 (95% CI 1.15-2.43), Path CRM status HR 
2.494 (95% CI 1.65-3.78), advanced T3 stage (>T3b) HR 3.39 (95% CI 2.40-4.80), 
Nodal status, HR 2.93 (95% CI 2.05-4.18) and EMVI status HR 2.34 (95% CI 1.63-
3.38), Table 7.6. 
On multivariate analysis, advanced T stage, HR 2.61 (95% CI 1.81-3.77) and nodal 
status were found to be significant, HR 2.195 (95% CI 1.51-3.20). Figure 7.5 outlines 
the Kaplan Meir survival curves for patients with 0, 1 or both prognostic features. 
There were significant survival differences among the three risk groups.  Five year 
survival for patients with no risk factors was 86.2%.  For patients with node positivity 
51.3% and for patients with poor T3 39.3% and patients with both risk factors, 5 year 
survival was 37.7%.  Compared to the good risk group, patients with either node 
positivity or advanced T stage had 3.81(95% CI 2.32-6.27) and 5.72 times the risk (p < 
0.001 for both) and with both factors combined a hazard ratio of 6.37 (p<0.001). 
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Figure 7.4: Kaplan Meier survival curve for Time to recurrence based on 
Histopathology prognostic factors 
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Table 7.6: Histopathology factors for univariate analysis on Disease-free survival 
Candidate Variable HR Significance 95% CI for HR 
Lower upper 
Age (>65) 1.027 0.881 0.726 1.452 
Sex 1.673 0.007 1.152 2.429 
Path CRM 2.494 0.000 1.645 3.782 
Advanced T stage 3.392 0.000 2.399 4.795 
Nodal status 2.927 0.000 2.050 4.178 
EMVI 2.344 0.000 1.625 3.382 
Short Course 
Radiotherapy 
0.881 0.671 0.492 1.579 
Chemoradiotherapy 
and long course 
radiotherapy 
1.512 0.028 1.045 2.188 
Surgery alone 1.313 0.125 0.928 1.858 
Operation 
(AR/APE) 
1.341 0.133 0.915 1.967 
 
For Multivariate analysis the following histopathology factors were found to be 
significant: 
 
Variable HR Significance 95% CI for HR 
Lower upper 
Advanced T stage 2.613 0.000 1.814 3.765 
Nodal status 2.195 0.000 1.507 3.195 
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Figure 7.5: Kaplan Meier survival curve for Pathology prognostic factors (Disease-
free survival) 
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7.4 Discussion 
The background review identified several of the potential factors that influence outcome 
in patients with rectal cancer.  The criteria to identify the poor prognosis tumours 
preoperatively have been explored within this thesis.  This chapter was able to compare 
both pre and post operative prognostic factors and assess their influence on outcome.  
MR measured height of tumour, MRI assessment of CRM and mrEMVI were each 
significant and independent factors for LR on multivariate analysis. Their impact was 
independent of preoperative treatment, age and sex of patient, depth of extramural 
spread and nodal status. Patients with none of these risk factors had a local recurrence 
rate of only 3.3% rising to 51% if all 3 factors were present and a hazard ratio of 26 
(95% CI 6.87-97.20). 
On pathological assessment, the significant risk factors for local recurrence were 
abdominoperineal excision, positive CRM and tumours with >5mm extramural spread.  
LR rates in patients with no risk factors, were 5.7%, rising to 79% at 38 months for 
patients with all three risk factors  (HR = 24, 95% CI 8.58-68.11). 
Neither imaging nor pathology assessment of nodal status predicted for local 
recurrence.  
In the past, nodal status has been considered an important indication for adjuvant 
radiotherapy.  This was based on pooled data analysis of rectal cancers predominantly 
treated in the1980s prior to the widespread use of TME surgery, histopathological 
evaluation of the CRM and audit of the quality of the specimen. 
The loss of predictive power of nodal status for local recurrence probably reflects the 
completeness of relevant nodal clearance in the era of TME surgery where the whole 
embryologically determined envelope of tissue is excised. 
The risk factors for local failure alone, according to both pathology and MRI staging, 
were CRM status and height of tumour <5cm associated with abdominoperineal 
excisions.  These are factors, identifiable on MRI which can be used to plan the 
treatment strategy. Consequently, initiatives using an MRI based surgical road map to 
plan extended resections and thus prevent involved margins are underway (Holm et al., 
2007, Marr et al., 2005, Salerno et al., 2009, Shihab et al., 2009).  MRI imaging and 
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corresponding pathology have identified patients with negligible risk of local failure 
who may safely avoid the toxicity and morbidity of preoperative radiotherapy prior to 
TME surgery. This low risk group of patients have tumours more than 5cm from the 
anal verge, no MR EMVI and MRI predicted clear CRM.  
Currently, mrEMVI is not generally accepted as an indication for preoperative therapy 
due to the lack of published data on preoperative assessment and outcome. However, 
this work demonstrates that it is a highly significant and independent prognostic factor 
for both LR and distant failure. Such patients have a LR rate of 24.5%, which is 
comparable with that of MRI predicted mesorectal margin involved patients and carries 
a hazard ratio of 3.9.  This is despite audited TME surgery and is independent of CRM 
status. 
 The identification of EMVI using MRI has been overlooked by radiologists compared 
with nodal status yet in this multi-centre study, trained radiologists have successfully 
identified this poor prognostic feature in 32% of patients scanned. The importance of 
mrEMVI has been previously documented using single centre data, the current study 
confirms its importance in the multi-centre setting (Mercury Study Group, 2006, Sobin 
and Wittekind, 1997, Smith et al., 2008a). Few studies have consistently reported rates 
of pEMVI but when it has been documented it has been shown to be associated with 
local recurrence (Bokey et al., 1999, Rich et al., 1983, Heald and Ryall, 1986). It is 
notable that detection of pEMVI was much lower than predicted on MRI (22% vs 32%).  
It is likely that some cases of venous invasion could not be determined pathologically 
due to complete destruction and replacement of venous architecture on histologically 
sampled sections (whereas mrEMVI has very characteristic appearances) or that there 
was significant under reporting despite its emphasis during pathology training (Smith et 
al., 2008b). 
Poor disease free survival was strongly influenced by the presence of extramural depth 
of tumour spread >5mm on both pathology and imaging. The other independent 
preoperative risk factor was MR detected extramural venous invasion.  Pathological 
node status was also associated with poor disease free survival. Compared with the MRI 
defined good prognosis tumours the risk of poor disease free survival for patients with 
either pathological extramural tumour spread >5mm or EMVI was significant (Hazard 
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ratio of 2.2. and 2.9 respectively).  In the MERCURY study this represented 48% of 
patients with at least one of these factors. 
The findings in  this  prospective multidisciplinary study indicates that  T and N staging 
to identify good versus poor prognosis tumours is inadequate and  that T substaging 
according to depth of extramural spread is better at distinguishing good versus poor 
prognosis tumours.  Although this has been highlighted in several pathological studies, 
it has not been tested prospectively in patients undergoing TME surgery (Harrison et al., 
1994, Jass et al., 1987, Merkel et al., 2001, Willett et al., 1999). 
This study has now confirmed that this important prognostic information can also be 
obtained from measuring radiological extramural depth of spread.  
In the preoperative assessment of rectal cancer, the decision to offer neoadjuvant 
therapy has been generally been determined by clinical palpation, sigmoidoscopy and/or 
imaging by EUS, CT and/or MRI assessment of T and N stage.  Predicted node positive 
patients, regardless of T stage, and ultrasound or radiologically staged T3 tumours have 
usually been selected for treatment in most preoperative chemoradiotherapy trials to 
date (Gunderson et al., 2008).   This study has identified factors which will enable more 
targeted treatment within groups of patients with rectal cancer. 
In conclusion this study has shown that preoperative imaging using MRI can identify 
patients who are at particular risk of local and systemic relapse and can enable MDT’s 
to plan neo-adjuvant and surgical detail before treatment is commenced.  
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Table 7.7: Summary of MRI data 
 
Factors Local recurrence Disease free survival Both 
CRM involved 
(64=17%) 
+ - - 
T3 advanced 
(126=33.7%) 
- + - 
EMVI 
(118=31.6%) 
+ + + 
Height 
(113=30.2%) 
+ - - 
Nodal status 
(183=48.9%) 
- - - 
 
Table 7.8: Summary of pathology data 
Factors Local recurrence Disease free survival Both 
CRM 
(53=14.2%) 
+ - - 
T3 advanced 
(112=29.9%) 
+ + + 
EMVI 
(85=22.7%) 
- - - 
APE 
(86=23%) 
+ - - 
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Chapter 8 - Discussion 
The prime limitation of the current staging process for rectal cancer is that prognosis is 
determined by postoperative histopathological staging systems and within each broad 
pathological stage, there is considerable heterogeneity. 
At the onset of this study MRI was gaining importance in the preoperative staging of 
rectal cancer.  There is now good evidence that it is able to identify many of the 
prognostic features that are necessary to stage patients more accurately; however, there 
have been no studies looking at the long term prognosis based upon these preoperative 
assessments.  
The aim of this thesis was to identify which of these factors are important in the 
preoperative identification of the high risk cancer patients. This is the first study linking 
MRI identification of prognostic features with clinical outcome. 
8.1 Early Tumours 
In the background review the growing need for accurate recognition of early tumours 
was highlighted.  The bowel cancer screening programme is picking up tumours at an 
earlier stage and it is likely that these numbers will continue to increase. It may be that 
some of these patients can avoid the significant morbidity of conventional surgery or 
adjuvant treatments. Accurate identification may allow of less invasive endoscopic 
treatments. At present there is no robust system to assist radiologists to identify the 
specific features of importance on MRI. This chapter focused on some additional 
measurements from the base of the tumour to the submucosa to improve the accuracy of 
identifying those with very early disease. The study was undertaken by a single 
observer in a subset of patients with rectal cancer.   
Whilst demonstrating a technique that may well enhance the ability to stage early 
cancer, the accurate identification of these tumours is not wholly encompassed by this 
method.   From the available evidence it seems likely that a pathway which includes   
MRI with other adjunctive techniques may be the best management for these patients in 
the future. The advantage of this technique is that it allows a reproducible staging to be 
kept with objective records.  As technology advances the ability to identify malignant 
cells within lymph nodes and locally applied ultrasound may show more promise. The 
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use of MRI to determine and highlight early tumours and act as adjunct to other 
methods, allows the MDT to consider all the possible options for management in each 
particular case. Therefore this shows promise for any future trials investigating the 
treatment of this group of patients.  To take this forward this method should be further 
tested, using a dedicated proforma with multiple radiologists and then compared to 
histopathological data from those patients that ultimately undergo resection.   
8.2 Good Prognosis Tumours 
As discussed in the background chapter, there are several treatment strategies for 
different stage rectal cancers. There is considerable morbidity and or mortality 
associated with preoperative adjunctive treatment and there is a recognised need to 
identify those patients who would benefit from proceeding straight to surgery.  The 
heterogeneity of patients with stage II and stage III disease is well recognised.  Thus 
there is a clear need to define those patients who would benefit from more or less 
intensive therapies and perhaps the need to further sub group these patients. This study 
highlighted the divergent group of patients included in the traditional pathological 
staging groups who would all have received the same treatment in many centres 
worldwide.  
Patients were identified as having a good prognosis based upon defined preoperative 
criteria; 
Those who were predicted to be CRM clear on preoperative MRI  (tumour >1mm from 
the mesorectal fascia) and showed no evidence on MRI of extramural venous invasion, 
were early MRI T stage i.e. T2 or less, T3a, T3b (spread less than 5 mm from bowel 
wall) regardless of N stage. For low rectal tumours good prognosis was defined as MRI 
stage 1 or 2 low rectal, namely tumour not encroaching into the intersphincteric plane or 
levators.  Within this group of patients, there were patients who were stage II or III 
disease and many centres would recommend preoperative therapy for this group. 
This data shows, for the first time, that in a multi centre setting, optimal preoperative 
MRI staging and good quality TME surgery, achieves LR rates of 3%, even including 
some patients with node positive disease. The benefits of neoadjuvant radiotherapy are 
likely to be outweighed by the side-effects in such patients.  The results of this study 
suggest that optimal pre-operative staging by MRI, can select patients with rectal cancer 
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amenable to cure by surgery alone. The factors identified are reproducible and easily 
identified on the staging MRI. 
One possible limitation of this study is that the results achieved were in centres with 
dedicated trained radiologists and TME surgeons. An important question remains as to 
whether such results can be reproduced by other less specialised centres. Our research 
suggests that this can be achieved with workshop training and standardisation of 
reporting using proformas with strict adherence to the scanning technique and reporting 
criteria.  Such a model of workshop training and standardisation has been used for 
national training of radiologists in the UK, Denmark and Sweden, with the development 
of specific specialist colorectal teams comprising TME surgeons, GI radiologists, GI 
pathologists and oncologists. Patients are always discussed prior to treatment plans by 
these combined teams in dedicated weekly multidisciplinary case conferences. It 
should, therefore, be possible to replicate this model in other healthcare systems. 
There is considerable variation in the proportion of patients selected for neoadjuvant 
therapy.  Few would disagree with maximal pre-operative therapy for fixed tumours 
invading local structures and most consider neoadjuvant therapy unnecessary for very 
early T1 or T2 cancers.  Between these extremes a large proportion of patients have 
intermediate risk tumours with a good prognosis by optimal surgical excision alone.  
Accurate prediction of these patients preoperatively may enable omission of 
preoperative therapy which could be over-treatment for such cases.   
This study has implications for future trials as patients can be more accurately grouped 
into prognostic categories and these patients could actually have less intensive follow 
up than those with a poor prognosis thus freeing up resources for those patients who 
would benefit from more intensive follow up. 
8.3 Margin Involvement 
8.3.1 What is the best Margin, in mm? 
A pathologically involved margin in rectal cancer is defined as tumour within 1 mm of 
the surgical resection margin.   
There is some variation in definition of MRI prediction of CRM involvement, which 
has led to differences in selection criteria for preoperative chemoradiotherapy. 
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This study explored the different values for a predicted margin and has clearly shown 
that for preoperative staging of rectal cancer, the best cut-off distance for predicting 
CRM involvement using MRI is 1 mm. Again this will enable more precise treatment 
planning and allow more accurate grouping of patients for clinical trials investigating 
different treatment regimes. 
At the start of this study, MRI was not in widespread use as a preoperative staging 
system. Indeed several important trials have been undertaken with lack of a 
standardised technique to stage the patients preoperatively.   Accurate identification of 
the CRM is not feasible using any of the other presently available staging methods.  
This study confirms that a margin of 1 mm or less measured by MRI correlates 
accurately with pathological CRM involvement and poor outcome.  Using a cut-off of 
greater than 1 mm would not have increased the accuracy of MRI in predicting CRM 
status. It would have resulted in substantial overtreatment which would achieve only 
minimal gain based on very low local recurrence rates observed following TME 
surgery.   
An investigation by Bernstein et al. (2012) on the impact of CRM on prognosis 
concluded that a histopathological CRM of 2 mm or less conferred a poorer prognosis.  
In that study the CRM was measured pathologically and patients with a margin of 1 mm 
had a local recurrence rate of 14.5 (95 per cent confidence interval 6.5 to 23.0) per cent, 
compared with 18.0 per cent (10.8 to 25.2) for those with a margin of 2 mm. The 
present data showed that, for both MRI and histopathology, local recurrence rates of 8 
per cent for tumours within 2 mm of the CRM were more in keeping with the Bernstein 
value of 8.9 per cent for tumours with a distance of 3 mm or more. It is likely that the 
differences observed here are due to an improvement in the quality of TME surgery in 
recent years as evidenced by only a 5 per cent incomplete specimen rate in the 
MERCURY study. 
In Norway, preoperative chemoradiotherapy is given to patients whose CRM is 
measured as less than or equal to 3mm based upon results from patients with pT3 
tumours (Eriksen et al., 2007), while others have suggested that the distance to the 
CRM would be more informative (Birbeck et al., 2002, Bozzetti, 1996, Marijnen et al., 
2001).  However, the shape of the mesorectum is somewhat uneven and it would be 
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very difficult to obtain consistent measurements. There would be variation in the angle 
of the slice and subjectivity as to where to start measuring the distance. Our data would 
not support these findings and in fact Birbeck et al. (2002) validated the definition of a 
1mm cut off by examining the effect of distance to the CRM on local recurrence rates. 
They did not confirm any advantage to using a wider margin (Nagtegaal and Quirke, 
2008, Birbeck et al., 2002). 
This study is in line with pathological CRM data and allows a common language for the 
definition across both radiological and pathological parameters. 
8.3.2 Circumferential Resection Margin Predicts Disease Free Survival and 
Local Recurrence 
This study demonstrated that high resolution MRI preoperative assessment of CRM 
status is superior to AJCC TNM based criteria for assessing risk of LR, DFS and OS. 
Furthermore, MRI, CRM involvement is significantly associated with distant failure; 
therefore colorectal cancer teams could intensify treatment and follow-up accordingly to 
improve survival outcomes.  This project involved a unique series of consecutive rectal 
cancer patients evaluated by high resolution MRI undergoing good quality TME 
surgery and careful histopathological assessment with long term follow up data.  
Patients with MRI predicted involved margins had a significantly lower median survival 
of less than 3 years compared to over 6 years if they were predicted CRM negative.  
This shows the same strength of association as histopathological assessment of the 
CRM in predicting outcome.  The study confirmed that radiological prediction of the 
margin status (using a cut off of <= 1mm) has prognostic significance and is the first 
prospective, multi centre study to show the importance of MRI in staging patients for 
CRM status. 
MRI is the key staging tool and these results validate its use in assessing the potential 
circumferential margin preoperatively that cannot be achieved by other modalities.  
MRI therefore provides us with an opportunity to conduct research studies with 
accurately defined entry criteria thereby optimising appropriate selection.  The ease of 
data capture and transfer of image data means that this can be externally validated in 
clinical studies for quality assurance.  The negative predictive value of MRI assessment 
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of the potential CRM in patients is also a key finding and provides further strong 
evidence again for using the 1mm cut off. 
The pathological identification of an involved margin has long been recognised as a 
significant predictor of poor prognosis. For the first time, it has been demonstrated that 
the MRI identification of a predicted involved margin holds significant association with 
poor prognosis. Current staging systems group patients into categories based upon 
tumour extension, nodal disease and metastatic disease. Highlighting these poor 
prognostic groups preoperatively enables clinicians to identify these tumours for 
neoadjuvant therapy. At the time this thesis was started, lack of MRI staging was 
leading to significant under and over treatment of patients.  Ensuring accurate 
identification of the margin will allow patients to be grouped selectively based upon 
their predicted prognosis. 
Tumour height from the anal verge is a known prognostic factor and MRI tumour height 
<5cm and abdominoperineal excision surgery significantly contributed to LR, despite 
preoperative chemoradiotherapy.  Low rectal cancer surgery is strongly associated with 
tumour perforation, high LR and poor survival rates. Local recurrence rates could be 
improved, in future, by using MRI criteria to define surgical planes and identify 
tumours amenable to resection by low anterior resection as well as modifying surgical 
technique in patients who require an APE through selective radical extra-levator APE. 
This approach is being tested in the MERCURY low rectal cancer study (Portfolio:, 
2007).  
Amongst the study limitations was the practice amongst centres of basing preoperative 
treatment upon MRI assessment. The policy at all units, was to discuss MRI scans prior 
to planning surgery as there was accumulating evidence for MRI prediction of margin; 
it was therefore considered unethical to withhold MRI margin status information for 
preoperative decision making. Also, treatments were not standardised amongst the 
recruiting centres. Approximately half of the patients received radiotherapy pre 
operatively without chemotherapy.  Despite this, multivariate analysis showed that final 
MRI CRM status still had an impact on patient outcomes, independent of preoperative 
treatment decisions and type of therapy given. 
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We did not account for adjuvant chemotherapy use in 58% of patients undergoing 
primary surgery. However, whilst none of the centres had a policy of treating patients 
with node positive disease on histology with postoperative radiotherapy, all offered 
node positive patients adjuvant fluoropyrimidine-based chemotherapy. It is therefore, 
unlikely that the use of adjuvant chemotherapy could have influenced the observed 20% 
difference in survival outcomes for patients by MRI predicted CRM status.  
Another limitation of this study was lack of a direct comparison with endorectal 
ultrasound. It could be argued that EUS identification of T3 and/or node positive 
patients effectively selects high risk patients which would, in any case, include patients 
with CRM involvement.  Since MRI and EUS have been shown to have very similar 
accuracies for T and N staging, there would be no additional value in using MRI. 
However, in this study AJCC TNM staging were inadequate predictors of local 
recurrence compared with CRM status – which is not assessable by EUS. 
8.4 Preoperative Prognostic Factors on MRI Predict Outcome at 5 
years in the MERCURY Study of Rectal Cancer 
Current clinical guidelines show considerable variation in the imaging criteria used to 
decide preoperative therapy meaning that a heterogeneous prognostic group are often 
included in clinical trials. The current generation of clinical trials, have tended to offer 
preoperative therapy to all T3 or T4 patients and any patient with suspected nodal 
involvement on preoperative imaging.  This results in considerable over-treatment, long 
term morbidity and the inability to consistently demonstrate improvements in outcomes 
from largely unselected patient cohorts. 
In this study, a multivariate analysis was performed of all the predicted prognostic 
factors to enable identification of those patients most at risk of disease relapse. 
MRI derived prognostic data can be utilised preoperatively to identify potential groups 
that are at risk of local failure, distant failure or both. Therefore, the multidisciplinary 
team have an opportunity to identify particularly high risk groups who might benefit 
from more intensive preoperative treatment and in some cases an alteration in the 
surgical procedure and more intensive follow up.  Our proposed pre-operative 
prognostic staging system would also facilitate trial recruitment of patients with clear 
risks of local recurrence into more targeted treatment pathways. Such future treatment 
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strategies could be directed at maximising systemic therapy whilst also addressing 
pelvic control. Recent reports of  5 year disease free survival of 80% seen in such 
patients treated within the EXPERT trial (Chua et al., 2010) suggests outcome benefits 
in patients with advanced rectal cancer treated by a multimodal aggressive strategy. 
There are some limitations in this study.  Firstly, patients included in this study received 
various neoadjuvant therapies and a variable use of 5-FU based adjuvant therapy which 
may have masked the importance of some factors.  Despite this, and even though the 
overall sample size is not very large and may have diluted some of the effect, we saw a 
highly significant difference in outcomes based on certain radiological and pathological 
factors.  Since adjuvant chemotherapy results in 3-10% improvement, it is unlikely that 
variations in its use could have accounted for the large differences in outcomes 
observed.  Secondly, data was collected on patients who underwent audited TME 
surgery and the results obtained are a reflection of this technique.  In patients not 
receiving TME surgery there are likely to be other unquantifiable factors involved.  A 
final caution to widespread applicability is that MRI is not universally performed to a 
high standard with high resolution images so that there is a need for standardisation of 
technique and workshop training of radiologists as was developed for the MERCURY 
project. 
This study was able to highlight a clinically applicable MRI prognostic model for 
disease free survival and local recurrence: preoperative imaging of EMVI, extramural 
depth of tumour spread and CRM status identifies patients who are at risk of local and 
systemic relapse, providing the multidisciplinary team with the opportunity to target 
preoperative therapy in high-risk groups. 
This will enable intensive treatment and follow up programmes for this group of 
patients. In the future such patients can be grouped into poor prognostic categories 
gaining priority for intensive therapy within trials and novel techniques in an attempt to   
improve survival. 
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8.5 Conclusions 
 
From the work presented within this thesis, the following conclusions can be made; 
 MRI can aid in the stratification of early tumours and using a closer analysis of 
the depth of invasion will help identify those patients who might be suitable for 
the less invasive treatment options. 
 MRI can identify patients with tumours that generally have a good result with 
surgery alone. There is a group of patients who attain a good outcome if they 
demonstrate none of the identifiable poor prognostic features i.e. CRM safe, T3a 
or less and no EMVI, and they  are safe to proceed straight to surgery without 
preoperative therapy. 
 For preoperative staging of rectal cancer, the best cut-off distance for predicting 
CRM involvement using MRI is <=1 mm. Using a cut-off greater than this does 
not appear to identify patients at higher risk of local recurrence. 
 High resolution MRI preoperative assessment of CRM status is superior to 
AJCCTNM based criteria for assessing risk of LR, DFS and OS. Furthermore, 
MRICRM involvement is significantly associated with distant failure; therefore 
colorectal cancer teams could intensify treatment and follow-up accordingly to 
improve survival outcomes. 
 Preoperative imaging of EMVI, extramural depth of tumour spread and CRM 
status identifies patients who are at significant risk of local and systemic relapse, 
providing the multidisciplinary team with the opportunity to target preoperative 
therapy in high-risk groups.  
This is the first study that has looked at preoperatively identified factors in relation to    
the long term outcome.  The MERCURY Study provided a unique opportunity to 
investigate the long term significance of several factors identified on preoperative MRI. 
In summary this thesis has demonstrated the prognostic significance of the 
identification preoperatively of the known pathological prognostic factors.  It will 
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enable better grouping of patients for clinical trials, allow stratification for more 
intense/ less intensive follow up and allow us to investigate newer therapies accurately. 
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